US20090162359A1 - Bivalent, bispecific antibodies - Google Patents
Bivalent, bispecific antibodies Download PDFInfo
- Publication number
- US20090162359A1 US20090162359A1 US12/332,486 US33248608A US2009162359A1 US 20090162359 A1 US20090162359 A1 US 20090162359A1 US 33248608 A US33248608 A US 33248608A US 2009162359 A1 US2009162359 A1 US 2009162359A1
- Authority
- US
- United States
- Prior art keywords
- antibody
- domain
- heavy chain
- igf
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to novel bivalent, bispecific antibodies, their manufacture and use.
- Engineered proteins such as bi- or multispecific antibodies capable of binding two or more antigens are known in the art. Such multispecific binding proteins can be generated using cell fusion, chemical conjugation, or recombinant DNA techniques.
- bispecific antibody formats have been developed in the recent past, e.g. tetravalent bispecific antibodies by fusion of, e.g. an IgG antibody format and single chain domains (see e.g. Morrison, S. L., et al, Nature Biotech 15 (1997) 159-163; WO2001077342; and Coloma, M. J., Nature Biotech 25 (2007) 1233-1234).
- linkers either to fuse the antibody core (IgA, IgD, IgE, IgG or IgM) to a further binding protein (e.g. scFv) or to fuse e.g. two Fab fragments or scFv.
- linkers While it is obvious that linkers have advantages for the engineering of bispecific antibodies, they may also cause problems in therapeutic settings. Indeed, these foreign peptides might elicit an immune response against the linker itself or the junction between the protein and the linker. Further more, the flexible nature of these peptides makes them more prone to proteolytic cleavage, potentially leading to poor antibody stability, aggregation and increased immunogenicity.
- effector functions such as e.g. complement-dependent cytotoxicity (CDC) or antibody dependent cellular cytotoxicity (ADCC), which are mediated through the Fcpart, by maintaining a high degree of similarity to naturally occurring antibodies.
- bispecific antibodies that are very similar in general structure to naturally occurring antibodies (like IgA, IgD, IgE, IgG or IgM) with minimal deviation from human sequences.
- bispecific antibodies that are very similar to natural antibodies have been produced using the quadroma technology (see Milstein, C. and A. C. Cuello, Nature, 305 (1983) 537-40) based on the somatic fusion of two different hybridoma cell lines expressing murine monoclonal antibodies with the desired specificities of the bispecific antibody. Because of the random pairing of two different antibody heavy and light chains within the resulting hybrid-hybridoma (or quadroma) cell line, up to ten different antibody species are generated of which only one is the desired, functional bispecific antibody. Due to the presence of mispaired byproducts, and significantly reduced production yields, means sophisticated purification procedures are required (see e.g. Morrison, S. L., Nature Biotech 25 (2007) 1233-1234). In general the same problem of mispaired byproducts remains if recombinant expression techniques are used.
- heterodimer formation By coexpressing these two heavy chains (and two identical light chains, which have to be appropriate for both heavy chains), high yields of heterodimer formation (‘knob-hole’) versus homodimer formation (‘hole-hole’ or ‘knob-knob’) was observed (Ridgway J B, Presta L G, Carter P; and WO1996027011).
- the percentage of heterodimer could be further increased by remodeling the interaction surfaces of the two CH3 domains using a phage display approach and the introduction of a disulfide bridge to stabilize the heterodimers (Merchant A.
- Xie, Z., et al, J Immunol Methods 286 (2005) 95-101 refers to a new format of bispecific antibody using scFvs in combination with knobs-into-holes technology for the FC part.
- the invention relates to a bivalent, bispecific antibody, comprising:
- variable domains VL and VH from the antibody specifically binding to a second antigen are replaced by each other.
- a further embodiment of the invention is a method for the preparation of an a bivalent, bispecific antibody according to the invention comprising the steps of
- vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a first antigen
- vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH from the antibody specifically binding to a second antigen are replaced by each other;
- a further embodiment of the invention is a host cell comprising
- vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a first antigen
- vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH are replaced by each other.
- a further embodiment of the invention is a composition, preferably a pharmaceutical or a diagnostic composition of the antibody according to the invention.
- a further embodiment of the invention is a pharmaceutical composition comprising an antibody according to the invention and at least one pharmaceutically acceptable excipient.
- a further embodiment of the invention is a method for the treatment of a patient in need of therapy, characterized by administering to the patient a therapeutically effective amount of an antibody according to the invention.
- the invention relates to a bivalent, bispecific antibody, comprising:
- variable domains VL and VH from the antibody specifically binding to a second antigen are replaced by each other.
- bivalent, bispecific antibody comprises:
- variable domains VL and VH of the second light chain and the second heavy chain are replaced by each other.
- variable light chain domain VL is replaced by the variable heavy chain domain VH of said antibody; and within the heavy chain the variable heavy chain domain VH is replaced by the variable light chain domain VL of said antibody.
- antibody refers to whole, monoclonal antibodies. Such whole antibodies consist of two pairs of a “light chain” (LC) and a “heavy chain” (HC) (such light chain (LC)/heavy chain pairs are abbreviated herein as LC/HC).
- the light chains and heavy chains of such antibodies are polypeptides consisting of several domains.
- each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVRor VH) and a heavy chain constant region.
- the heavy chain constant region comprises the heavy chain constant domains CH1, CH2 and CH3 (antibody classes IgA, IgD, and IgG) and optionally the heavy chain constant domain CH4 (antibody classes IgE and IgM).
- Each light chain comprises a light chain variable domain VL and a light chain constant domain CL.
- the structure of one naturally occurring whole antibody, the IgG antibody, is shown e.g. in FIG. 1 .
- the variable domains VH and VL can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).
- CDR complementarity determining regions
- FR framework regions
- Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 ((Janeway C A, Jr et al (2001).
- antibody The two pairs of heavy chain and light chain (HC/LC) are capable of specifically binding to same antigen.
- whole antibody is a bivalent, monospecific antibody.
- antibodies include e.g. mouse antibodies, human antibodies, chimeric antibodies, humanized antibodies and genetically engineered antibodies (variant or mutant antibodies) as long as their characteristic properties are retained.
- human or humanized antibodies especially as recombinant human or humanized antibodies.
- Each heavy chain has two regions, the constant region and the variable region.
- the constant region is identical in all antibodies of the same isotype, but differs in antibodies of different isotype.
- Heavy chains ⁇ , ⁇ and ⁇ have a constant region composed of three constant domains CH1, CH2, and CH3 (in a line), and a hinge region for added flexibility (Woof J. Burton D Nat Rev Immunol 4 (2004) 89-99); heavy chains ⁇ and ⁇ have a constant region composed of four constant domains CH1, CH2, CH3, and CH4 (janeway C A, Jr et al (2001). Immunobiology., 5th ed., Garland Publishing).
- the variable region of the heavy chain differs in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or B cell clone.
- the variable region of each heavy chain is approximately 110 amino acids long and is composed of a single antibody domain.
- a light chain has two successive domains: one constant domain CL and one variable domain VL.
- the approximate length of a light chain is 211 to 217 amino acids.
- the light chain is a kappa ( ⁇ ) light chain
- the constant domain CL is preferably derived from a kappa ( ⁇ ) light chain (the constant domain C ⁇ )
- monoclonal antibody or “monoclonal antibody composition” as used herein refer to a preparation of antibody molecules of a single amino acid composition.
- the “antibodies” according to the invention can be of any class (e.g. IgA, IgD, IgE, IgG, and IgM, preferably IgG or IgE), or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2, preferably IgG1), whereby both antibodies, from which the bivalent bispecific antibody according to the invention is derived, have an Fc part of the same subclass (e.g. IgG1, IgG4 and the like, preferably IgG1), preferably of the same allotype (e.g. Caucasian)
- subclass e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2, preferably IgG1
- a “Fc part of an antibody” is a term well known to the skilled artisan and defined on the basis of papain cleavage of antibodies.
- the antibodies according to the invention contain as Fc part, preferably a Fc part derived from human origin and preferably all other parts of the human constant regions.
- the Fc part of an antibody is directly involved in complement activation, C1q binding, C3 activation and Fc receptor binding. While the influence of an antibody on the complement system is dependent on certain conditions, binding to C1q is caused by defined binding sites in the Fc part. Such binding sites are known in the state of the art and described e.g. by Lukas, T. J., et al., J. Immunol.
- binding sites are e.g. L234, L235, D270, N297, E318, K320, K322, P331 and P329 (numbering according to EU index of Kabat, see below).
- Antibodies of subclass IgG1, IgG2 and IgG3 usually show complement activation, C1q binding and C3 activation, whereas IgG4 do not activate the complement system, do not bind C1q and do not activate C3.
- the Fc part is a human Fc part.
- chimeric antibody refers to an antibody comprising a variable region, i.e., binding region, from one source or species and at least a portion of a constant region derived from a different source or species, usually prepared by recombinant DNA techniques. Chimeric antibodies comprising a murine variable region and a human constant region are preferred. Other preferred forms of “chimeric antibodies” encompassed by the present invention are those in which the constant region has been modified or changed from that of the original antibody to generate the properties according to the invention, especially in regard to C1q binding and/or Fc receptor (FcR) binding. Such chimeric antibodies are also referred to as “class-switched antibodies.”.
- Chimeric antibodies are the product of expressed immunoglobulin genes comprising DNA segments encoding immunoglobulin variable regions and DNA segments encoding immunoglobulin constant regions. Methods for producing chimeric antibodies involve conventional recombinant DNA and gene transfection techniques are well known in the art. See, e.g., Morrison, S. L., et al., Proc. Natl. Acad. Sci. USA 81 (1984) 6851-6855; U.S. Pat. Nos. 5,202,238 and 5,204,244.
- humanized antibody refers to antibodies in which the framework or “complementarity determining regions” (CDR) have been modified to comprise the CDR of an immunoglobulin of different specificity as compared to that of the parent immunoglobulin.
- CDR complementarity determining regions
- a murine CDR is grafted into the framework region of a human antibody to prepare the “humanized antibody.” See, e.g., Riechmann, L., et al., Nature 332 (1988) 323-327; and Neuberger, M. S., et al., Nature 314 (1985) 268-270.
- Particularly preferred CDRs correspond to those representing sequences recognizing the antigens noted above for chimeric antibodies.
- humanized antibodies encompassed by the present invention are those in which the constant region has been additionally modified or changed from that of the original antibody to generate the properties according to the invention, especially in regard to C1q binding and/or Fc receptor (FcR) binding.
- FcR Fc receptor
- human antibody is intended to include antibodies having variable and constant regions derived from human germ line immunoglobulin sequences.
- Human antibodies are well-known in the state of the art (van Dijk, M. A., and van de Winkel, J. G., Curr. Opin. Chem. Biol. 5 (2001) 368-374).
- Human antibodies can also be produced in transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire or a selection of human antibodies in the absence of endogenous immunoglobulin production.
- Human antibodies can also be produced in phage display libraries (Hoogenboom, H. R., and Winter, G., J. Mol. Biol. 227 (1992) 381-388; Marks, J.
- human antibody as used herein also comprises such antibodies which are modified in the constant region to generate the properties according to the invention, especially in regard to C1q binding and/or FcR binding, e.g. by “class switching” i.e. change or mutation of Fc parts (e.g. from IgG1 to IgG4 and/or IgG1/IgG4 mutation.)
- recombinant human antibody is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from a host cell such as a NS0 or CHO cell or from an animal (e.g. a mouse) that is transgenic for human immunoglobulin genes or antibodies expressed using a recombinant expression vector transfected into a host cell.
- recombinant human antibodies have variable and constant regions in a rearranged form.
- the recombinant human antibodies according to the invention have been subjected to in vivo somatic hypermutation.
- the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germ line VH and VL sequences, may not naturally exist within the human antibody germ line repertoire in vivo.
- variable domain denotes each of the pair of light and heavy chains which is involved directly in binding the antibody to the antigen.
- the domains of variable human light and heavy chains have the same general structure and each domain comprises four framework (FR) regions whose sequences are widely conserved, connected by three “hypervariable regions” (or complementarity determining regions, CDRs).
- the framework regions adopt a ⁇ -sheet conformation and the CDRs may form loops connecting the ⁇ -sheet structure.
- the CDRs in each chain are held in their three-dimensional structure by the framework regions and form together with the CDRs from the other chain the antigen binding site.
- the antibody heavy and light chain CDR3 regions play a particularly important role in the binding specificity/affinity of the antibodies according to the invention and therefore provide a further object of the invention.
- hypervariable region or “antigen-binding portion of an antibody” when used herein refer to the amino acid residues of an antibody which are responsible for antigen-binding.
- the hypervariable region comprises amino acid residues from the “complementarity determining regions” or “CDRs”.
- “Framework” or “FR” regions are those variable domain regions other than the hypervariable region residues as herein defined. Therefore, the light and heavy chains of an antibody comprise from N- to C-terminus the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. CDRs on each chain are separated by such framework amino acids. Especially, CDR3 of the heavy chain is the region which contributes most to antigen binding.
- CDR and FR regions are determined according to the standard definition of Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991).
- antibodies or immunoglobulins are divided into the classes:
- bispecific antibody refers to an antibody as described above in which each of the two pairs of heavy chain and light chain (HC/LC) is specifically binding to a different antigen, i.e. the first heavy and the first light chain (originating from an antibody against a first antigen) are specifically binding together to a first antigen, and, the second heavy and the second light chain (originating from an antibody against a second antigen) are specifically binding together to a second antigen (as depicted in FIG.
- bivalent, bispecific antibodies are capable of specifically binding to two different antigens at the same time, and not to more than two antigens, in contrary to, on the one hand a monospecific antibody capable of binding only to one antigen, and on the other hand e.g. a tetravalent, tetraspecific antibody which can bind to four antigen molecules at the same time.
- the ratio of a desired bivalent, bispecific antibody compared to undesired side products can be improved by the replacement of certain domains in only one pair of heavy chain and light chain (HC/LC). While the first of the two HC/LC pairs originates from an antibody specifically binding to a first antigen and is left essentially unchanged, the second of the two HC/LC pairs originates from an antibody specifically binding to a second antigen, and is altered by the following replacement:
- variable light chain replacement of the variable light chain domain VL by the variable heavy chain domain VH of said antibody specifically binding to a second antigen
- variable heavy chain replacement of the variable heavy chain domain VH by the variable light chain domain VL of said antibody specifically binding to a second antigen.
- bivalent, bispecific antibodies are artificial antibodies which comprise
- such improved ratio of a desired bivalent, bispecific antibody compared to undesired side products can be further improved by one of the following two alternatives:
- the CH3 domains of said bivalent, bispecific antibody according to the invention can be altered by the “knob-into-holes” technology which described with in detail with several examples in e.g. WO96/027011, Ridgway J B, et al, Protein Eng 9 (1996) 617-621; and Merchant A. M., et al, Nat Biotechnol 16 (1998) 677-681.
- the interaction surfaces of the two CH3 domains are altered to increase the heterodimerisation of both heavy chains containing these two CH3 domains.
- Each of the two CH3 domains (of the two heavy chains) can be the “knob”, while the other is the “hole”.
- the introduction of a disulfide bridge stabilizes the heterodimers (Merchant A. M, et al, Nature Biotech 16 (1998) 677-681; Atwell S, Ridgway J B, Wells J A, Carter P., J Mol Biol 270 (1997) 26-35) and increases the yield.
- the CH3 domains of a bivalent, bispecific antibody wherein the first CH3 domain and second CH3 domain each meet at an interface which comprises an original interface between the antibody CH3 domains are altered by the “knob-into-holes” technology including further stabilization by introduction of a disulfide bridge in the CH3 domains (described in WO96/027011, Ridgway J B, et al, Protein Eng 9 (1996) 617-621; Merchant A. M, et al, Nature Biotech 16 (1998) 677-681; and Atwell S, Ridgway J B, Wells J A, Carter P., J Mol Biol 270 (1997) 26-35) to promote the formation of the bivalent, bispecific antibody.
- a disulfide bridge in the CH3 domains
- said bivalent, bispecific antibody is characterized in that
- the CH3 domain of one heavy chain and the CH3 domain of the other heavy chain each meet at an interface which comprises an original interface between the antibody CH3 domains; wherein said interface is altered to promote the formation of the bivalent, bispecific antibody, wherein the alteration is characterized in that: a) the CH3 domain of one heavy chain is altered, so that within the original interface the CH3 domain of one heavy chain that meets the original interface of the CH3 domain of the other heavy chain within the bivalent, bispecific antibody, an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance within the interface of the CH3 domain of one heavy chain which is positionable in a cavity within the interface of the CH3 domain of the other heavy chain and b) the CH3 domain of the other heavy chain is altered, so that within the original interface of the second CH3 domain that meets the original interface of the first CH3 domain within the bivalent, bispecific antibody an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the
- amino acid residue having a larger side chain volume is selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y), tryptophan (W).
- amino acid residue having a smaller side chain volume is selected from the group consisting of alanine (A), serine (S), threonine (T), valine (V).
- both CH3 domains are further altered the introduction of cysteine (C) as amino acid in the corresponding positions of each CH3 domain such that a disulfide bridge between both CH3 domains can be formed.
- C cysteine
- both CH3 domains are altered by the use of residues R409D; K370E (K409D) for knobs residues and D399K; E357K for hole residues described eg. in EP 1870459A1;
- the constant heavy chain domain CH1 by which the heavy chain domain CH3 is replaced can be of any Ig class (e.g. IgA, IgD, IgE, IgG, and IgM), or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2).
- Ig class e.g. IgA, IgD, IgE, IgG, and IgM
- subclass e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2).
- the constant light chain domain CL by which the heavy chain domain CH3 is replaced can be of the lambda ( ⁇ ) or kappa ( ⁇ ) type, preferably the kappa ( ⁇ ) type.
- bivalent, bispecific antibody comprising:
- the variable domains VL and VH are replaced by each other, and wherein optionally c) the CH3 domain of one heavy chain and the CH3 domain of the other heavy chain each meet at an interface which comprises an original interface between the antibody CH3 domains; wherein said interface is altered to promote the formation of the bivalent, bispecific antibody, wherein the alteration is characterized in that: ca) the CH3 domain of one heavy chain is altered, so that within the original interface the CH3 domain of one heavy chain that meets the original interface of the CH3 domain of the other heavy chain within the bivalent, bispecific antibody, an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance within the interface of the CH3 domain of one heavy chain which is positionable in a cavity within the interface of the CH3 domain of the other heavy chain and cb) the CH3 domain
- antigen or “antigen molecule” as used herein are used interchangeable and refer to all molecules that can be specifically bound by an antibody.
- the bivalent, bispecific antibody is specifically binding to a first antigen and a second distinct antigen.
- antigens include e.g. proteins, different epitopes on proteins (as different antigens within the meaning of the invention), and polysaccharides. This mainly includes parts (coats, capsules, cell walls, flagella, fimbrae, and toxins) of bacteria, viruses, and other microorganisms. Lipids and nucleic acids are antigenic only when combined with proteins and polysaccharides.
- Non-microbial exogenous (non-self) antigens can include pollen, egg white, and proteins from transplanted tissues and organs or on the surface of transfused blood cells.
- the antigen is selected from the group consisting of cytokines, cell surface proteins, enzymes and receptors cytokines, cell surface proteins, enzymes and receptors.
- Tumor antigens are those antigens that are presented by MHC I or MHC II molecules on the surface of tumor cells. These antigens can sometimes be presented by tumor cells and never by the normal ones. In this case, they are called tumor-specific antigens (TSAs) and typically result from a tumor specific mutation. More common are antigens that are presented by tumor cells and normal cells, and they are called tumor-associated antigens (TAAs). Cytotoxic T lymphocytes that recognized these antigens may be able to destroy the tumor cells before they proliferate or metastasize. Tumor antigens can also be on the surface of the tumor in the form of, for example, a mutated receptor, in which case they will be recognized by B cells.
- At least one of the two different antigens (first and second antigen), to which the bivalent, bispecific antibody specifically binds to, is a tumor antigen.
- both of the two different antigens (first and second antigen), to which the bivalent, bispecific antibody specifically binds to are tumor antigens; in this case the first and second antigen can also be two different epitopes at the same tumor specific protein.
- one of the two different antigens (first and second antigen), to which the bivalent, bispecific antibody specifically binds to, is a tumor antigen and the other is an effector cell antigen, as e.g. an T-Cell receptor, CD3, CD16 and the like.
- one of the two different antigens (first and second antigen), to which the bivalent, bispecific antibody specifically binds to, is a tumor antigen and the other is an anti-cancer substance such as a toxin or a kinase inhibitor.
- binding affinity refers to an antibody specifically binding an antigen.
- the binding affinity of the antibody specifically binding this antigen is of KD-value of 10 ⁇ 9 mol/l or lower (e.g. 10 ⁇ 10 mol/l), preferably with a KD-value of 10 ⁇ 10 mol/l or lower (e.g. 10 ⁇ 12 mol/l).
- the binding affinity is determined with a standard binding assay, such as surface plasmon resonance technique (Biacore®).
- epitope includes any polypeptide determinant capable of specific binding to an antibody.
- epitope determinant include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl, or sulfonyl, and, in certain embodiments, may have specific three dimensional structural characteristics, and or specific charge characteristics.
- An epitope is a region of an antigen that is bound by an antibody.
- an antibody is said to specifically bind an antigen when it preferentially recognizes its target antigen in a complex mixture of proteins and/or macromolecules.
- An further embodiment of the invention is a method for the preparation of a bivalent, bispecific antibody according to the invention comprising
- vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a first antigen
- vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH are replaced by each other;
- the invention encompasses a method for the preparation of the antibodies comprising culturing the corresponding host cells under conditions that allow synthesis of said antibody molecules and recovering said antibodies from said culture, e.g. by expressing
- variable heavy chain domain VH by the variable light chain domain VL.
- vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a first antigen
- vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH are replaced by each other.
- a further embodiment of the invention is a composition, preferably a pharmaceutical or a diagnostic composition of the bivalent, bispecific antibody according to the invention.
- a further embodiment of the invention is a pharmaceutical composition
- a pharmaceutical composition comprising a bivalent, bispecific antibody according to the invention and at least one pharmaceutically acceptable excipient.
- a further embodiment of the invention is a method for the treatment of a patient in need of therapy, characterized by administering to the patient a therapeutically effective amount of a bivalent, bispecific antibody according to the invention.
- nucleic acid or nucleic acid molecule is intended to include DNA molecules and RNA molecules.
- a nucleic acid molecule may be single-stranded or double-stranded, but preferably is double-stranded DNA.
- the expressions “cell,” “cell line,” and “cell culture” are used interchangeably and all such designations include progeny.
- the words “transformants” and “transformed cells” include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Variant progeny that have the same function or biological activity as screened for in the originally transformed cell are included. Where distinct designations are intended, it will be clear from the context.
- transfection refers to process of transfer of a vectors/nucleic acid into a host cell. If cells without daunting cell wall barriers are used as host cells, transfection is carried out e.g. by the calcium phosphate precipitation method as described by Graham and Van der Eh, Virology 52 (1978) 546ff. However, other methods for introducing DNA into cells such as by nuclear injection or by protoplast fusion may also be used. If prokaryotic cells or cells which contain substantial cell wall constructions are used, e.g. one method of transfection is calcium treatment using calcium chloride as described by Cohen, F. N, et al, PNAS. 69 (1972) 7110ff.
- expression refers to the process by which a nucleic acid is transcribed into mRNA and/or to the process by which the transcribed mRNA (also referred to as transcript) is subsequently being translated into peptides, polypeptides, or proteins.
- the transcripts and the encoded polypeptides are collectively referred to as gene product. If the polynucleotide is derived from genomic DNA, expression in a eukaryotic cell may include splicing of the mRNA.
- a “vector” is a nucleic acid molecule, in particular self-replicating, which transfers an inserted nucleic acid molecule into and/or between host cells.
- the term includes vectors that function primarily for insertion of DNA or RNA into a cell (e.g., chromosomal integration), replication of vectors that function primarily for the replication of DNA or RNA, and expression vectors that function for transcription and/or translation of the DNA or RNA. Also included are vectors that provide more than one of the functions as described.
- an “expression vector” is a polynucleotide which, when introduced into an appropriate host cell, can be transcribed and translated into a polypeptide.
- An “expression system” usually refers to a suitable host cell comprised of an expression vector that can function to yield a desired expression product.
- the bivalent, bispecific antibodies according to the invention are preferably produced by recombinant means.
- Such methods are widely known in the state of the art and comprise protein expression in prokaryotic and eukaryotic cells with subsequent isolation of the antibody polypeptide and usually purification to a pharmaceutically acceptable purity.
- nucleic acids encoding light and heavy chains or fragments thereof are inserted into expression vectors by standard methods. Expression is performed in appropriate prokaryotic or eukaryotic host cells like CHO cells, NS0 cells, SP2/0 cells, HEK293 cells, COS cells, yeast, or E. coli cells, and the antibody is recovered from the cells (supernatant or cells after lysis).
- the bivalent, bispecific antibodies may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form. Purification is performed in order to eliminate other cellular components or other contaminants, e.g. other cellular nucleic acids or proteins, by standard techniques, including alkaline/SDS treatment, column chromatography and others well known in the art. See Ausubel, F., et al., ed., Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York (1987).
- NS0 cells Expression in NS0 cells is described by, e.g., Barnes, L. M., et al., Cytotechnology 32 (2000) 109-123; and Barnes, L. M., et al., Biotech. Bioeng. 73 (2001) 261-270.
- Transient expression is described by, e.g., Durocher, Y., et al., Nucl. Acids. Res. 30 (2002) E9.
- Cloning of variable domains is described by Orlandi, R., et al., Proc. Natl. Acad. Sci. USA 86 (1989) 3833-3837; Carter, P., et al., Proc. Natl. Acad. Sci.
- HEK 293 A preferred transient expression system (HEK 293) is described by Schlaeger, E.-J., and Christensen, K., in Cytotechnology 30 (1999) 71-83 and by Schlaeger, E.-J., in J. Immunol. Methods 194 (1996) 191-199.
- Nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
- DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide;
- a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or
- a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
- “operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading frame. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
- the bivalent, bispecific antibodies are suitably separated from the culture medium by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
- DNA or RNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures.
- the hybridoma cells can serve as a source of such DNA and RNA.
- the DNA may be inserted into expression vectors, which are then transfected into host cells such as HEK 293 cells, CHO cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of recombinant monoclonal antibodies in the host cells.
- Amino acid sequence variants (or mutants) of the bivalent, bispecific antibody are prepared by introducing appropriate nucleotide changes into the antibody DNA, or by nucleotide synthesis. Such modifications can be performed, however, only in a very limited range, e.g. as described above. For example, the modifications do not alter the above mentioned antibody characteristics such as the IgG isotype and antigen binding, but may improve the yield of the recombinant production, protein stability or facilitate the purification.
- SEQ ID NO: 3 amino acid sequence of the heavy chain*** (HC***) of ⁇ IGF-1R> VL-VH exchange antibody, wherein the heavy chain domain VH is replaced by the light chain domain VL—variant A.
- SEQ ID NO: 4 amino acid sequence of the light chain*** (LC***) of ⁇ IGF-1R> VL-VH exchange antibody, wherein the light chain domain VL is replaced by the heavy chain domain VH—variant A.
- SEQ ID NO: 10 amino acid sequence of the heavy chain*** (HC***) of ⁇ IGF-1R> VL-VH exchange antibody, wherein the heavy chain domain VH is replaced by the light chain domain VL—variant B.
- FIG. 1 Schematic figure of IgG, a naturally occurring whole antibody specific for one antigen with two pairs of heavy and light chain which comprise variable and constant domains in a typical order.
- FIG. 2 Schematic figure of a bivalent, bispecific antibody, comprising: a) the light chain and heavy chain of an antibody specifically binding to a first antigen; and b) the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH are replaced by each other.
- FIG. 3 Schematic figure of a bivalent, bispecific antibody, comprising: a) the light chain and heavy chain of an antibody specifically binding to a first antigen; and b) the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH are replaced by each other, and wherein the CH3 domains of both heavy chains are altered by the knobs-into-holes technology.
- FIG. 4 Schematic figure of a bivalent, bispecific antibody, comprising: a) the light chain and heavy chain of an antibody specifically binding to a first antigen; and b) the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH are replaced by each other, and wherein one of the constant heavy chain domains CH3 of both heavy chains is replaced by a constant heavy chain domain CH1; and the other constant heavy chain domain CH3 is replaced by a constant light chain domain CL.
- FIG. 5 Protein sequence scheme of the heavy chain*** ⁇ IGF-1R> HC*** of the ⁇ IGF-1R> VL-VH exchange antibody
- FIG. 7 Plasmid map of heavy chain*** ⁇ IGF-1R> HC*** expression vector pUC-HC***-IGF-1R
- FIG. 8 Plasmid map of light chain*** ⁇ IGF-1R> LC*** expression vector pUC-LC***-IGF-1R
- FIG. 9 Plasmid map of the 4700-Hyg-OriP expression vector
- FIG. 10 Assay principle of cellular FACS IGF-1R-ANGPT2 bridging assay on I24 IGF-1R expressing cells to detect the presence of functional bispecific ⁇ ANGPT2-IGF-1R> VL-VH exchange antibody
- FIG. 11 Scheme IGF-1 R ECD Biacore
- FIG. 12 SDS-PAGE and size exclusion chromatography of purified monospecific, bivalent ⁇ IGF-1R> VL-VH exchange antibody (IgG1***) with HC*** and LC*** isolated from cell culture supernatants after transient transfection of HEK293-F cells.
- FIG. 13 Binding of monospecific ⁇ IGF-1R> VL-VH exchange antibody and wildtype ⁇ IGF-1R> antibody to the IGF-1R ECD in an ELISA-based binding assay.
- FIG. 14 SDS-PAGE of ⁇ ANGPT2-IGF-1R> VL-VH exchange antibody mix purified from cell culture supernatants from transiently transfected HEK293-F cells.
- FIG. 15 Results for Samples A to F of cellular FACS IGF-1R-ANGPT2 bridging assay on I24 IGF-1R expressing cells to detect the presence of functional bispecific ⁇ ANGPT2-IGF-1R> VL-VH exchange antibody in purified antibody mix.
- F I24+2 ⁇ g/mL hANGPT2+ ⁇ IGF-1R> wildtype antibody
- Desired gene segments were prepared from oligonucleotides made by chemical synthesis.
- the 600-1800 bp long gene segments, which are flanked by singular restriction endonuclease cleavage sites, were assembled by annealing and ligation of oligonucleotides including PCR amplification and subsequently cloned via the indicated restriction sites e.g. KpnI/SacI or AscI/PacI into a pPCRScript (Stratagene) based pGA4 cloning vector.
- the DNA sequences of the subcloned gene fragments were confirmed by DNA sequencing. Gene synthesis fragments were ordered according to given specifications at Geneart (Regensburg, Germany).
- DNA sequences were determined by double strand sequencing performed at MediGenomix GmbH (Martinsried, Germany) or Sequiserve GmbH (Vaterstetten, Germany).
- variants of expression plasmids for transient expression e.g. in HEK293 EBNA or HEK293-F
- cells based either on a cDNA organization with a CMV-Intron A promoter or on a genomic organization with a CMV promoter were applied.
- the transcription unit of the antibody gene is composed of the following elements:
- the human antibody chain (wildtype or with domain exchange) either as cDNA or as genomic organization with an the immunoglobulin exon-intron organization
- the fusion genes comprising the described antibody chains as described below were generated by PCR and/or gene synthesis and assembled with known recombinant methods and techniques by connection of the according nucleic acid segments e.g. using unique restriction sites in the respective vectors. The subcloned nucleic acid sequences were verified by DNA sequencing. For transient transfections larger quantities of the plasmids were prepared by plasmid preparation from transformed E. coli cultures (Nucleobond AX, Macherey-Nagel).
- Bispecific antibodies were expressed by transient co-transfection of the respective expression plasmids in adherently growing HEK293-EBNA or in HEK29-F cells growing in suspension as described below.
- Bispecific antibodies were expressed by transient co-transfection of the respective expression plasmids (e.g. encoding the heavy and modified heavy chain, as well as the corresponding light and modified light chain) in adherently growing HEK293-EBNA cells (human embryonic kidney cell line 293 expressing Epstein-Barr-Virus nuclear antigen; American type culture collection deposit number ATCC # CRL-10852, Lot. 959 218) cultivated in DMEM (Dulbecco's modified Eagle's medium, Gibco) supplemented with 10% Ultra Low IgG FCS (fetal calf serum, Gibco), 2 mM L-Glutamine (Gibco), and 250 ⁇ g/ml Geneticin (Gibco).
- DMEM Dulbecco's modified Eagle's medium, Gibco
- Ultra Low IgG FCS fetal calf serum, Gibco
- 2 mM L-Glutamine Gibco
- 250 ⁇ g/ml Geneticin Gabco
- FuGENETM 6 Transfection Reagent (Roche Molecular Biochemicals) was used in a ratio of FuGENETM reagent ( ⁇ l) to DNA ( ⁇ g) of 4:1 (ranging from 3:1 to 6:1). Proteins were expressed from the respective plasmids using a molar ratio of (modified and wildtype) light chain and heavy chain encoding plasmids of 1:1 (equimolar) ranging from 1:2 to 2:1, respectively. Cells were feeded at day 3 with L-Glutamine ad 4 mM, Glucose [Sigma] and NAA [Gibco]. Bispecific antibody containing cell culture supernatants were harvested from day 5 to 11 after transfection by centrifugation and stored at ⁇ 20° C.
- Bispecific antibodies were generated by transient transfection of the respective plasmids (e.g. encoding the heavy and modified heavy chain, as well as the corresponding light and modified light chain) using the HEK293-F system (Invitrogen) according to the manufacturer's instruction. Briefly, HEK293-F cells (Invitrogen) growing in suspension either in a shake flask or in a stirred fermenter in serumfree FreeStyle 293 expression medium (Invitrogen) were transfected with a mix of the four expression plasmids and 293fectin or fectin (Invitrogen).
- HEK293-F cells Invitrogen growing in suspension either in a shake flask or in a stirred fermenter in serumfree FreeStyle 293 expression medium (Invitrogen) were transfected with a mix of the four expression plasmids and 293fectin or fectin (Invitrogen).
- HEK293-F cells were seeded at a density of 1.0E*6 cells/mL in 600 mL and incubated at 120 rpm, 8% CO2. The day after the cells were transfected at a cell density of ca. 1.5E*6 cells/mL with ca. 42 mL mix of A) 20 mL Opti-MEM (Invitrogen) with 600 ⁇ g total plasmid DNA (1 ⁇ g/mL) encoding the heavy or modified heavy chain, respectively and the corresponding light chain in an equimolar ratio and B) 20 ml Opti-MEM+1.2 mL 293 fectin or fectin (2 ⁇ l/mL). According to the glucose consumption glucose solution was added during the course of the fermentation. The supernatant containing the secreted antibody was harvested after 5-10 days and antibodies were either directly purified from the supernatant or the supernatant was frozen and stored.
- the protein concentration of purified antibodies and derivatives was determined by determining the optical density (OD) at 280 nm, using the molar extinction coefficient calculated on the basis of the amino acid sequence according to Pace et al., Protein Science, 1995, 4, 2411-1423.
- the concentration of antibodies and derivatives in cell culture supernatants was estimated by immunoprecipitation with Protein A Agarose-beads (Roche). 60 ⁇ L Protein A Agarose beads are washed three times in TBS-NP40 (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Nonidet-P40). Subsequently, 1-15 mL cell culture supernatant were applied to the Protein A Agarose beads pre-equilibrated in TBS-NP40.
- the concentration of antibodies and derivatives in cell culture supernatants was quantitatively measured by affinity HPLC chromatography. Briefly, cell culture supernatants containing antibodies and derivatives that bind to Protein A were applied to an Applied Biosystems Poros A/20 column in 200 mM KH2PO4, 100 mM sodium citrate, pH 7.4 and eluted from the matrix with 200 mM NaCl, 100 mM citric acid, pH 2.5 on an Agilent HPLC 1100 system. The eluted protein was quantified by UV absorbance and integration of peak areas. A purified standard IgG1 antibody served as a standard.
- the concentration of antibodies and derivatives in cell culture supernatants was measured by Sandwich-IgG-ELISA. Briefly, StreptaWell High Bind Strepatavidin A-96 well microtiter plates (Roche) were coated with 100 ⁇ L/well biotinylated anti-human IgG capture molecule F(ab′)2 ⁇ h-Fc ⁇ > BI (Dianova) at 0.1 ⁇ g/mL for 1 h at room temperature or alternatively over night at 4° C. and subsequently washed three times with 200 ⁇ L/well PBS, 0.05% Tween (PBST, Sigma).
- PBST 0.05% Tween
- Proteins were purified from filtered cell culture supernatants referring to standard protocols. In brief, antibodies were applied to a Protein A Sepharose column (GE healthcare) and washed with PBS. Elution of antibodies was achieved at pH 2.8 followed by immediate neutralization of the sample. Aggregated protein was separated from monomeric antibodies by size exclusion chromatography (Superdex 200, GE Healthcare) in PBS or in 20 mM Histidine, 150 mM NaCl pH 6.0. Monomeric antibody fractions were pooled, concentrated if required using e.g. a MILLIPORE Amicon Ultra (30 MWCO) centrifugal concentrator, frozen and stored at ⁇ 20° C. or ⁇ 80° C. Part of the samples were provided for subsequent protein analytics and analytical characterization e.g. by SDS-PAGE, size exclusion chromatography or mass spectrometry.
- the NuPAGE® Pre-Cast gel system (Invitrogen) was used according to the manufacturer's instruction. In particular, 10% or 4-12% NuPAGE® Novex® Bis-TRIS Pre-Cast gels (pH 6.4) and a NuPAGE® MES (reduced gels, with NuPAGE® Antioxidant running buffer additive) or MOPS (non-reduced gels) running buffer was used.
- Size exclusion chromatography for the determination of the aggregation and oligomeric state of antibodies was performed by HPLC chromatography. Briefly, Protein A purified antibodies were applied to a Tosoh TSKgel G3000SW column in 300 mM NaCl, 50 mM KH2PO4/K2HPO4, pH 7.5 on an Agilent HPLC 1100 system or to a Superdex 200 column (GE Healthcare) in 2 ⁇ PBS on a Dionex HPLC-System. The eluted protein was quantified by UV absorbance and integration of peak areas. BioRad Gel Filtration Standard 151-1901 served as a standard.
- the total deglycosylated mass of crossover antibodies was determined and confirmed via electrospray ionization mass spectrometry (ESI-MS). Briefly, 100 ⁇ g purified antibodies were deglycosylated with 50 mU N-Glycosidase F (PNGaseF, ProZyme) in 100 mM KH2PO4/K2HPO4, pH 7 at 37° C. for 12-24 h at a protein concentration of up to 2 mg/ml and subsequently desalted via HPLC on a Sephadex G25 column (GE Healthcare). The mass of the respective heavy and light chains was determined by ESI-MS after deglycosylation and reduction.
- PNGaseF N-Glycosidase F
- the binding properties of the generated antibodies were evaluated in an ELISA assay with the IGF-1R extracellular domain (ECD).
- ECD IGF-1R extracellular domain
- IGF-1R extracellular domain
- the extracellular domain of IGF-1R comprising the natural leader sequence and the LI-cysteine rich-12 domains of the human IGF-IR ectodomain of the alpha chain (according to the McKern et al., 1997; Ward et al., 2001) fused to an N-terminal His-Streptavidin binding peptide-tag (His-SBP) was cloned into a pcDNA3 vector derivative and transiently expressed in HEK293F cells.
- the protein sequence of the IGF-1R-His-SBP ECD is given in SEQ ID NO: 12. StreptaWell High Bind Strepatavidin A-96 well microtiter plates (Roche) were coated with 100 ⁇ L/well cell culture supernatant containing soluble IGF-1R-ECD-SBP fusion protein over night at 4° C. and washed three times with 200 ⁇ L/well PBS, 0.05% Tween (PBST, Sigma).
- Unbound detection antibody was washed away three times with 200 ⁇ L/well PBST and the bound detection antibody was detected by addition of 100 ⁇ L ABTS/well. Determination of absorbance was performed on a Tecan Fluor Spectrometer at a measurement wavelength of 405 nm (reference wavelength 492 nm).
- Binding of the generated antibodies to human IGF-1R ECD was also investigated by surface plasmon resonance using a BIACORE T100 instrument (GE Healthcare Biosciences AB, Uppsala, Sweden). Briefly, for affinity measurements Goat-Anti-Human IgG, JIR 109-005-098 antibodies were immobilized on a CM5 chip via amine coupling for presentation of the antibodies against human IGF-1R ECD-Fc tagged. Binding was measured in HBS buffer (HBS-P (10 mM HEPES, 150 mM NaCl, 0.005% Tween 20, ph 7.4), 25° C. IGF-1RECD (R&D Systems or in house purified) was added in various concentrations in solution.
- HBS buffer HBS-P (10 mM HEPES, 150 mM NaCl, 0.005% Tween 20, ph 7.4
- IGF-1RECD R&D Systems or in house purified
- sequences for the heavy and light chain variable domains of the monospecific, bivalent ⁇ IGF-1R> VL-VH exchange antibody including the respective leader sequences described in this example are derived from a human ⁇ IGF-1R> antibody heavy chain (SEQ ID NO: 1, plasmid 4843-pUC-HC-IGF-1R) and a light chain (SEQ ID NO: 2, plasmid 4842-pUC-LC-IGF-1R) described in WO 2005/005635, and the heavy and light chain constant domains are derived from a human antibody (C-kappa and IgG1).
- the gene segments encoding the ⁇ IGF-1R> antibody leader sequence, light chain variable domain (VL) and the human heavy chain constant domain 1 (CH1) were joined and fused to the 5′-end of the Fc domains of the human ⁇ 1-heavy chain constant domains (Hinge-CH2-CH3).
- the DNA coding for the respective fusion protein resulting from the exchange of the VH domain by the VL domain (VH-VL exchange) was generated by gene synthesis and is denoted ⁇ IGF-1R> HC*** (SEQ ID NO: 10) in the following.
- VL-CH1 domains were fused with a slightly different sequence (SEQ ID NO: 3); due to the reduced expression yields of this connection, SEQ10 that shows expression yields comparable to wildtype antibodies, was chosen.
- the gene segments for the ⁇ IGF-1R> antibody leader sequence, heavy chain variable domain (VH) and the human light chain constant domain (CL) were joined as independent chain.
- the DNA coding for the respective fusion protein resulting from the exchange of the VL domain by the VH domain (VL-VH exchange) was generated by gene synthesis and is denoted ⁇ IGF-1R> LC*** (Heavy Chain***) (SEQ ID NO: 11) in the following.
- the VH-CL domains were fused with a slightly different sequence (SEQ ID NO: 4); due to the reduced expression yields of this connection, SEQ ID NO: 11 that shows expression yields comparable to wildtype antibodies was chosen.
- FIG. 5 and FIG. 6 show a schematic view of the protein sequence of the modified ⁇ IGF-1R> HC*** heavy chain and the modified ⁇ IGF-1R> LC*** light chain.
- Vector pUC-HC***-IGF-1R is an expression plasmid e.g. for transient expression of a VL-VH exchange ⁇ IGF-1R> heavy chain HC*** (cDNA organized expression cassette; with CMV-Intron A) in HEK293 (EBNA) cells or for stable expression in CHO cells.
- VL-VH exchange ⁇ IGF-1R> heavy chain HC*** (cDNA organized expression cassette; with CMV-Intron A) in HEK293 (EBNA) cells or for stable expression in CHO cells.
- this vector contains:
- the transcription unit of the ⁇ IGF-1R> HC*** gene is composed of the following elements:
- the plasmid map of the heavy chain*** VL-VH exchange ⁇ IGF-1R> HC*** expression vector pUC-HC***-IGF-1R is shown in FIG. 7 .
- the amino acid sequence of the ⁇ IGF-1R> HC*** (including signal sequence) is given in SEQ ID NO: 10.
- Vector pUC-LC***-IGF-1R is an expression plasmid e.g. for transient expression of a VL-VH exchange ⁇ IGF-1R> light chain LC*** (cDNA organized expression cassette; with CMV-Intron A) in HEK293 (EBNA) cells or for stable expression in CHO cells.
- this vector contains:
- the transcription unit of the ⁇ IGF-1R> LC*** gene is composed of the following elements:
- the plasmid map of the light chain*** VL-VH exchange ⁇ IGF-1R> LC*** expression vector pUC-LC***-IGF-1R is shown in FIG. 8 .
- the amino acid sequence of the ⁇ IGF-1R> LC*** (including signal sequence) is given in SEQ ID NO: 11.
- Plasmids pUC-HC**-IGF-1Rand pUC-LC***-IGF-1R can be used for transient or stable co-transfections e.g. into HEK293, HEK293 EBNA or CHO cells (2-vector system).
- the wildtype ⁇ IGF-1R> antibody was transiently expressed from plasmids 4842-pUC-LC-IGF-1R (SEQ ID NO: 2) and 4843-pUC-HC-IGF-1R (SEQ ID NO: 1) analogous to the ones described in this example.
- the ⁇ IGF-1R> HC*** expression cassette can be sub-cloned via AscI, SgrAI sites and the ⁇ IGF-1R> LC*** expression cassette can be sub-cloned via Sse83871 and FseI sites into the 4700 pUC-Hyg_OriP expression vector containing
- hygromycine resistance gene as a selectable marker.
- Heavy and light chain transcription units can either be sub-cloned into two independent 4700-pUC-Hyg-OriP vectors for co-transfection (2-vector system) or they can be cloned into one common 4700-pUC-Hyg-OriP vector (1-vector system) for subsequent transient or stable transfections with the resulting vectors.
- FIG. 9 shows a plasmid map of the basic vector 4700-pUC-OriP.
- ⁇ IGF-1R> fusion genes (HC*** and LC*** fusion genes) comprising the exchanged Fab sequences of the wildtype ⁇ IGF-1R> antibody were assembled with known recombinant methods and techniques by connection of the according nucleic acid segments.
- the nucleic acid sequences encoding the IGF-1R HC*** and LC*** were each synthesized by chemical synthesis and subsequently cloned into a pPCRScript (Stratagene) based pGA4 cloning vector at Geneart (Regensburg, Germany).
- the expression cassette encoding the IGF-1R HC*** was ligated into the respective E. coli plasmid via PvuII and BmgBI restriction sites resulting in the final vector pUC-HC***-IGF-1R; the expression cassette encoding the respective IGF-1R LC*** was ligated into the respective E. coli plasmid via PvuII and SalI restriction sites resulting in the final vector pUC-LC***-IGF-1R.
- Recombinant ⁇ IGF-1R> VL-VH exchange antibody was expressed by transient co-transfection of plasmids pUC-HC***-IGF-1Rand pUC-LC***-IGF-1R in HEK293-F suspension cells as described above.
- the expressed and secreted monospecific, bivalent ⁇ IGF-1R> VL-VH exchange antibody was purified from filtered cell culture supernatants by Protein A affinity chromatography according as described above.
- the ⁇ IGF-1R> VL-VH exchange antibody containing cell culture supernatants from transient transfections were clarified by centrifugation and filtration and applied to a Protein A HiTrap MabSelect Xtra column (GE Healthcare) equilibrated with PBS buffer (10 mM Na2HPO4, 1 mM KH2PO4, 137 mM NaCl and 2.7 mM KCl, pH 7.4).
- Unbound proteins were washed out with PBS equilibration buffer followed by 0.1 M sodium citrate buffer, pH 5.5 and washed with PBS. Elution of antibody was achieved with 100 mM sodium citrate, pH 2.8 followed by immediate neutralization of the sample with 300 ⁇ l 2 M Tris pH 9.0 per 2 ml fraction. Aggregated protein was separated from monomeric antibodies by size exclusion chromatography on a HiLoad 26/60 Superdex 200 prep grade column (GE Healthcare) in 20 mM Histidine, 150 mM NaCl pH 6.0 and monomeric antibody fractions were subsequently concentrated using a MILLIPORE Amicon Ultra-15 centrifugal concentrator.
- ⁇ IGF-1R> VL-VH exchange antibody was frozen and stored at ⁇ 20° C. or ⁇ 80° C.
- the integrity of the ⁇ IGF-1R> VL-VH exchange antibody was analyzed by SDS-PAGE in the presence and absence of a reducing agent and subsequent staining with Coomassie brilliant blue as described above.
- Monomeric state of the ⁇ IGF-1R> VL-VH exchange antibody was confirmed by analytical size exclusion chromatography. ( FIG. 12 ) Characterized samples were provided for subsequent protein analytics and functional characterization. ESI mass spectrometry confirmed the theoretical molecular mass of the completely deglycosylated ⁇ IGF-1R> VL-VH exchange antibody.
- the binding properties of monospecific, bivalent ⁇ IGF-1R> VL-VH exchange antibody were evaluated in an ELISA assay with the IGF-1R extracellular domain (ECD) as descried above.
- ECD IGF-1R extracellular domain
- IGF-1R extracellular domain
- the extracellular domain of IGF-1R comprising the natural leader sequence and the LI-cysteine rich-12 domains of the human IGF-1R ectodomain of the alpha chain (according to the McKern et al., 1997; Ward et al., 2001) fused to an N-terminal His-Streptavidin binding peptide-tag (His-SBP) was cloned into a pcDNA3 vector derivative and transiently expressed in HEK293F cells.
- the protein sequence of the IGF-1R-His-SBP ECD is given in see above.
- the obtained titration curve showed that ⁇ IGF-1R> VL-VH exchange antibody was functional and showed comparable binding characteristics and kinetics as the wildtype ⁇ IGF-1R> antibody within the error of the method and thus appeared fully functional ( FIG. 13 ).
- VL-VH exchange antibody In order to confirm the binding activity of ⁇ IGF-1R> VL-VH exchange antibody to the IGF-1R over-expressed on the surface of I24 cells (NIH3T3 cells expressing recombinant human IGF-1R, Roche) is studied by FACS. Briefly, 5 ⁇ 10E5 I24 cells per FACS tube are incubated with a dilution of purified ⁇ IGF-1R> VL-VH exchange antibody and wildtype ⁇ IGF-1R> antibody as a reference and incubated on ice for 1 h. Unbound antibody is washed away with 4 ml ice cold PBS (Gibco)+2% FCS (Gibco).
- sequences for the heavy and light chain variable domains of a monospecific, bivalent ANGPT2 ⁇ ANGPT2> wildtype antibody including the respective leader sequences described in this example are derived from a human ⁇ ANGPT2> antibody heavy chain (SEQ ID NO: 6) and a light chain (SEQ ID NO: 7) described in WO 2006/045049 and the heavy and light chain constant domains are derived from a human antibody (C-kappa and IgG1).
- the wildtype ⁇ ANGPT2> antibody was cloned into plasmids SB04-pUC-HC-ANGPT2 (SEQ ID NO: 6) and SB06-pUC-LC-ANGPT2 (SEQ ID NO: 7) that are analogous to the vectors described in the previous example 1A.
- the wildtype ⁇ ANGPT2> antibody was transiently (co-) expressed from plasmids SB04-pUC-HC-ANGPT2 and SB06-pUC-LC-ANGPT2.
- the nucleic acid sequences encoding the ANGPT2> HC and LC were each synthesized by chemical synthesis and subsequently cloned into a pPCRScript (Stratagene) based pGA4 cloning vector at Geneart (Regensburg, Germany).
- the expression cassette encoding the ⁇ ANGPT2> HC was cloned into the respective E. coli plasmid resulting in the final vector SB04-pUC-HC-ANGPT2; the expression cassette encoding the respective ⁇ ANGPT2> LC was cloned into the respective E. coli plasmid resulting in the final vector SBO6-pUC-LC-ANGPT2.
- the subcloned nucleic acid sequences were verified by DNA sequencing. For transient and stable transfections larger quantities of the plasmids were prepared by plasmid preparation from transformed E. coli cultures (Nucleobond AX, Macherey-Nagel).
- ⁇ ANGPT2> wildtype antibody showed higher expression transient expression yields than the ⁇ IGF-1R> wildtype and ⁇ IGF-1R> VL-VH exchange antibodies the ratio of ⁇ ANGPT2> wildtype antibody plasmids and ⁇ IGF-1R> VL-VH exchange antibody plasmids was shifted in favour of the expression of ⁇ ANGPT2> wildtype antibody.
- the integrity of the antibody mix was analyzed by SDS-PAGE in the presence and absence of a reducing agent and subsequent staining with Coomassie brilliant blue and by size exclusion chromatography as described.
- the SDS-PAGE showed that there were 2 different heavy and light chain presents in the preparation as expected (reduced gel) ( FIG. 14 ). Characterized samples were provided for subsequent protein analytics and functional characterization.
- a bispecific ⁇ ANGPT2-IGF-1R> VL-VH exchange antibody that is present in the purified antibody mix is capable of binding to IGF-1R in I24 cells and to ANGPT2 simultaneously; and thus will bridge its two target antigens with the two opposed Fab regions.
- ANGPT2 was washed away once or twice with 4 ml ice cold PBS (Gibco)+2% FCS (Gibco), cells were centrifuged (5 min at 400 g) and bound ANGPT2 was detected with 50 ⁇ l 5 ⁇ g/mL ⁇ ANGPT2> mIgG1-Biotin antibody (BAM0981, R&D Systems) for 45 min on ice; alternatively, cells were incubated with 50 ⁇ l 5 ⁇ g/mL mIgG1-Biotin-Isotype control (R&D Systems).
- Unbound detection antibody was washed away with 4 ml ice cold PBS (Gibco)+2% FCS (Gibco), cells were centrifuged (5 min at 400 g) and bound detection antibody was detected with 50 ⁇ l 1:400 Streptavidin-PE conjugate (Invitrogen/Zymed) for 45 min on ice protected from light. Unbound Streptavidin-PE conjugate was washed away with 4 ml ice cold PBS+2% FCS. Subsequently, cells were centrifuged (5 min 400 g), resuspended in 300-500 ⁇ L PBS and bound Streptavidin-PE conjugate was quantified on a FACSCalibur (BD (FL2 channel, 10.000 cells per acquisition). During the experiment the respective isotype controls were included to exclude any unspecific binding events. In addition, purified monospecific, bivalent IgG1 antibodies ⁇ IGF-1R> and ⁇ ANGPT2> were included as controls.
- FIG. 15 show that the incubation with purified antibody crossover mix ( ⁇ ANGPT2-IGF-1R> VL-VH exchange antibody) from the co-expression of a crossover antibody ( ⁇ IGF-1R> VL-VH exchange antibody) with a wildtype antibody ( ⁇ ANGPT2> wildtype antibody) resulted in a significant shift in fluorescence indicating the presence of a functional bispecific ⁇ ANGPT2-IGF-1R> VL-VH exchange antibody that was capable of binding to IGF-1R in I24 cells and to ANGPT2 simultaneously; and thus bridges its two target antigens with the two opposed Fab regions.
- the respective ⁇ IGF-1R> and ⁇ Ang-2> control antibodies did not result in shift in fluorescence in the FACS bridging assay
- knobs-into-holes technology is applied to the co-expression of ⁇ IGF-1R> VL-VH exchange and wildtype ⁇ ANGPT2> antibodies to obtain a homogenous and functional bispecific antibody preparation.
- the CH3 domain in the heavy chain* HC* of the ⁇ IGF-1R> VL-VH exchange antibody is replaced by the CH3 domain (Knobs) of the SEQ ID NO: 8 with a T366W exchange and the CH3 domain in the heavy chain of the wildtype ⁇ ANGPT2> antibody is replaced by the CH3 domain (Hole) of the SEQ ID NO: 9 with a T366S, L368A, Y407V exchange or vice versa.
- a disulfide can be included to increase the stability and yields as well as additional residues forming ionic bridges and increasing the heterodimerization yields (EP 1870459A1).
- an optimization of heterodimerization can be achieved e.g. by using different knobs-in-holes technologies such as the introduction of an additional disulfide bridge into the CH3 domain e.g. Y349C into the “knobs chain” and D356C into the “hole chain” and/or combined with the use of residues R409D; K370E (K409D) for knobs residues and D399K; E357K for hole residues described by EP 1870459A1.
Abstract
The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use.
Description
- This application claims the benefit of European Patent Application No. 07024864.6, filed Dec. 21, 2007, which is hereby incorporated by reference in its entirety.
- The present invention relates to novel bivalent, bispecific antibodies, their manufacture and use.
- Engineered proteins, such as bi- or multispecific antibodies capable of binding two or more antigens are known in the art. Such multispecific binding proteins can be generated using cell fusion, chemical conjugation, or recombinant DNA techniques.
- A wide variety of recombinant bispecific antibody formats have been developed in the recent past, e.g. tetravalent bispecific antibodies by fusion of, e.g. an IgG antibody format and single chain domains (see e.g. Morrison, S. L., et al, Nature Biotech 15 (1997) 159-163; WO2001077342; and Coloma, M. J., Nature Biotech 25 (2007) 1233-1234).
- Also several other new formats wherein the antibody core structure (IgA, IgD, IgE, IgG or IgM) is no longer retained such as dia-, tria- or tetrabodies, minibodies, several single chain formats (scFv, Bis-scFv), which are capable of binding two or more antigens, have been developed (Holliger P, et al, Nature Biotech 23 (2005) 1126-1136 2005; Fischer N., Léger O., Pathobiology 74 (2007) 3-14; Shen J. et al, Journal of Immunological Methods 318 (2007) 65-74; Wu, C. et al Nature Biotech 25 (2007) 1290-1297).
- All such formats use linkers either to fuse the antibody core (IgA, IgD, IgE, IgG or IgM) to a further binding protein (e.g. scFv) or to fuse e.g. two Fab fragments or scFv. (Fischer N., Leger O., Pathobiology 74 (2007) 3-14). While it is obvious that linkers have advantages for the engineering of bispecific antibodies, they may also cause problems in therapeutic settings. Indeed, these foreign peptides might elicit an immune response against the linker itself or the junction between the protein and the linker. Further more, the flexible nature of these peptides makes them more prone to proteolytic cleavage, potentially leading to poor antibody stability, aggregation and increased immunogenicity. In addition one may want to retain effector functions, such as e.g. complement-dependent cytotoxicity (CDC) or antibody dependent cellular cytotoxicity (ADCC), which are mediated through the Fcpart, by maintaining a high degree of similarity to naturally occurring antibodies.
- Thus ideally, one should aim at developing bispecific antibodies that are very similar in general structure to naturally occurring antibodies (like IgA, IgD, IgE, IgG or IgM) with minimal deviation from human sequences.
- In one approach bispecific antibodies that are very similar to natural antibodies have been produced using the quadroma technology (see Milstein, C. and A. C. Cuello, Nature, 305 (1983) 537-40) based on the somatic fusion of two different hybridoma cell lines expressing murine monoclonal antibodies with the desired specificities of the bispecific antibody. Because of the random pairing of two different antibody heavy and light chains within the resulting hybrid-hybridoma (or quadroma) cell line, up to ten different antibody species are generated of which only one is the desired, functional bispecific antibody. Due to the presence of mispaired byproducts, and significantly reduced production yields, means sophisticated purification procedures are required (see e.g. Morrison, S. L., Nature Biotech 25 (2007) 1233-1234). In general the same problem of mispaired byproducts remains if recombinant expression techniques are used.
- An approach to circumvent the problem of mispaired byproducts, which is known as ‘knobs-into-holes’, aims at forcing the pairing of two different antibody heavy chains by introducing mutations into the CH3 domains to modify the contact interface. On one chain bulky amino acids were replaced by amino acids with short side chains to create a ‘hole’. Conversely, amino acids with large side chains were introduced into the other CH3 domain, to create a ‘knob’. By coexpressing these two heavy chains (and two identical light chains, which have to be appropriate for both heavy chains), high yields of heterodimer formation (‘knob-hole’) versus homodimer formation (‘hole-hole’ or ‘knob-knob’) was observed (Ridgway J B, Presta L G, Carter P; and WO1996027011). The percentage of heterodimer could be further increased by remodeling the interaction surfaces of the two CH3 domains using a phage display approach and the introduction of a disulfide bridge to stabilize the heterodimers (Merchant A. M, et al, Nature Biotech 16 (1998) 677-681; Atwell S, Ridgway J B, Wells J A, Carter P., J Mol Biol 270 (1997) 26-35). New approaches for the knobs-into-holes technology are described in e.g. in EP 1870459A1. Although this format appears very attractive, no data describing progression towards the clinic are currently available. One important constraint of this strategy is that the light chains of the two parent antibodies have to be identical to prevent mispairing and formation of inactive molecules. Thus this technique is not appropriate for easily developing recombinant, bivalent, bispecific antibodies against two antigens starting from two antibodies against the first and the second antigen, as either the heavy chains of these antibodies an/or the identical light chains have to be optimized.
- Xie, Z., et al, J Immunol Methods 286 (2005) 95-101 refers to a new format of bispecific antibody using scFvs in combination with knobs-into-holes technology for the FC part.
- The invention relates to a bivalent, bispecific antibody, comprising:
- a) the light chain and heavy chain of an antibody specifically binding to a first antigen; and
b) the light chain and heavy chain of an antibody specifically binding to a second antigen,
wherein the variable domains VL and VH from the antibody specifically binding to a second antigen are replaced by each other. - A further embodiment of the invention is a method for the preparation of an a bivalent, bispecific antibody according to the invention comprising the steps of
- a) transforming a host cell with
- vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a first antigen
- vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH from the antibody specifically binding to a second antigen are replaced by each other;
- b) culturing the host cell under conditions that allow synthesis of said antibody molecule; and
c) recovering said antibody molecule from said culture.
A further embodiment of the invention is a host cell comprising - vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a first antigen
- vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH are replaced by each other.
- A further embodiment of the invention is a composition, preferably a pharmaceutical or a diagnostic composition of the antibody according to the invention.
- A further embodiment of the invention is a pharmaceutical composition comprising an antibody according to the invention and at least one pharmaceutically acceptable excipient.
- A further embodiment of the invention is a method for the treatment of a patient in need of therapy, characterized by administering to the patient a therapeutically effective amount of an antibody according to the invention.
- The invention relates to a bivalent, bispecific antibody, comprising:
- a) the light chain and heavy chain of an antibody specifically binding to a first antigen; and
b) the light chain and heavy chain of an antibody specifically binding to a second antigen,
wherein the variable domains VL and VH from the antibody specifically binding to a second antigen are replaced by each other. - Therefore said bivalent, bispecific antibody, comprises:
- a) a first light chain and a first heavy chain of an antibody specifically binding to a first antigen; and
b) a second light chain and a second heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH of the second light chain and the second heavy chain are replaced by each other. - Thus for said antibody specifically binding to a second antigen the following applies: within the light chain
- the variable light chain domain VL is replaced by the variable heavy chain domain VH of said antibody;
and within the heavy chain the variable heavy chain domain VH is replaced by the variable light chain domain VL of said antibody. - The term “antibody” as used herein refers to whole, monoclonal antibodies. Such whole antibodies consist of two pairs of a “light chain” (LC) and a “heavy chain” (HC) (such light chain (LC)/heavy chain pairs are abbreviated herein as LC/HC). The light chains and heavy chains of such antibodies are polypeptides consisting of several domains. In a whole antibody, each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVRor VH) and a heavy chain constant region. The heavy chain constant region comprises the heavy chain constant domains CH1, CH2 and CH3 (antibody classes IgA, IgD, and IgG) and optionally the heavy chain constant domain CH4 (antibody classes IgE and IgM). Each light chain comprises a light chain variable domain VL and a light chain constant domain CL. The structure of one naturally occurring whole antibody, the IgG antibody, is shown e.g. in
FIG. 1 . The variable domains VH and VL can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 ((Janeway C A, Jr et al (2001). Immunobiology., 5th ed., Garland Publishing; and Woof J. Burton D Nat Rev Immunol 4 (2004) 89-99). The two pairs of heavy chain and light chain (HC/LC) are capable of specifically binding to same antigen. Thus said whole antibody is a bivalent, monospecific antibody. Such “antibodies” include e.g. mouse antibodies, human antibodies, chimeric antibodies, humanized antibodies and genetically engineered antibodies (variant or mutant antibodies) as long as their characteristic properties are retained. Especially preferred are human or humanized antibodies, especially as recombinant human or humanized antibodies. - There are five types of mammalian antibody heavy chains denoted by the Greek letters: α, δ, ε, γ, and μ (Janeway C A, Jr et al (2001). Immunobiology., 5th ed., Garland Publishing). The type of heavy chain present defines the class of antibody; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively (Rhoades R A, Pflanzer R G (2002). Human Physiology, 4th ed., Thomson Learning). Distinct heavy chains differ in size and composition; α and γ contain approximately 450 amino acids, while μ and ε have approximately 550 amino acids.
- Each heavy chain has two regions, the constant region and the variable region. The constant region is identical in all antibodies of the same isotype, but differs in antibodies of different isotype. Heavy chains γ, α and δ have a constant region composed of three constant domains CH1, CH2, and CH3 (in a line), and a hinge region for added flexibility (Woof J. Burton D Nat Rev Immunol 4 (2004) 89-99); heavy chains μ and ε have a constant region composed of four constant domains CH1, CH2, CH3, and CH4 (janeway C A, Jr et al (2001). Immunobiology., 5th ed., Garland Publishing). The variable region of the heavy chain differs in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or B cell clone. The variable region of each heavy chain is approximately 110 amino acids long and is composed of a single antibody domain.
- In mammals there are only two types of light chain, which are called lambda (λ) and kappa (κ). A light chain has two successive domains: one constant domain CL and one variable domain VL. The approximate length of a light chain is 211 to 217 amino acids. Preferably the light chain is a kappa (κ) light chain, and the constant domain CL is preferably derived from a kappa (κ) light chain (the constant domain Cκ)
- The terms “monoclonal antibody” or “monoclonal antibody composition” as used herein refer to a preparation of antibody molecules of a single amino acid composition.
- The “antibodies” according to the invention can be of any class (e.g. IgA, IgD, IgE, IgG, and IgM, preferably IgG or IgE), or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2, preferably IgG1), whereby both antibodies, from which the bivalent bispecific antibody according to the invention is derived, have an Fc part of the same subclass (e.g. IgG1, IgG4 and the like, preferably IgG1), preferably of the same allotype (e.g. Caucasian)
- A “Fc part of an antibody” is a term well known to the skilled artisan and defined on the basis of papain cleavage of antibodies. The antibodies according to the invention contain as Fc part, preferably a Fc part derived from human origin and preferably all other parts of the human constant regions. The Fc part of an antibody is directly involved in complement activation, C1q binding, C3 activation and Fc receptor binding. While the influence of an antibody on the complement system is dependent on certain conditions, binding to C1q is caused by defined binding sites in the Fc part. Such binding sites are known in the state of the art and described e.g. by Lukas, T. J., et al., J. Immunol. 127 (1981) 2555-2560; Brunhouse, R., and Cebra, J. J., Mol. Immunol. 16 (1979) 907-917; Burton, D. R., et al., Nature 288 (1980) 338-344; Thommesen, J. E., et al., Mol. Immunol. 37 (2000) 995-1004; Idusogie, E. E., et al., J. Immunol. 164 (2000) 4178-4184; Hezareh, M., et al., J. Virol. 75 (2001) 12161-12168; Morgan, A., et al., Immunology 86 (1995) 319-324; and
EP 0 307 434. Such binding sites are e.g. L234, L235, D270, N297, E318, K320, K322, P331 and P329 (numbering according to EU index of Kabat, see below). Antibodies of subclass IgG1, IgG2 and IgG3 usually show complement activation, C1q binding and C3 activation, whereas IgG4 do not activate the complement system, do not bind C1q and do not activate C3. Preferably the Fc part is a human Fc part. - The term “chimeric antibody” refers to an antibody comprising a variable region, i.e., binding region, from one source or species and at least a portion of a constant region derived from a different source or species, usually prepared by recombinant DNA techniques. Chimeric antibodies comprising a murine variable region and a human constant region are preferred. Other preferred forms of “chimeric antibodies” encompassed by the present invention are those in which the constant region has been modified or changed from that of the original antibody to generate the properties according to the invention, especially in regard to C1q binding and/or Fc receptor (FcR) binding. Such chimeric antibodies are also referred to as “class-switched antibodies.”. Chimeric antibodies are the product of expressed immunoglobulin genes comprising DNA segments encoding immunoglobulin variable regions and DNA segments encoding immunoglobulin constant regions. Methods for producing chimeric antibodies involve conventional recombinant DNA and gene transfection techniques are well known in the art. See, e.g., Morrison, S. L., et al., Proc. Natl. Acad. Sci. USA 81 (1984) 6851-6855; U.S. Pat. Nos. 5,202,238 and 5,204,244.
- The term “humanized antibody” refers to antibodies in which the framework or “complementarity determining regions” (CDR) have been modified to comprise the CDR of an immunoglobulin of different specificity as compared to that of the parent immunoglobulin. In a preferred embodiment, a murine CDR is grafted into the framework region of a human antibody to prepare the “humanized antibody.” See, e.g., Riechmann, L., et al., Nature 332 (1988) 323-327; and Neuberger, M. S., et al., Nature 314 (1985) 268-270. Particularly preferred CDRs correspond to those representing sequences recognizing the antigens noted above for chimeric antibodies. Other forms of “humanized antibodies” encompassed by the present invention are those in which the constant region has been additionally modified or changed from that of the original antibody to generate the properties according to the invention, especially in regard to C1q binding and/or Fc receptor (FcR) binding.
- The term “human antibody”, as used herein, is intended to include antibodies having variable and constant regions derived from human germ line immunoglobulin sequences. Human antibodies are well-known in the state of the art (van Dijk, M. A., and van de Winkel, J. G., Curr. Opin. Chem. Biol. 5 (2001) 368-374). Human antibodies can also be produced in transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire or a selection of human antibodies in the absence of endogenous immunoglobulin production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge (see, e.g., Jakobovits, A., et al., Proc. Natl. Acad. Sci. USA 90 (1993) 2551-2555; Jakobovits, A., et al., Nature 362 (1993) 255-258; Bruggemann, M., et al., Year Immunol. 7 (1993) 33-40). Human antibodies can also be produced in phage display libraries (Hoogenboom, H. R., and Winter, G., J. Mol. Biol. 227 (1992) 381-388; Marks, J. D., et al., J. Mol. Biol. 222 (1991) 581-597). The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); and Boerner, P., et al., J. Immunol. 147 (1991) 86-95). As already mentioned for chimeric and humanized antibodies according to the invention the term “human antibody” as used herein also comprises such antibodies which are modified in the constant region to generate the properties according to the invention, especially in regard to C1q binding and/or FcR binding, e.g. by “class switching” i.e. change or mutation of Fc parts (e.g. from IgG1 to IgG4 and/or IgG1/IgG4 mutation.)
- The term “recombinant human antibody”, as used herein, is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from a host cell such as a NS0 or CHO cell or from an animal (e.g. a mouse) that is transgenic for human immunoglobulin genes or antibodies expressed using a recombinant expression vector transfected into a host cell. Such recombinant human antibodies have variable and constant regions in a rearranged form. The recombinant human antibodies according to the invention have been subjected to in vivo somatic hypermutation. Thus, the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germ line VH and VL sequences, may not naturally exist within the human antibody germ line repertoire in vivo.
- The “variable domain” (variable domain of a light chain (VL), variable region of a heavy chain (VH)) as used herein denotes each of the pair of light and heavy chains which is involved directly in binding the antibody to the antigen. The domains of variable human light and heavy chains have the same general structure and each domain comprises four framework (FR) regions whose sequences are widely conserved, connected by three “hypervariable regions” (or complementarity determining regions, CDRs). The framework regions adopt a β-sheet conformation and the CDRs may form loops connecting the β-sheet structure. The CDRs in each chain are held in their three-dimensional structure by the framework regions and form together with the CDRs from the other chain the antigen binding site. The antibody heavy and light chain CDR3 regions play a particularly important role in the binding specificity/affinity of the antibodies according to the invention and therefore provide a further object of the invention.
- The terms “hypervariable region” or “antigen-binding portion of an antibody” when used herein refer to the amino acid residues of an antibody which are responsible for antigen-binding. The hypervariable region comprises amino acid residues from the “complementarity determining regions” or “CDRs”. “Framework” or “FR” regions are those variable domain regions other than the hypervariable region residues as herein defined. Therefore, the light and heavy chains of an antibody comprise from N- to C-terminus the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. CDRs on each chain are separated by such framework amino acids. Especially, CDR3 of the heavy chain is the region which contributes most to antigen binding. CDR and FR regions are determined according to the standard definition of Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991).
- The “constant domains” of the heavy chain and of the light chain are not involved directly in binding of an antibody to an antigen, but exhibit various effector functions. Depending on the amino acid sequence of the constant region of their heavy chains, antibodies or immunoglobulins are divided into the classes:
- The term “bivalent, bispecific antibody” as used herein refers to an antibody as described above in which each of the two pairs of heavy chain and light chain (HC/LC) is specifically binding to a different antigen, i.e. the first heavy and the first light chain (originating from an antibody against a first antigen) are specifically binding together to a first antigen, and, the second heavy and the second light chain (originating from an antibody against a second antigen) are specifically binding together to a second antigen (as depicted in
FIG. 2 ); such bivalent, bispecific antibodies are capable of specifically binding to two different antigens at the same time, and not to more than two antigens, in contrary to, on the one hand a monospecific antibody capable of binding only to one antigen, and on the other hand e.g. a tetravalent, tetraspecific antibody which can bind to four antigen molecules at the same time. - According to the invention, the ratio of a desired bivalent, bispecific antibody compared to undesired side products can be improved by the replacement of certain domains in only one pair of heavy chain and light chain (HC/LC). While the first of the two HC/LC pairs originates from an antibody specifically binding to a first antigen and is left essentially unchanged, the second of the two HC/LC pairs originates from an antibody specifically binding to a second antigen, and is altered by the following replacement:
- light chain: replacement of the variable light chain domain VL by the variable heavy chain domain VH of said antibody specifically binding to a second antigen, and
- heavy chain: replacement of the variable heavy chain domain VH by the variable light chain domain VL of said antibody specifically binding to a second antigen.
- Thus the resulting bivalent, bispecific antibodies are artificial antibodies which comprise
- a) the light chain and heavy chain of an antibody specifically binding to a first antigen; and
b) the light chain and heavy chain of an antibody specifically binding to a second antigen,
wherein said light chain (of an antibody specifically binding to a second antigen) contains a variable domain VH instead of VL, and
wherein said heavy chain (of an antibody specifically binding to a second antigen) contains a variable domain VL instead of VH. - In an additional aspect of the invention such improved ratio of a desired bivalent, bispecific antibody compared to undesired side products can be further improved by one of the following two alternatives:
- The CH3 domains of said bivalent, bispecific antibody according to the invention can be altered by the “knob-into-holes” technology which described with in detail with several examples in e.g. WO96/027011, Ridgway J B, et al, Protein Eng 9 (1996) 617-621; and Merchant A. M., et al, Nat Biotechnol 16 (1998) 677-681. In this method the interaction surfaces of the two CH3 domains are altered to increase the heterodimerisation of both heavy chains containing these two CH3 domains. Each of the two CH3 domains (of the two heavy chains) can be the “knob”, while the other is the “hole”. The introduction of a disulfide bridge stabilizes the heterodimers (Merchant A. M, et al, Nature Biotech 16 (1998) 677-681; Atwell S, Ridgway J B, Wells J A, Carter P., J Mol Biol 270 (1997) 26-35) and increases the yield.
- Therefore in preferred embodiment the CH3 domains of a bivalent, bispecific antibody wherein the first CH3 domain and second CH3 domain each meet at an interface which comprises an original interface between the antibody CH3 domains are altered by the “knob-into-holes” technology including further stabilization by introduction of a disulfide bridge in the CH3 domains (described in WO96/027011, Ridgway J B, et al, Protein Eng 9 (1996) 617-621; Merchant A. M, et al, Nature Biotech 16 (1998) 677-681; and Atwell S, Ridgway J B, Wells J A, Carter P., J Mol Biol 270 (1997) 26-35) to promote the formation of the bivalent, bispecific antibody.
- Thus in one aspect of the invention said bivalent, bispecific antibody is characterized in that
- the CH3 domain of one heavy chain and the CH3 domain of the other heavy chain each meet at an interface which comprises an original interface between the antibody CH3 domains;
wherein said interface is altered to promote the formation of the bivalent, bispecific antibody,
wherein the alteration is characterized in that:
a) the CH3 domain of one heavy chain is altered, so that within the original interface the CH3 domain of one heavy chain that meets the original interface of the CH3 domain of the other heavy chain within the bivalent, bispecific antibody, an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance within the interface of the CH3 domain of one heavy chain which is positionable in a cavity within the interface of the CH3 domain of the other heavy chain and
b) the CH3 domain of the other heavy chain is altered,
so that within the original interface of the second CH3 domain that meets the original interface of the first CH3 domain within the bivalent, bispecific antibody
an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the interface of the second CH3 domain within which a protuberance within the interface of the first CH3 domain is positionable. - Preferably said amino acid residue having a larger side chain volume is selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y), tryptophan (W).
- Preferably said amino acid residue having a smaller side chain volume is selected from the group consisting of alanine (A), serine (S), threonine (T), valine (V).
- In one aspect of the invention both CH3 domains are further altered the introduction of cysteine (C) as amino acid in the corresponding positions of each CH3 domain such that a disulfide bridge between both CH3 domains can be formed.
- In another preferred embodiment of the invention both CH3 domains are altered by the use of residues R409D; K370E (K409D) for knobs residues and D399K; E357K for hole residues described eg. in EP 1870459A1;
- or
- by the replacement of one constant heavy chain domain CH3 by a constant heavy chain domain CH1; and the other constant heavy chain domain CH3 is replaced by a constant light chain domain CL.
- The constant heavy chain domain CH1 by which the heavy chain domain CH3 is replaced can be of any Ig class (e.g. IgA, IgD, IgE, IgG, and IgM), or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2).
- The constant light chain domain CL by which the heavy chain domain CH3 is replaced can be of the lambda (λ) or kappa (κ) type, preferably the kappa (κ) type.
- Thus one preferred embodiment of the invention is a bivalent, bispecific antibody, comprising:
- a) the light chain and heavy chain of an antibody specifically binding to a first antigen; and
b) the light chain and heavy chain of an antibody specifically binding to a second antigen,
wherein the variable domains VL and VH are replaced by each other, and wherein optionally
c) the CH3 domain of one heavy chain and the CH3 domain of the other heavy chain each meet at an interface which comprises an original interface between the antibody CH3 domains;
wherein said interface is altered to promote the formation of the bivalent, bispecific antibody,
wherein the alteration is characterized in that:
ca) the CH3 domain of one heavy chain is altered,
so that within the original interface the CH3 domain of one heavy chain that meets the original interface of the CH3 domain of the other heavy chain within the bivalent, bispecific antibody, an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance within the interface of the CH3 domain of one heavy chain which is positionable in a cavity within the interface of the CH3 domain of the other heavy chain
and
cb) the CH3 domain of the other heavy chain is altered, so that within the original interface of the second CH3 domain that meets the original interface of the first CH3 domain within the bivalent, bispecific antibody
an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the interface of the second CH3 domain within which a protuberance within the interface of the first CH3 domain is positionable;
or
d) one constant heavy chain domain CH3 is replaced by a constant heavy chain domain CH1; and the other constant heavy chain domain CH3 is replaced by a constant light chain domain CL. - The terms “antigen” or “antigen molecule” as used herein are used interchangeable and refer to all molecules that can be specifically bound by an antibody. The bivalent, bispecific antibody is specifically binding to a first antigen and a second distinct antigen. The term “antigens” as used herein include e.g. proteins, different epitopes on proteins (as different antigens within the meaning of the invention), and polysaccharides. This mainly includes parts (coats, capsules, cell walls, flagella, fimbrae, and toxins) of bacteria, viruses, and other microorganisms. Lipids and nucleic acids are antigenic only when combined with proteins and polysaccharides. Non-microbial exogenous (non-self) antigens can include pollen, egg white, and proteins from transplanted tissues and organs or on the surface of transfused blood cells. Preferably the antigen is selected from the group consisting of cytokines, cell surface proteins, enzymes and receptors cytokines, cell surface proteins, enzymes and receptors.
- Tumor antigens are those antigens that are presented by MHC I or MHC II molecules on the surface of tumor cells. These antigens can sometimes be presented by tumor cells and never by the normal ones. In this case, they are called tumor-specific antigens (TSAs) and typically result from a tumor specific mutation. More common are antigens that are presented by tumor cells and normal cells, and they are called tumor-associated antigens (TAAs). Cytotoxic T lymphocytes that recognized these antigens may be able to destroy the tumor cells before they proliferate or metastasize. Tumor antigens can also be on the surface of the tumor in the form of, for example, a mutated receptor, in which case they will be recognized by B cells.
- In one preferred embodiment at least one of the two different antigens (first and second antigen), to which the bivalent, bispecific antibody specifically binds to, is a tumor antigen.
- In another preferred embodiment both of the two different antigens (first and second antigen), to which the bivalent, bispecific antibody specifically binds to, are tumor antigens; in this case the first and second antigen can also be two different epitopes at the same tumor specific protein.
- In another preferred embodiment one of the two different antigens (first and second antigen), to which the bivalent, bispecific antibody specifically binds to, is a tumor antigen and the other is an effector cell antigen, as e.g. an T-Cell receptor, CD3, CD16 and the like.
- In another preferred embodiment one of the two different antigens (first and second antigen), to which the bivalent, bispecific antibody specifically binds to, is a tumor antigen and the other is an anti-cancer substance such as a toxin or a kinase inhibitor.
- As used herein, “specifically binding” or “binds specifically to” refers to an antibody specifically binding an antigen. Preferably the binding affinity of the antibody specifically binding this antigen is of KD-value of 10−9 mol/l or lower (e.g. 10−10 mol/l), preferably with a KD-value of 10−10 mol/l or lower (e.g. 10−12 mol/l). The binding affinity is determined with a standard binding assay, such as surface plasmon resonance technique (Biacore®).
- The term “epitope” includes any polypeptide determinant capable of specific binding to an antibody. In certain embodiments, epitope determinant include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl, or sulfonyl, and, in certain embodiments, may have specific three dimensional structural characteristics, and or specific charge characteristics. An epitope is a region of an antigen that is bound by an antibody. In certain embodiments, an antibody is said to specifically bind an antigen when it preferentially recognizes its target antigen in a complex mixture of proteins and/or macromolecules.
- An further embodiment of the invention is a method for the preparation of a bivalent, bispecific antibody according to the invention comprising
- a) transforming a host cell with
- vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a first antigen
- vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH are replaced by each other;
- b) culturing the host cell under conditions that allow synthesis of said antibody molecule; and
c) recovering said antibody molecule from said culture. - In general there are two vectors encoding the light chain and heavy chain of said antibody specifically binding to a first antigen, and further two vectors encoding the light chain and heavy chain of said antibody specifically binding to a second antigen. One of the two vectors is encoding the respective light chain and the other of the two vectors is encoding the respective heavy chain. However in an alternative method for the preparation of a bivalent, bispecific antibody according to the invention, only one first vector encoding the light chain and heavy chain of the antibody specifically binding to a first antigen and only one second vector encoding the light chain and heavy chain of the antibody specifically binding to a second antigen can be used for transforming the host cell.
- The invention encompasses a method for the preparation of the antibodies comprising culturing the corresponding host cells under conditions that allow synthesis of said antibody molecules and recovering said antibodies from said culture, e.g. by expressing
- a first nucleic acid sequence encoding the light chain of an antibody specifically binding to a first antigen,
- a second nucleic acid sequence encoding the heavy chain of said antibody specifically binding to a first antigen,
- a third nucleic acid sequence encoding the light chain of an antibody specifically binding to a second antigen, wherein the variable light chain domain VL is replaced by the variable heavy chain domain VH, and
- a fourth nucleic acid sequence encoding the heavy chain of said antibody specifically binding to a second antigen, wherein variable heavy chain domain VH by the variable light chain domain VL.
- A further embodiment of the invention is a host cell comprising
- vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a first antigen
- vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH are replaced by each other.
- A further embodiment of the invention is a host cell comprising
- a) a vector comprising a nucleic acid molecule encoding the light chain and a vector comprising a nucleic acid molecule encoding the heavy chain, of an antibody specifically binding to a first antigen
b) a vector comprising a nucleic acid molecule encoding the light chain and a vector comprising a nucleic acid molecule encoding the heavy chain, of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH are replaced by each other. - A further embodiment of the invention is a composition, preferably a pharmaceutical or a diagnostic composition of the bivalent, bispecific antibody according to the invention.
- A further embodiment of the invention is a pharmaceutical composition comprising a bivalent, bispecific antibody according to the invention and at least one pharmaceutically acceptable excipient.
- A further embodiment of the invention is a method for the treatment of a patient in need of therapy, characterized by administering to the patient a therapeutically effective amount of a bivalent, bispecific antibody according to the invention.
- The term “nucleic acid or nucleic acid molecule”, as used herein, is intended to include DNA molecules and RNA molecules. A nucleic acid molecule may be single-stranded or double-stranded, but preferably is double-stranded DNA.
- As used herein, the expressions “cell,” “cell line,” and “cell culture” are used interchangeably and all such designations include progeny. Thus, the words “transformants” and “transformed cells” include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Variant progeny that have the same function or biological activity as screened for in the originally transformed cell are included. Where distinct designations are intended, it will be clear from the context.
- The term “transformation” as used herein refers to process of transfer of a vectors/nucleic acid into a host cell. If cells without formidable cell wall barriers are used as host cells, transfection is carried out e.g. by the calcium phosphate precipitation method as described by Graham and Van der Eh, Virology 52 (1978) 546ff. However, other methods for introducing DNA into cells such as by nuclear injection or by protoplast fusion may also be used. If prokaryotic cells or cells which contain substantial cell wall constructions are used, e.g. one method of transfection is calcium treatment using calcium chloride as described by Cohen, F. N, et al, PNAS. 69 (1972) 7110ff.
- Recombinant production of antibodies using transformation is well-known in the state of the art and described, for example, in the review articles of Makrides, S. C., Protein Expr. Purif. 17 (1999) 183-202; Geisse, S., et al., Protein Expr. Purif. 8 (1996) 271-282; Kaufman, R. J., Mol. Biotechnol. 16 (2000) 151-161; Werner, R. G., et al., Arzneimittelforschung 48 (1998) 870-880 as well as in U.S. Pat. No. 6,331,415 and U.S. Pat. No. 4,816,567.
- As used herein, “expression” refers to the process by which a nucleic acid is transcribed into mRNA and/or to the process by which the transcribed mRNA (also referred to as transcript) is subsequently being translated into peptides, polypeptides, or proteins. The transcripts and the encoded polypeptides are collectively referred to as gene product. If the polynucleotide is derived from genomic DNA, expression in a eukaryotic cell may include splicing of the mRNA.
- A “vector” is a nucleic acid molecule, in particular self-replicating, which transfers an inserted nucleic acid molecule into and/or between host cells. The term includes vectors that function primarily for insertion of DNA or RNA into a cell (e.g., chromosomal integration), replication of vectors that function primarily for the replication of DNA or RNA, and expression vectors that function for transcription and/or translation of the DNA or RNA. Also included are vectors that provide more than one of the functions as described.
- An “expression vector” is a polynucleotide which, when introduced into an appropriate host cell, can be transcribed and translated into a polypeptide. An “expression system” usually refers to a suitable host cell comprised of an expression vector that can function to yield a desired expression product.
- The bivalent, bispecific antibodies according to the invention are preferably produced by recombinant means. Such methods are widely known in the state of the art and comprise protein expression in prokaryotic and eukaryotic cells with subsequent isolation of the antibody polypeptide and usually purification to a pharmaceutically acceptable purity. For the protein expression, nucleic acids encoding light and heavy chains or fragments thereof are inserted into expression vectors by standard methods. Expression is performed in appropriate prokaryotic or eukaryotic host cells like CHO cells, NS0 cells, SP2/0 cells, HEK293 cells, COS cells, yeast, or E. coli cells, and the antibody is recovered from the cells (supernatant or cells after lysis). The bivalent, bispecific antibodies may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form. Purification is performed in order to eliminate other cellular components or other contaminants, e.g. other cellular nucleic acids or proteins, by standard techniques, including alkaline/SDS treatment, column chromatography and others well known in the art. See Ausubel, F., et al., ed., Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York (1987).
- Expression in NS0 cells is described by, e.g., Barnes, L. M., et al., Cytotechnology 32 (2000) 109-123; and Barnes, L. M., et al., Biotech. Bioeng. 73 (2001) 261-270. Transient expression is described by, e.g., Durocher, Y., et al., Nucl. Acids. Res. 30 (2002) E9. Cloning of variable domains is described by Orlandi, R., et al., Proc. Natl. Acad. Sci. USA 86 (1989) 3833-3837; Carter, P., et al., Proc. Natl. Acad. Sci. USA 89 (1992) 4285-4289; and Norderhaug, L., et al., J. Immunol. Methods 204 (1997) 77-87. A preferred transient expression system (HEK 293) is described by Schlaeger, E.-J., and Christensen, K., in Cytotechnology 30 (1999) 71-83 and by Schlaeger, E.-J., in J. Immunol. Methods 194 (1996) 191-199.
- The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, enhancers and polyadenylation signals.
- Nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, “operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading frame. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
- The bivalent, bispecific antibodies are suitably separated from the culture medium by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. DNA or RNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures. The hybridoma cells can serve as a source of such DNA and RNA. Once isolated, the DNA may be inserted into expression vectors, which are then transfected into host cells such as HEK 293 cells, CHO cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of recombinant monoclonal antibodies in the host cells.
- Amino acid sequence variants (or mutants) of the bivalent, bispecific antibody are prepared by introducing appropriate nucleotide changes into the antibody DNA, or by nucleotide synthesis. Such modifications can be performed, however, only in a very limited range, e.g. as described above. For example, the modifications do not alter the above mentioned antibody characteristics such as the IgG isotype and antigen binding, but may improve the yield of the recombinant production, protein stability or facilitate the purification.
- The following examples, sequence listing and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.
- SEQ ID NO: 1 amino acid sequence of wild type <IGF-1R> antibody heavy chain
- SEQ ID NO: 2 amino acid sequence of wild type <IGF-1R> antibody light chain
- SEQ ID NO: 3 amino acid sequence of the heavy chain*** (HC***) of <IGF-1R> VL-VH exchange antibody, wherein the heavy chain domain VH is replaced by the light chain domain VL—variant A.
- SEQ ID NO: 4 amino acid sequence of the light chain*** (LC***) of <IGF-1R> VL-VH exchange antibody, wherein the light chain domain VL is replaced by the heavy chain domain VH—variant A.
- SEQ ID NO: 5 amino acid sequence of IGF-1R ectodomain His-Streptavidin binding peptide-tag (IGF-1R-His-SBP ECD)
- SEQ ID NO: 6 amino acid sequence of wild type Angiopoietin-2<ANGPT2> antibody heavy chain
- SEQ ID NO: 7 amino acid sequence of wild type Angiopoietin-2<ANGPT2> antibody light chain
- SEQ ID NO: 8 amino acid sequence of CH3 domain (Knobs) with a T366W exchange for use in the knobs-into-holes technology
- SEQ ID NO: 9 amino acid sequence CH3 domain (Hole) with a T366S, L368A, Y407V exchange for use in the knobs-into-holes technology
- SEQ ID NO: 10 amino acid sequence of the heavy chain*** (HC***) of <IGF-1R> VL-VH exchange antibody, wherein the heavy chain domain VH is replaced by the light chain domain VL—variant B.
- SEQ ID NO: 11 amino acid sequence of the light chain*** (LC***) of <IGF-1R> VL-VH exchange antibody, wherein the light chain domain VL is replaced by the heavy chain domain VH—variant B.
- SEQ ID NO: 12 amino acid sequence of IGF-1R ectodomain His-Streptavidin binding peptide-tag (IGF-1R-His-SBP ECD)
-
FIG. 1 Schematic figure of IgG, a naturally occurring whole antibody specific for one antigen with two pairs of heavy and light chain which comprise variable and constant domains in a typical order. -
FIG. 2 Schematic figure of a bivalent, bispecific antibody, comprising: a) the light chain and heavy chain of an antibody specifically binding to a first antigen; and b) the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH are replaced by each other. -
FIG. 3 Schematic figure of a bivalent, bispecific antibody, comprising: a) the light chain and heavy chain of an antibody specifically binding to a first antigen; and b) the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH are replaced by each other, and wherein the CH3 domains of both heavy chains are altered by the knobs-into-holes technology. -
FIG. 4 Schematic figure of a bivalent, bispecific antibody, comprising: a) the light chain and heavy chain of an antibody specifically binding to a first antigen; and b) the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH are replaced by each other, and wherein one of the constant heavy chain domains CH3 of both heavy chains is replaced by a constant heavy chain domain CH1; and the other constant heavy chain domain CH3 is replaced by a constant light chain domain CL. -
FIG. 5 Protein sequence scheme of the heavy chain***<IGF-1R> HC*** of the <IGF-1R> VL-VH exchange antibody -
FIG. 6 Protein sequence scheme of the light chain***<IGF-1R> LC*** of the <IGF-1R> VL-VH exchange antibody (with a kappa constant light chain domain CL) -
FIG. 7 Plasmid map of heavy chain***<IGF-1R> HC*** expression vector pUC-HC***-IGF-1R -
FIG. 8 Plasmid map of light chain***<IGF-1R> LC*** expression vector pUC-LC***-IGF-1R -
FIG. 9 Plasmid map of the 4700-Hyg-OriP expression vector -
FIG. 10 Assay principle of cellular FACS IGF-1R-ANGPT2 bridging assay on I24 IGF-1R expressing cells to detect the presence of functional bispecific <ANGPT2-IGF-1R> VL-VH exchange antibody -
FIG. 11 Scheme IGF-1 R ECD Biacore -
FIG. 12 SDS-PAGE and size exclusion chromatography of purified monospecific, bivalent <IGF-1R> VL-VH exchange antibody (IgG1***) with HC*** and LC*** isolated from cell culture supernatants after transient transfection of HEK293-F cells. -
FIG. 13 Binding of monospecific <IGF-1R> VL-VH exchange antibody and wildtype <IGF-1R> antibody to the IGF-1R ECD in an ELISA-based binding assay. -
FIG. 14 SDS-PAGE of <ANGPT2-IGF-1R> VL-VH exchange antibody mix purified from cell culture supernatants from transiently transfected HEK293-F cells. -
FIG. 15 Results for Samples A to F of cellular FACS IGF-1R-ANGPT2 bridging assay on I24 IGF-1R expressing cells to detect the presence of functional bispecific <ANGPT2-IGF-1R> VL-VH exchange antibody in purified antibody mix. - A=I24 untreated
B=I24+2 μg/mL hANGPT2+hIgG Isotype
D=I24+2 μg/mL hANGPT2+Mix from co-expression of <IGF-1R> VL-VH exchange antibody and <ANGPT2> wildtype antibody comprising bispecific <ANGPT2-IGF-1R> VL-VH exchange antibody
E=I24+2 μg/mL hANGPT2+<ANGPT2> wildtype antibody
F=I24+2 μg/mL hANGPT2+<IGF-1R> wildtype antibody - General information regarding the nucleotide sequences of human immunoglobulins light and heavy chains is given in: Kabat, E. A., et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991). Amino acids of antibody chains are numbered and referred to according to EU numbering (Edelman, G. M., et al., Proc. Natl. Acad. Sci. USA 63 (1969) 78-85; Kabat, E. A., et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md., (1991)).
- Standard methods were used to manipulate DNA as described in Sambrook, J. et al., Molecular cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989. The molecular biological reagents were used according to the manufacturer's instructions.
- Desired gene segments were prepared from oligonucleotides made by chemical synthesis. The 600-1800 bp long gene segments, which are flanked by singular restriction endonuclease cleavage sites, were assembled by annealing and ligation of oligonucleotides including PCR amplification and subsequently cloned via the indicated restriction sites e.g. KpnI/SacI or AscI/PacI into a pPCRScript (Stratagene) based pGA4 cloning vector. The DNA sequences of the subcloned gene fragments were confirmed by DNA sequencing. Gene synthesis fragments were ordered according to given specifications at Geneart (Regensburg, Germany).
- DNA sequences were determined by double strand sequencing performed at MediGenomix GmbH (Martinsried, Germany) or Sequiserve GmbH (Vaterstetten, Germany).
- The GCG's (Genetics Computer Group, Madison, Wis.) software package version 10.2 and Infomax's Vector NT1 Advance suite version 8.0 was used for sequence creation, mapping, analysis, annotation and illustration.
- For the expression of the described antibodies variants of expression plasmids for transient expression (e.g. in HEK293 EBNA or HEK293-F) cells based either on a cDNA organization with a CMV-Intron A promoter or on a genomic organization with a CMV promoter were applied.
- Beside the antibody expression cassette the vectors contained:
- an origin of replication which allows replication of this plasmid in E. coli, and
- a β-lactamase gene which confers ampicillin resistance in E. coli.
- The transcription unit of the antibody gene is composed of the following elements:
- unique restriction site(s) at the 5′ end
- the immediate early enhancer and promoter from the human cytomegalovirus,
- followed by the Intron A sequence in the case of the cDNA organization,
- a 5′-untranslated region of a human antibody gene,
- a immunoglobulin heavy chain signal sequence,
- the human antibody chain (wildtype or with domain exchange) either as cDNA or as genomic organization with an the immunoglobulin exon-intron organization
- a 3′ untranslated region with a polyadenylation signal sequence, and
- unique restriction site(s) at the 3′ end.
- The fusion genes comprising the described antibody chains as described below were generated by PCR and/or gene synthesis and assembled with known recombinant methods and techniques by connection of the according nucleic acid segments e.g. using unique restriction sites in the respective vectors. The subcloned nucleic acid sequences were verified by DNA sequencing. For transient transfections larger quantities of the plasmids were prepared by plasmid preparation from transformed E. coli cultures (Nucleobond AX, Macherey-Nagel).
- Standard cell culture techniques were used as described in Current Protocols in Cell Biology (2000), Bonifacino, J. S., Dasso, M., Harford, J. B., Lippincott-Schwartz, J. and Yamada, K. M. (eds.), John Wiley & Sons, Inc.
- Bispecific antibodies were expressed by transient co-transfection of the respective expression plasmids in adherently growing HEK293-EBNA or in HEK29-F cells growing in suspension as described below.
- Bispecific antibodies were expressed by transient co-transfection of the respective expression plasmids (e.g. encoding the heavy and modified heavy chain, as well as the corresponding light and modified light chain) in adherently growing HEK293-EBNA cells (human embryonic kidney cell line 293 expressing Epstein-Barr-Virus nuclear antigen; American type culture collection deposit number ATCC # CRL-10852, Lot. 959 218) cultivated in DMEM (Dulbecco's modified Eagle's medium, Gibco) supplemented with 10% Ultra Low IgG FCS (fetal calf serum, Gibco), 2 mM L-Glutamine (Gibco), and 250 μg/ml Geneticin (Gibco). For transfection FuGENE™ 6 Transfection Reagent (Roche Molecular Biochemicals) was used in a ratio of FuGENE™ reagent (μl) to DNA (μg) of 4:1 (ranging from 3:1 to 6:1). Proteins were expressed from the respective plasmids using a molar ratio of (modified and wildtype) light chain and heavy chain encoding plasmids of 1:1 (equimolar) ranging from 1:2 to 2:1, respectively. Cells were feeded at
day 3 with L-Glutamine ad 4 mM, Glucose [Sigma] and NAA [Gibco]. Bispecific antibody containing cell culture supernatants were harvested from day 5 to 11 after transfection by centrifugation and stored at −20° C. General information regarding the recombinant expression of human immunoglobulins in e.g. HEK293 cells is given in: Meissner, P. et al., Biotechnol. Bioeng. 75 (2001) 197-203. - Bispecific antibodies were generated by transient transfection of the respective plasmids (e.g. encoding the heavy and modified heavy chain, as well as the corresponding light and modified light chain) using the HEK293-F system (Invitrogen) according to the manufacturer's instruction. Briefly, HEK293-F cells (Invitrogen) growing in suspension either in a shake flask or in a stirred fermenter in serumfree FreeStyle 293 expression medium (Invitrogen) were transfected with a mix of the four expression plasmids and 293fectin or fectin (Invitrogen). For 2 L shake flask (Corning) HEK293-F cells were seeded at a density of 1.0E*6 cells/mL in 600 mL and incubated at 120 rpm, 8% CO2. The day after the cells were transfected at a cell density of ca. 1.5E*6 cells/mL with ca. 42 mL mix of A) 20 mL Opti-MEM (Invitrogen) with 600 μg total plasmid DNA (1 μg/mL) encoding the heavy or modified heavy chain, respectively and the corresponding light chain in an equimolar ratio and B) 20 ml Opti-MEM+1.2 mL 293 fectin or fectin (2 μl/mL). According to the glucose consumption glucose solution was added during the course of the fermentation. The supernatant containing the secreted antibody was harvested after 5-10 days and antibodies were either directly purified from the supernatant or the supernatant was frozen and stored.
- The protein concentration of purified antibodies and derivatives was determined by determining the optical density (OD) at 280 nm, using the molar extinction coefficient calculated on the basis of the amino acid sequence according to Pace et al., Protein Science, 1995, 4, 2411-1423.
- The concentration of antibodies and derivatives in cell culture supernatants was estimated by immunoprecipitation with Protein A Agarose-beads (Roche). 60 μL Protein A Agarose beads are washed three times in TBS-NP40 (50 mM Tris, pH 7.5, 150 mM NaCl, 1% Nonidet-P40). Subsequently, 1-15 mL cell culture supernatant were applied to the Protein A Agarose beads pre-equilibrated in TBS-NP40. After incubation for at 1 h at room temperature the beads were washed on an Ultrafree-MC-filter column (Amicon] once with 0.5 mL TBS-NP40, twice with 0.5
mL 2× phosphate buffered saline (2×PBS, Roche) and briefly four times with 0.5mL 100 mM Na-citrate pH 5.0. Bound antibody was eluted by addition of 35 μl NuPAGE® LDS Sample Buffer (Invitrogen). Half of the sample was combined with NuPAGE® Sample Reducing Agent or left unreduced, respectively, and heated for 10 min at 70° C. Consequently, 5-30 μl were applied to an 4-12% NuPAGE® Bis-Tris SDS-PAGE (Invitrogen) (with MOPS buffer for non-reduced SDS-PAGE and MES buffer with NuPAGE® Antioxidant running buffer additive (Invitrogen) for reduced SDS-PAGE) and stained with Coomassie Blue. - The concentration of antibodies and derivatives in cell culture supernatants was quantitatively measured by affinity HPLC chromatography. Briefly, cell culture supernatants containing antibodies and derivatives that bind to Protein A were applied to an Applied Biosystems Poros A/20 column in 200 mM KH2PO4, 100 mM sodium citrate, pH 7.4 and eluted from the matrix with 200 mM NaCl, 100 mM citric acid, pH 2.5 on an Agilent HPLC 1100 system. The eluted protein was quantified by UV absorbance and integration of peak areas. A purified standard IgG1 antibody served as a standard.
- Alternatively, the concentration of antibodies and derivatives in cell culture supernatants was measured by Sandwich-IgG-ELISA. Briefly, StreptaWell High Bind Strepatavidin A-96 well microtiter plates (Roche) were coated with 100 μL/well biotinylated anti-human IgG capture molecule F(ab′)2<h-Fcγ> BI (Dianova) at 0.1 μg/mL for 1 h at room temperature or alternatively over night at 4° C. and subsequently washed three times with 200 μL/well PBS, 0.05% Tween (PBST, Sigma). 100 μL/well of a dilution series in PBS (Sigma) of the respective antibody containing cell culture supernatants was added to the wells and incubated for 1-2 h on a microtiterplate shaker at room temperature. The wells were washed three times with 200 μL/well PBST and bound antibody was detected with 100 μF(ab′)2<hFcγ> POD (Dianova) at 0.1 μg/mL as detection antibody for 1-2 h on a microtiterplate shaker at room temperature. Unbound detection antibody was washed away three times with 200 μL/well PBST and the bound detection antibody was detected by addition of 100 μL ABTS/well. Determination of absorbance was performed on a Tecan Fluor Spectrometer at a measurement wavelength of 405 nm (reference wavelength 492 nm).
- Proteins were purified from filtered cell culture supernatants referring to standard protocols. In brief, antibodies were applied to a Protein A Sepharose column (GE healthcare) and washed with PBS. Elution of antibodies was achieved at pH 2.8 followed by immediate neutralization of the sample. Aggregated protein was separated from monomeric antibodies by size exclusion chromatography (Superdex 200, GE Healthcare) in PBS or in 20 mM Histidine, 150 mM NaCl pH 6.0. Monomeric antibody fractions were pooled, concentrated if required using e.g. a MILLIPORE Amicon Ultra (30 MWCO) centrifugal concentrator, frozen and stored at −20° C. or −80° C. Part of the samples were provided for subsequent protein analytics and analytical characterization e.g. by SDS-PAGE, size exclusion chromatography or mass spectrometry.
- The NuPAGE® Pre-Cast gel system (Invitrogen) was used according to the manufacturer's instruction. In particular, 10% or 4-12% NuPAGE® Novex® Bis-TRIS Pre-Cast gels (pH 6.4) and a NuPAGE® MES (reduced gels, with NuPAGE® Antioxidant running buffer additive) or MOPS (non-reduced gels) running buffer was used.
- Size exclusion chromatography for the determination of the aggregation and oligomeric state of antibodies was performed by HPLC chromatography. Briefly, Protein A purified antibodies were applied to a Tosoh TSKgel G3000SW column in 300 mM NaCl, 50 mM KH2PO4/K2HPO4, pH 7.5 on an Agilent HPLC 1100 system or to a Superdex 200 column (GE Healthcare) in 2×PBS on a Dionex HPLC-System. The eluted protein was quantified by UV absorbance and integration of peak areas. BioRad Gel Filtration Standard 151-1901 served as a standard.
- The total deglycosylated mass of crossover antibodies was determined and confirmed via electrospray ionization mass spectrometry (ESI-MS). Briefly, 100 μg purified antibodies were deglycosylated with 50 mU N-Glycosidase F (PNGaseF, ProZyme) in 100 mM KH2PO4/K2HPO4,
pH 7 at 37° C. for 12-24 h at a protein concentration of up to 2 mg/ml and subsequently desalted via HPLC on a Sephadex G25 column (GE Healthcare). The mass of the respective heavy and light chains was determined by ESI-MS after deglycosylation and reduction. In brief, 50 μg antibody in 115 μl were incubated with 60 μl IM TCEP and 50 μl 8 M Guanidine-hydrochloride subsequently desalted. The total mass and the mass of the reduced heavy and light chains was determined via ESI-MS on a Q-Star Elite MS system equipped with a NanoMate source. - The binding properties of the generated antibodies were evaluated in an ELISA assay with the IGF-1R extracellular domain (ECD). For this sake the extracellular domain of IGF-1R (residues 1-462) comprising the natural leader sequence and the LI-cysteine rich-12 domains of the human IGF-IR ectodomain of the alpha chain (according to the McKern et al., 1997; Ward et al., 2001) fused to an N-terminal His-Streptavidin binding peptide-tag (His-SBP) was cloned into a pcDNA3 vector derivative and transiently expressed in HEK293F cells. The protein sequence of the IGF-1R-His-SBP ECD is given in SEQ ID NO: 12. StreptaWell High Bind Strepatavidin A-96 well microtiter plates (Roche) were coated with 100 μL/well cell culture supernatant containing soluble IGF-1R-ECD-SBP fusion protein over night at 4° C. and washed three times with 200 μL/well PBS, 0.05% Tween (PBST, Sigma). Subsequently, 100 μL/well of a dilution series of the respective antibody and as a reference wildtype <IGF-1R> antibody in PBS (Sigma) including 1% BSA (fraction V, Roche) was added to the wells and incubated for 1-2 h on a microtiterplate shaker at room temperature. For the dilution series the same amount of purified antibody were applied to the wells. The wells were washed three times with 200 μL/well PBST and bound antibody was detected with 100 μL/well F(ab′)2<hFcγ> POD (Dianova) at 0.1 μg/mL (1:8000) as detection antibody for 1-2 h on a microtiterplate shaker at room temperature. Unbound detection antibody was washed away three times with 200 μL/well PBST and the bound detection antibody was detected by addition of 100 μL ABTS/well. Determination of absorbance was performed on a Tecan Fluor Spectrometer at a measurement wavelength of 405 nm (reference wavelength 492 nm).
- Binding of the generated antibodies to human IGF-1R ECD was also investigated by surface plasmon resonance using a BIACORE T100 instrument (GE Healthcare Biosciences AB, Uppsala, Sweden). Briefly, for affinity measurements Goat-Anti-Human IgG, JIR 109-005-098 antibodies were immobilized on a CM5 chip via amine coupling for presentation of the antibodies against human IGF-1R ECD-Fc tagged. Binding was measured in HBS buffer (HBS-P (10 mM HEPES, 150 mM NaCl, 0.005
% Tween 20, ph 7.4), 25° C. IGF-1RECD (R&D Systems or in house purified) was added in various concentrations in solution. Association was measured by an IGF-1R ECD injection of 80 seconds to 3 minutes; dissociation was measured by washing the chip surface with HBS buffer for 3-10 minutes and a KD value was estimated using a 1:1 Langmuir binding model. Due to low loading density and capturing level of <IGF-1R> antibodies monovalent IGF-1R ECD binding was obtained. Negative control data (e.g. buffer curves) were subtracted from sample curves for correction of system intrinsic baseline drift and for noise signal reduction. Biacore T100 Evaluation Software version 1.1.1 was used for analysis of sensorgrams and for calculation of affinity data.FIG. 11 shows a scheme of the Biacore assay. - The sequences for the heavy and light chain variable domains of the monospecific, bivalent <IGF-1R> VL-VH exchange antibody including the respective leader sequences described in this example are derived from a human <IGF-1R> antibody heavy chain (SEQ ID NO: 1, plasmid 4843-pUC-HC-IGF-1R) and a light chain (SEQ ID NO: 2, plasmid 4842-pUC-LC-IGF-1R) described in WO 2005/005635, and the heavy and light chain constant domains are derived from a human antibody (C-kappa and IgG1).
- The gene segments encoding the <IGF-1R> antibody leader sequence, light chain variable domain (VL) and the human heavy chain constant domain 1 (CH1) were joined and fused to the 5′-end of the Fc domains of the human γ1-heavy chain constant domains (Hinge-CH2-CH3). The DNA coding for the respective fusion protein resulting from the exchange of the VH domain by the VL domain (VH-VL exchange) was generated by gene synthesis and is denoted <IGF-1R> HC*** (SEQ ID NO: 10) in the following. Initially, the VL-CH1 domains were fused with a slightly different sequence (SEQ ID NO: 3); due to the reduced expression yields of this connection, SEQ10 that shows expression yields comparable to wildtype antibodies, was chosen. The gene segments for the <IGF-1R> antibody leader sequence, heavy chain variable domain (VH) and the human light chain constant domain (CL) were joined as independent chain. The DNA coding for the respective fusion protein resulting from the exchange of the VL domain by the VH domain (VL-VH exchange) was generated by gene synthesis and is denoted <IGF-1R> LC*** (Heavy Chain***) (SEQ ID NO: 11) in the following. Initially, the VH-CL domains were fused with a slightly different sequence (SEQ ID NO: 4); due to the reduced expression yields of this connection, SEQ ID NO: 11 that shows expression yields comparable to wildtype antibodies was chosen.
-
FIG. 5 andFIG. 6 show a schematic view of the protein sequence of the modified <IGF-1R> HC*** heavy chain and the modified <IGF-1R> LC*** light chain. - In the following the respective expression vectors are briefly described:
- Vector pUC-HC***-IGF-1R
Vector pUC-HC***-IGF-1R is an expression plasmid e.g. for transient expression of a VL-VH exchange <IGF-1R> heavy chain HC*** (cDNA organized expression cassette; with CMV-Intron A) in HEK293 (EBNA) cells or for stable expression in CHO cells. - Beside the <IGF-1R> HC*** expression cassette this vector contains:
- an origin of replication from the vector pUC18 which allows replication of this plasmid in E. coli, and
- a β-lactamase gene which confers ampicillin resistance in E. coli.
- The transcription unit of the <IGF-1R> HC*** gene is composed of the following elements:
- the AscI restriction site at the 5′-end
- the immediate early enhancer and promoter from the human cytomegalovirus,
- followed by the Intron A sequence,
- a 5′-untranslated region of a human antibody gene,
- a immunoglobulin light chain signal sequence,
- the human <IGF-1R> mature HC*** chain encoding a fusion of the human heavy chain variable domain (VH) and the human kappa-light chain constant domain (CL) fused to the 5′
- end of the Fc domains of the human γ1-heavy chain constant domains (Hinge-CH2-CH3).
- a 3′ untranslated region with a polyadenylation signal sequence, and
- the restriction site SgrAI at the 3′-end.
- The plasmid map of the heavy chain*** VL-VH exchange <IGF-1R> HC*** expression vector pUC-HC***-IGF-1R is shown in
FIG. 7 . The amino acid sequence of the <IGF-1R> HC*** (including signal sequence) is given in SEQ ID NO: 10. - Vector pUC-LC**-IGF-1R
- Vector pUC-LC***-IGF-1R is an expression plasmid e.g. for transient expression of a VL-VH exchange <IGF-1R> light chain LC*** (cDNA organized expression cassette; with CMV-Intron A) in HEK293 (EBNA) cells or for stable expression in CHO cells.
- Beside the <IGF-1R> LC*** expression cassette this vector contains:
- an origin of replication from the vector pUC18 which allows replication of this plasmid in E. coli, and
- a β-lactamase gene which confers ampicillin resistance in E. coli.
- The transcription unit of the <IGF-1R> LC*** gene is composed of the following elements:
- the restriction site Sse8387I at the 5′ end
- the immediate early enhancer and promoter from the human cytomegalovirus,
- followed by the Intron A sequence,
- a 5′-untranslated region of a human antibody gene,
- a immunoglobulin heavy chain signal sequence,
- the human <IGF-1R> antibody mature LC*** chain encoding a fusion of the human light chain variable domain (VL) and the human γ1-heavy chain constant domains (CH1).
- a 3′ untranslated region with a polyadenylation signal sequence, and
- the restriction sites SalI and FseI at the 3′-end.
- The plasmid map of the light chain*** VL-VH exchange <IGF-1R> LC*** expression vector pUC-LC***-IGF-1R is shown in
FIG. 8 . The amino acid sequence of the <IGF-1R> LC*** (including signal sequence) is given in SEQ ID NO: 11. - Plasmids pUC-HC**-IGF-1Rand pUC-LC***-IGF-1R can be used for transient or stable co-transfections e.g. into HEK293, HEK293 EBNA or CHO cells (2-vector system). For comparative reasons the wildtype <IGF-1R> antibody was transiently expressed from plasmids 4842-pUC-LC-IGF-1R (SEQ ID NO: 2) and 4843-pUC-HC-IGF-1R (SEQ ID NO: 1) analogous to the ones described in this example.
- In order to achieve higher expression levels in transient expressions in HEK293 EBNA cells the <IGF-1R> HC*** expression cassette can be sub-cloned via AscI, SgrAI sites and the <IGF-1R> LC*** expression cassette can be sub-cloned via Sse83871 and FseI sites into the 4700 pUC-Hyg_OriP expression vector containing
- an OriP element, and
- a hygromycine resistance gene as a selectable marker.
- Heavy and light chain transcription units can either be sub-cloned into two independent 4700-pUC-Hyg-OriP vectors for co-transfection (2-vector system) or they can be cloned into one common 4700-pUC-Hyg-OriP vector (1-vector system) for subsequent transient or stable transfections with the resulting vectors.
FIG. 9 shows a plasmid map of the basic vector 4700-pUC-OriP. - The <IGF-1R> fusion genes (HC*** and LC*** fusion genes) comprising the exchanged Fab sequences of the wildtype <IGF-1R> antibody were assembled with known recombinant methods and techniques by connection of the according nucleic acid segments.
- The nucleic acid sequences encoding the IGF-1R HC*** and LC*** were each synthesized by chemical synthesis and subsequently cloned into a pPCRScript (Stratagene) based pGA4 cloning vector at Geneart (Regensburg, Germany). The expression cassette encoding the IGF-1R HC*** was ligated into the respective E. coli plasmid via PvuII and BmgBI restriction sites resulting in the final vector pUC-HC***-IGF-1R; the expression cassette encoding the respective IGF-1R LC*** was ligated into the respective E. coli plasmid via PvuII and SalI restriction sites resulting in the final vector pUC-LC***-IGF-1R. The subcloned nucleic acid sequences were verified by DNA sequencing. For transient and stable transfections larger quantities of the plasmids were prepared by plasmid preparation from transformed E. coli cultures (Nucleobond AX, Macherey-Nagel)
- Recombinant <IGF-1R> VL-VH exchange antibody was expressed by transient co-transfection of plasmids pUC-HC***-IGF-1Rand pUC-LC***-IGF-1R in HEK293-F suspension cells as described above.
- The expressed and secreted monospecific, bivalent <IGF-1R> VL-VH exchange antibody was purified from filtered cell culture supernatants by Protein A affinity chromatography according as described above. In brief, the <IGF-1R> VL-VH exchange antibody containing cell culture supernatants from transient transfections were clarified by centrifugation and filtration and applied to a Protein A HiTrap MabSelect Xtra column (GE Healthcare) equilibrated with PBS buffer (10 mM Na2HPO4, 1 mM KH2PO4, 137 mM NaCl and 2.7 mM KCl, pH 7.4). Unbound proteins were washed out with PBS equilibration buffer followed by 0.1 M sodium citrate buffer, pH 5.5 and washed with PBS. Elution of antibody was achieved with 100 mM sodium citrate, pH 2.8 followed by immediate neutralization of the sample with 300 μl 2 M Tris pH 9.0 per 2 ml fraction. Aggregated protein was separated from monomeric antibodies by size exclusion chromatography on a HiLoad 26/60 Superdex 200 prep grade column (GE Healthcare) in 20 mM Histidine, 150 mM NaCl pH 6.0 and monomeric antibody fractions were subsequently concentrated using a MILLIPORE Amicon Ultra-15 centrifugal concentrator. <IGF-1R> VL-VH exchange antibody was frozen and stored at −20° C. or −80° C. The integrity of the <IGF-1R> VL-VH exchange antibody was analyzed by SDS-PAGE in the presence and absence of a reducing agent and subsequent staining with Coomassie brilliant blue as described above. Monomeric state of the <IGF-1R> VL-VH exchange antibody was confirmed by analytical size exclusion chromatography. (
FIG. 12 ) Characterized samples were provided for subsequent protein analytics and functional characterization. ESI mass spectrometry confirmed the theoretical molecular mass of the completely deglycosylated <IGF-1R> VL-VH exchange antibody. - The binding properties of monospecific, bivalent <IGF-1R> VL-VH exchange antibody were evaluated in an ELISA assay with the IGF-1R extracellular domain (ECD) as descried above. For this sake the extracellular domain of IGF-1R (residues 1-462) comprising the natural leader sequence and the LI-cysteine rich-12 domains of the human IGF-1R ectodomain of the alpha chain (according to the McKern et al., 1997; Ward et al., 2001) fused to an N-terminal His-Streptavidin binding peptide-tag (His-SBP) was cloned into a pcDNA3 vector derivative and transiently expressed in HEK293F cells. The protein sequence of the IGF-1R-His-SBP ECD is given in see above. The obtained titration curve showed that <IGF-1R> VL-VH exchange antibody was functional and showed comparable binding characteristics and kinetics as the wildtype <IGF-1R> antibody within the error of the method and thus appeared fully functional (
FIG. 13 ). - These findings are being confirmed by Biacore with the respective purified antibodies.
- In order to confirm the binding activity of <IGF-1R> VL-VH exchange antibody to the IGF-1R over-expressed on the surface of I24 cells (NIH3T3 cells expressing recombinant human IGF-1R, Roche) is studied by FACS. Briefly, 5×10E5 I24 cells per FACS tube are incubated with a dilution of purified <IGF-1R> VL-VH exchange antibody and wildtype <IGF-1R> antibody as a reference and incubated on ice for 1 h. Unbound antibody is washed away with 4 ml ice cold PBS (Gibco)+2% FCS (Gibco). Subsequently, cells are centrifuged (5 min at 400 g) and bound antibody is detected with F(ab′)2<hFcγ> PE conjugate (Dianova) on ice for 1 h protected from light. Unbound detection antibody is washed away with 4 ml ice cold PBS+2% FCS. Subsequently, cells are centrifuged (5 min 400 g), resuspended in 300-500 μL PBS and bound detection antibody is quantified on a FACSCalibur or FACS Canto (BD (FL2 channel, 10.000 cells per acquisition). During the experiment the respective isotype controls are included to exclude any unspecific binding events. Binding of <IGF-1R> VL-VH exchange antibody and wildtype <IGF-1R> reference antibody to IGF-1R on I24 cells result in a comparable, concentration dependent shift of mean fluorescence intensity.
- The sequences for the heavy and light chain variable domains of a monospecific, bivalent ANGPT2<ANGPT2> wildtype antibody including the respective leader sequences described in this example are derived from a human <ANGPT2> antibody heavy chain (SEQ ID NO: 6) and a light chain (SEQ ID NO: 7) described in WO 2006/045049 and the heavy and light chain constant domains are derived from a human antibody (C-kappa and IgG1).
- The wildtype <ANGPT2> antibody was cloned into plasmids SB04-pUC-HC-ANGPT2 (SEQ ID NO: 6) and SB06-pUC-LC-ANGPT2 (SEQ ID NO: 7) that are analogous to the vectors described in the previous example 1A.
- For comparative reasons and for co-expression experiments (see example 3) the wildtype <ANGPT2> antibody was transiently (co-) expressed from plasmids SB04-pUC-HC-ANGPT2 and SB06-pUC-LC-ANGPT2.
- Making of the Monospecific, Bivalent <ANGPT2> Wildtype Antibody Expression Plasmids
- The nucleic acid sequences encoding the ANGPT2> HC and LC were each synthesized by chemical synthesis and subsequently cloned into a pPCRScript (Stratagene) based pGA4 cloning vector at Geneart (Regensburg, Germany). The expression cassette encoding the <ANGPT2> HC was cloned into the respective E. coli plasmid resulting in the final vector SB04-pUC-HC-ANGPT2; the expression cassette encoding the respective <ANGPT2> LC was cloned into the respective E. coli plasmid resulting in the final vector SBO6-pUC-LC-ANGPT2. The subcloned nucleic acid sequences were verified by DNA sequencing. For transient and stable transfections larger quantities of the plasmids were prepared by plasmid preparation from transformed E. coli cultures (Nucleobond AX, Macherey-Nagel).
- In order to generate a functional bispecific antibody recognizing IGF-1R via the <IGF-1R> VL-VH exchange antibody Fab on one side and <ANGPT2> via the <ANGPT2> wildtype Fab region on the other side the two expression plasmids coding for the <IGF-1R> VL-VH exchange antibody (example 1A) were co-expressed with two expression plasmids coding for the <ANGPT2> wildtype antibody. (example 2A). Assuming a statistical association of wildtype heavy chains HC and VL-VH exchange heavy chains HC*** this results in the generation of bispecific and bivalent <IGF-1R-ANGPT2> VL-VH exchange antibody. Under the assumption that both antibodies are equally well expressed and without taking side products into account this should result in a 1:2:1 ratio of the three main products A)<IGF-1R> VL-VH exchange antibody, B) bispecific <IGF-1R-ANGPT2> VL-VH exchange antibody, and C)<ANGPT2> wildtype antibody. Several side products can be expected. However, due to the exchange of only the VL-VH domains the frequency of side products should be reduced compared to the complete Fab crossover. Please note as the <ANGPT2> wildtype antibody showed higher expression transient expression yields than the <IGF-1R> wildtype and <IGF-1R> VL-VH exchange antibodies the ratio of <ANGPT2> wildtype antibody plasmids and <IGF-1R> VL-VH exchange antibody plasmids was shifted in favour of the expression of <ANGPT2> wildtype antibody.
- To generate the mix of the main products A)<IGF-1R> VL-VH exchange antibody, B) bispecific <ANGPT2-IGF-1R> VL-VH exchange antibody, and C)<ANGPT2> wildtype antibody the four plasmids pUC-HC***-IGF-1Rand pUC-LC***-IGF-1R and plasmids SB04-pUC-HC-ANGPT2 and SBO6-pUC-LC-ANGPT2 were transiently co-transfected in suspension HEK293-F cells as described above The harvested supernatant contained a mix of the main products A)<IGF-1R> VL-VH exchange antibody, B) bispecific <ANGPT2-IGF-1R> VL-VH exchange antibody, and C)<ANGPT2> wildtype antibody and is denoted as “Bispecific VL-VH exchange mix”. Bispecific VL-VH exchange mix containing cell culture supernatants, were harvested by centrifugation and subsequently purified as described above.
- The integrity of the antibody mix was analyzed by SDS-PAGE in the presence and absence of a reducing agent and subsequent staining with Coomassie brilliant blue and by size exclusion chromatography as described. The SDS-PAGE showed that there were 2 different heavy and light chain presents in the preparation as expected (reduced gel) (
FIG. 14 ). Characterized samples were provided for subsequent protein analytics and functional characterization. - In order to confirm the presence of functional bispecific <ANGPT2-IGF-1R> VL-VH exchange antibody in the purified bispecific VL-VH exchange mix of the main products A)<IGF-1R> VL-VH exchange antibody, B) bispecific <ANGPT2-IGF-1R> VL-VH exchange antibody, and C)<ANGPT2> wildtype antibody from the transient co-expression described in example 3A, a cellular FACS IGF-1R-ANGPT2 bridging assay on I24 cells (NIH3T3 cells expressing recombinant human IGF-1R, Roche) was performed. The assay principle is depicted in
FIG. 10 . A bispecific <ANGPT2-IGF-1R> VL-VH exchange antibody that is present in the purified antibody mix is capable of binding to IGF-1R in I24 cells and to ANGPT2 simultaneously; and thus will bridge its two target antigens with the two opposed Fab regions. - Briefly, 5×10E5 I24 cells per FACS tube were incubated with total purified antibody mix and incubated on ice for 1 h (titration 160 μg/ml mix). The respective purified antibodies wildtype <IGF-1R> and <ANGPT2> were applied to the I24 cells as controls. Unbound antibody was washed away with 4 ml ice cold PBS (Gibco)+2% FCS (Gibco), cells were centrifuged (5 min at 400 g) and bound bispecific antibody was detected with 50
μl 2 μg/mL human ANGPT2 (R&D Systems) for 1 h on ice. Subsequently, unbound ANGPT2 was washed away once or twice with 4 ml ice cold PBS (Gibco)+2% FCS (Gibco), cells were centrifuged (5 min at 400 g) and bound ANGPT2 was detected with 50 μl 5 μg/mL <ANGPT2> mIgG1-Biotin antibody (BAM0981, R&D Systems) for 45 min on ice; alternatively, cells were incubated with 50 μl 5 μg/mL mIgG1-Biotin-Isotype control (R&D Systems). Unbound detection antibody was washed away with 4 ml ice cold PBS (Gibco)+2% FCS (Gibco), cells were centrifuged (5 min at 400 g) and bound detection antibody was detected with 50 μl 1:400 Streptavidin-PE conjugate (Invitrogen/Zymed) for 45 min on ice protected from light. Unbound Streptavidin-PE conjugate was washed away with 4 ml ice cold PBS+2% FCS. Subsequently, cells were centrifuged (5 min 400 g), resuspended in 300-500 μL PBS and bound Streptavidin-PE conjugate was quantified on a FACSCalibur (BD (FL2 channel, 10.000 cells per acquisition). During the experiment the respective isotype controls were included to exclude any unspecific binding events. In addition, purified monospecific, bivalent IgG1 antibodies <IGF-1R> and <ANGPT2> were included as controls. - The results in
FIG. 15 show that the incubation with purified antibody crossover mix (<ANGPT2-IGF-1R> VL-VH exchange antibody) from the co-expression of a crossover antibody (<IGF-1R> VL-VH exchange antibody) with a wildtype antibody (<ANGPT2> wildtype antibody) resulted in a significant shift in fluorescence indicating the presence of a functional bispecific <ANGPT2-IGF-1R> VL-VH exchange antibody that was capable of binding to IGF-1R in I24 cells and to ANGPT2 simultaneously; and thus bridges its two target antigens with the two opposed Fab regions. In contrast to this the respective <IGF-1R> and <Ang-2> control antibodies did not result in shift in fluorescence in the FACS bridging assay - Taken together these data show that by co-expressing the respective wildtype and crossover plasmids functional bispecific antibodies can be generated. The yields of correct bispecific antibody can be increased by forcing the correct heterodimerization of wildtype and modified crossover heavy chains e.g. using the knobs-into-holes technology as well as disulfide stabilization (see examples 4)
- To further improve the yield of the bispecific <ANGPT2-IGF-1R> VL-VH exchange antibody the knobs-into-holes technology is applied to the co-expression of <IGF-1R> VL-VH exchange and wildtype <ANGPT2> antibodies to obtain a homogenous and functional bispecific antibody preparation. For this purpose, the CH3 domain in the heavy chain* HC* of the <IGF-1R> VL-VH exchange antibody is replaced by the CH3 domain (Knobs) of the SEQ ID NO: 8 with a T366W exchange and the CH3 domain in the heavy chain of the wildtype <ANGPT2> antibody is replaced by the CH3 domain (Hole) of the SEQ ID NO: 9 with a T366S, L368A, Y407V exchange or vice versa. In addition, a disulfide can be included to increase the stability and yields as well as additional residues forming ionic bridges and increasing the heterodimerization yields (EP 1870459A1).
- The transient co-expression, and the purification of the resulting bivalent, bispecific <ANGPT2-IGF-1R> VL-VH exchange antibody with modified CH3 domains (knobs-into-holes) is performed as described in Example 3.
- It should be noted that an optimization of heterodimerization can be achieved e.g. by using different knobs-in-holes technologies such as the introduction of an additional disulfide bridge into the CH3 domain e.g. Y349C into the “knobs chain” and D356C into the “hole chain” and/or combined with the use of residues R409D; K370E (K409D) for knobs residues and D399K; E357K for hole residues described by EP 1870459A1.
- Analogously, further bivalent, bispecific VL-VH exchange antibodies with modified CH3 domains (knobs-into-holes) directed against ANGPT2 and another target antigen (using the above described ANGPT2 heavy and light chain and the VL-VH exchange heavy and light chain*** HC*** and LC*** of an antibody directed against said other target, whereby both heavy chains are modified by “knobs-in-holes”), or directed against IGF-1Rand another target (using the heavy and light chain of an antibody directed against said other target and the above described IGF-1R VL-VH exchange heavy and light chain*** HC*** and LC ***, whereby both heavy chains are modified by “knobs-in-holes”) can be prepared.
Claims (14)
1. A bivalent, bispecific antibody, comprising:
a) the light chain and heavy chain of an antibody specifically binding to a first antigen; and
b) the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH from the antibody specifically binding to a second antigen are replaced by each other.
2. The antibody according to claim 1 , wherein the CH3 domain of one heavy chain and the CH3 domain of the other heavy chain each meet at an interface;
wherein the CH3 domain of one heavy chain is altered so that within the interface the CH3 domain of one heavy chain that meets the interface of the CH3 domain of the other heavy chain within the bivalent, bispecific antibody, an amino acid residue is replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance within the interface of the CH3 domain of one heavy chain which is positionable in a cavity within the interface of the CH3 domain of the other heavy chain; and
wherein the CH3 domain of the other heavy chain is altered, so that within the interface of the second CH3 domain that meets the interface of the first CH3 domain within the bivalent, bispecific antibody an amino acid residue is replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity within the interface of the second CH3 domain within which a protuberance within the interface of the first CH3 domain is positionable.
3. The antibody according to claim 2 , wherein the amino acid residue having a larger side chain volume is selected from the group consisting of arginine (R), phenylalanine (F), tyrosine (Y), tryptophan (W).
4. The antibody according to claim 2 , wherein the amino acid residue having a smaller side chain volume is selected from the group consisting of alanine (A), serine (S), threonine (T), valine (V).
5. The antibody according to claim 2 , wherein both CH3 domains are further altered by the introduction of cysteine (C) as amino acid in the corresponding positions of each CH3 domain.
6. The antibody according to claim 3 , wherein both CH3 domains are further altered by the introduction of cysteine (C) as amino acid in the corresponding positions of each CH3 domain.
7. The antibody according to claim 4 , wherein both CH3 domains are further altered by the introduction of cysteine (C) as amino acid in the corresponding positions of each CH3 domain.
8. The antibody according to claim 1 , wherein one of the CH3 domains is replaced by a constant heavy chain domain CH1; and the other CH3 domain is replaced by a constant light chain domain CL.
9. A method for the preparation of a bivalent, bispecific antibody according to claim 1 comprising the steps of
a) transforming a host cell with
vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a first antigen;
vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH from the antibody specifically binding to a second antigen are replaced by each other;
b) culturing the host cell under conditions that allow synthesis of said antibody molecule; and
c) recovering said antibody molecule from said culture.
10. A host cell comprising:
vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a first antigen;
vectors comprising nucleic acid molecules encoding the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein the variable domains VL and VH from the antibody specifically binding to a second antigen are replaced by each other.
11. A composition comprising a bivalent, bispecific antibody according to claim 1 and at least one pharmaceutically acceptable excipient.
12. A composition comprising a bivalent, bispecific antibody according to claim 2 and at least one pharmaceutically acceptable excipient.
13. A composition comprising a bivalent, bispecific antibody according to claim 5 and at least one pharmaceutically acceptable excipient.
14. A composition comprising a bivalent, bispecific antibody according to claim 8 and at least one pharmaceutically acceptable excipient.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/362,010 US20120164726A1 (en) | 2007-12-21 | 2012-01-31 | Bivalent, bispecific antibodies |
US13/362,000 US10138293B2 (en) | 2007-12-21 | 2012-01-31 | Bivalent, bispecific antibodies |
US14/015,952 US20140120613A1 (en) | 2007-12-21 | 2013-08-30 | Bivalent, bispecific antibodies |
US16/200,295 US10927163B2 (en) | 2007-12-21 | 2018-11-26 | Bivalent, bispecific antibodies |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07024864 | 2007-12-21 | ||
EP07024864.6 | 2007-12-21 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/362,000 Continuation US10138293B2 (en) | 2007-12-21 | 2012-01-31 | Bivalent, bispecific antibodies |
US13/362,010 Division US20120164726A1 (en) | 2007-12-21 | 2012-01-31 | Bivalent, bispecific antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090162359A1 true US20090162359A1 (en) | 2009-06-25 |
Family
ID=39093026
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/332,486 Abandoned US20090162359A1 (en) | 2007-12-21 | 2008-12-11 | Bivalent, bispecific antibodies |
US13/362,010 Abandoned US20120164726A1 (en) | 2007-12-21 | 2012-01-31 | Bivalent, bispecific antibodies |
US13/362,000 Active 2028-12-27 US10138293B2 (en) | 2007-12-21 | 2012-01-31 | Bivalent, bispecific antibodies |
US14/015,952 Abandoned US20140120613A1 (en) | 2007-12-21 | 2013-08-30 | Bivalent, bispecific antibodies |
US16/200,295 Active 2029-02-08 US10927163B2 (en) | 2007-12-21 | 2018-11-26 | Bivalent, bispecific antibodies |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/362,010 Abandoned US20120164726A1 (en) | 2007-12-21 | 2012-01-31 | Bivalent, bispecific antibodies |
US13/362,000 Active 2028-12-27 US10138293B2 (en) | 2007-12-21 | 2012-01-31 | Bivalent, bispecific antibodies |
US14/015,952 Abandoned US20140120613A1 (en) | 2007-12-21 | 2013-08-30 | Bivalent, bispecific antibodies |
US16/200,295 Active 2029-02-08 US10927163B2 (en) | 2007-12-21 | 2018-11-26 | Bivalent, bispecific antibodies |
Country Status (22)
Country | Link |
---|---|
US (5) | US20090162359A1 (en) |
EP (1) | EP2225279B1 (en) |
JP (1) | JP5281097B2 (en) |
KR (1) | KR101249607B1 (en) |
CN (1) | CN101903404B (en) |
AR (1) | AR071547A1 (en) |
AU (1) | AU2008340693A1 (en) |
BR (1) | BRPI0821791B1 (en) |
CA (1) | CA2709023C (en) |
CL (1) | CL2008003781A1 (en) |
CO (1) | CO6280542A2 (en) |
CR (1) | CR11460A (en) |
EC (1) | ECSP10010270A (en) |
ES (1) | ES2469791T3 (en) |
IL (1) | IL206161A0 (en) |
MA (1) | MA31904B1 (en) |
MX (1) | MX2010006396A (en) |
NZ (1) | NZ585627A (en) |
PE (1) | PE20091172A1 (en) |
RU (1) | RU2587616C2 (en) |
TW (1) | TWI359027B (en) |
WO (1) | WO2009080252A1 (en) |
Cited By (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090162360A1 (en) * | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US20100256338A1 (en) * | 2009-04-02 | 2010-10-07 | Ulrich Brinkmann | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
US20100316645A1 (en) * | 2009-06-16 | 2010-12-16 | Sabine Imhof-Jung | Bispecific Antigen Binding Proteins |
US20100322935A1 (en) * | 2009-05-27 | 2010-12-23 | Rebecca Croasdale | Tri- or Tetraspecific Antibodies |
US20130058937A1 (en) * | 2011-08-23 | 2013-03-07 | Johannes Auer | Bispecific antigen binding molecules |
US8703130B2 (en) | 2008-10-08 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
US20140242080A1 (en) * | 2013-02-26 | 2014-08-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
US20150210765A1 (en) * | 2011-05-24 | 2015-07-30 | Zyngenia, Inc. | Multivalent and Monovalent Multispecific Complexes and Their Uses |
WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
WO2016044605A1 (en) | 2014-09-17 | 2016-03-24 | Beatty, Gregory | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
WO2016164731A2 (en) | 2015-04-08 | 2016-10-13 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
WO2016207240A1 (en) * | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
WO2017019894A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
WO2017106810A2 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof |
WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
US9688758B2 (en) | 2012-02-10 | 2017-06-27 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
US9695233B2 (en) | 2012-07-13 | 2017-07-04 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
WO2017125897A1 (en) | 2016-01-21 | 2017-07-27 | Novartis Ag | Multispecific molecules targeting cll-1 |
WO2017149515A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
WO2017181119A2 (en) | 2016-04-15 | 2017-10-19 | Novartis Ag | Compositions and methods for selective protein expression |
WO2017210617A2 (en) | 2016-06-02 | 2017-12-07 | Porter, David, L. | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
WO2018013918A2 (en) | 2016-07-15 | 2018-01-18 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
US9879095B2 (en) | 2010-08-24 | 2018-01-30 | Hoffman-La Roche Inc. | Bispecific antibodies comprising a disulfide stabilized-Fv fragment |
WO2018023025A1 (en) | 2016-07-28 | 2018-02-01 | Novartis Ag | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors |
US9884921B2 (en) | 2014-07-01 | 2018-02-06 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
WO2018026819A2 (en) | 2016-08-01 | 2018-02-08 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
US9890204B2 (en) | 2009-04-07 | 2018-02-13 | Hoffmann-La Roche Inc. | Trivalent, bispecific antibodies |
WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
US9982036B2 (en) | 2011-02-28 | 2018-05-29 | Hoffmann-La Roche Inc. | Dual FC antigen binding proteins |
US9994646B2 (en) | 2009-09-16 | 2018-06-12 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
WO2018160731A1 (en) | 2017-02-28 | 2018-09-07 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
US10106612B2 (en) | 2012-06-27 | 2018-10-23 | Hoffmann-La Roche Inc. | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
US10106600B2 (en) | 2010-03-26 | 2018-10-23 | Roche Glycart Ag | Bispecific antibodies |
WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
US10150800B2 (en) | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
US10155815B2 (en) | 2013-02-26 | 2018-12-18 | Roche Glycart Ag | Bispecific T cell activating antigen binding molecules |
WO2018237157A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
WO2019006007A1 (en) | 2017-06-27 | 2019-01-03 | Novartis Ag | Dosage regimens for anti-tim-3 antibodies and uses thereof |
WO2019018730A1 (en) | 2017-07-20 | 2019-01-24 | Novartis Ag | Dosage regimens of anti-lag-3 antibodies and uses thereof |
WO2019089798A1 (en) | 2017-10-31 | 2019-05-09 | Novartis Ag | Anti-car compositions and methods |
WO2019099838A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
US10323099B2 (en) | 2013-10-11 | 2019-06-18 | Hoffmann-La Roche Inc. | Multispecific domain exchanged common variable light chain antibodies |
EP3514179A1 (en) | 2014-01-24 | 2019-07-24 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
US10364292B2 (en) | 2014-01-06 | 2019-07-30 | Hoffmann-La Roche Inc. | Monovalent blood brain barrier shuttle modules |
WO2019152660A1 (en) | 2018-01-31 | 2019-08-08 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
WO2019200229A1 (en) | 2018-04-13 | 2019-10-17 | Novartis Ag | Dosage regimens for anti-pd-l1 antibodies and uses thereof |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
WO2019226658A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Multispecific antigen-binding compositions and methods of use |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
WO2019226617A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
WO2019241426A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
WO2019246293A2 (en) | 2018-06-19 | 2019-12-26 | Atarga, Llc | Antibody molecules to complement component 5 and uses thereof |
WO2020012337A1 (en) | 2018-07-10 | 2020-01-16 | Novartis Ag | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
US10596257B2 (en) | 2016-01-08 | 2020-03-24 | Hoffmann-La Roche Inc. | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
US10611825B2 (en) | 2011-02-28 | 2020-04-07 | Hoffmann La-Roche Inc. | Monovalent antigen binding proteins |
US10633457B2 (en) | 2014-12-03 | 2020-04-28 | Hoffmann-La Roche Inc. | Multispecific antibodies |
EP3660042A1 (en) | 2014-07-31 | 2020-06-03 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
WO2020128898A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Pharmaceutical combinations |
WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020165868A1 (en) | 2019-02-15 | 2020-08-20 | Perkinelmer Cellular Technologies Germany Gmbh | Low-power microscope-objective pre-scan and high-power microscope-objective scan in x,y and z-direction for imaging objects such as cells using a microscope |
WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020172553A1 (en) | 2019-02-22 | 2020-08-27 | Novartis Ag | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
US10766967B2 (en) | 2015-10-02 | 2020-09-08 | Hoffmann-La Roche Inc. | Bispecific T cell activating antigen binding molecules |
EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
WO2020205523A1 (en) | 2019-03-29 | 2020-10-08 | Atarga, Llc | Anti fgf23 antibody |
EP3722316A1 (en) | 2014-07-21 | 2020-10-14 | Novartis AG | Treatment of cancer using a cd33 chimeric antigen receptor |
US10927163B2 (en) | 2007-12-21 | 2021-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US10941205B2 (en) | 2015-10-02 | 2021-03-09 | Hoffmann-La Roche Inc. | Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use |
WO2021079188A1 (en) | 2019-10-21 | 2021-04-29 | Novartis Ag | Combination therapies with venetoclax and tim-3 inhibitors |
WO2021079195A1 (en) | 2019-10-21 | 2021-04-29 | Novartis Ag | Tim-3 inhibitors and uses thereof |
US11013801B2 (en) | 2015-12-09 | 2021-05-25 | Hoffmann-La Roche Inc. | Treatment method |
WO2021108661A2 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
WO2021123996A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
US20210189011A1 (en) * | 2011-03-28 | 2021-06-24 | Sanofi | Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation |
US11046769B2 (en) | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
WO2021144657A1 (en) | 2020-01-17 | 2021-07-22 | Novartis Ag | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
WO2021146636A1 (en) | 2020-01-17 | 2021-07-22 | Becton, Dickinson And Company | Methods and compositions for single cell secretomics |
WO2021173995A2 (en) | 2020-02-27 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
US11161911B2 (en) | 2017-10-23 | 2021-11-02 | Go Therapeutics, Inc. | Anti-glyco-MUC1 antibodies and their uses |
WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2022013787A1 (en) | 2020-07-16 | 2022-01-20 | Novartis Ag | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules |
WO2022026592A2 (en) | 2020-07-28 | 2022-02-03 | Celltas Bio, Inc. | Antibody molecules to coronavirus and uses thereof |
WO2022029573A1 (en) | 2020-08-03 | 2022-02-10 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022097065A2 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | ANTIBODY Fc VARIANTS |
WO2022104061A1 (en) | 2020-11-13 | 2022-05-19 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
WO2022162569A1 (en) | 2021-01-29 | 2022-08-04 | Novartis Ag | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
US11421022B2 (en) | 2012-06-27 | 2022-08-23 | Hoffmann-La Roche Inc. | Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
WO2022215011A1 (en) | 2021-04-07 | 2022-10-13 | Novartis Ag | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
WO2022243846A1 (en) | 2021-05-18 | 2022-11-24 | Novartis Ag | Combination therapies |
US11603411B2 (en) | 2015-10-02 | 2023-03-14 | Hoffmann-La Roche Inc. | Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use |
WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
US11618790B2 (en) | 2010-12-23 | 2023-04-04 | Hoffmann-La Roche Inc. | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
WO2023150778A1 (en) | 2022-02-07 | 2023-08-10 | Visterra, Inc. | Anti-idiotype antibody molecules and uses thereof |
US11752207B2 (en) | 2017-07-11 | 2023-09-12 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and uses thereof |
WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
WO2024030976A2 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
EP4324518A2 (en) | 2014-01-31 | 2024-02-21 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
US11970538B2 (en) | 2021-05-20 | 2024-04-30 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
Families Citing this family (302)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
EP1523496B1 (en) | 2002-07-18 | 2011-06-29 | Merus B.V. | Recombinant production of mixtures of antibodies |
EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
KR20110124368A (en) | 2009-04-07 | 2011-11-16 | 로슈 글리카트 아게 | Bispecific anti-erbb-2/anti-c-met antibodies |
CN102378768A (en) | 2009-04-07 | 2012-03-14 | 罗氏格黎卡特股份公司 | Bispecific anti-erbb-3/anti-c-met antibodies |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
CN102712769B (en) | 2010-01-29 | 2014-12-03 | 东丽株式会社 | Polylactic acid-based resin sheet |
AR080794A1 (en) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2 |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
SG187120A1 (en) | 2010-07-19 | 2013-02-28 | Hoffmann La Roche | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
WO2012010549A1 (en) | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
KR20130049196A (en) | 2010-08-05 | 2013-05-13 | 에프. 호프만-라 로슈 아게 | Anti-mhc antibody anti-viral cytokine fusion protein |
TR201815863T4 (en) | 2010-11-30 | 2018-11-21 | Chugai Pharmaceutical Co Ltd | Therapeutic agent that induces cytotoxicity. |
CN103502273A (en) | 2011-04-20 | 2014-01-08 | 罗氏格黎卡特股份公司 | Method and constructs for the pH dependent passage of the blood-brain-barrier |
BR112013032235A2 (en) | 2011-06-15 | 2016-11-22 | Hoffmann La Roche | anti-human epo receptor antibodies and methods of use |
BR112013029746B1 (en) | 2011-06-22 | 2021-02-02 | F. Hoffmann-La Roche Ag | method for recombinant production of a complex, complex, pharmaceutical formulation and use of the complex |
BR112014004168A2 (en) | 2011-08-23 | 2017-12-12 | Roche Glycart Ag | bispecific antibody, pharmaceutical composition, use of bispecific antibody, prokaryotic or eukaryotic host cell, antibody production method and invention |
EP2758435A1 (en) | 2011-09-23 | 2014-07-30 | Roche Glycart AG | Bispecific anti-egfr/anti igf-1r antibodies |
ES2732712T3 (en) | 2011-10-31 | 2019-11-25 | Chugai Pharmaceutical Co Ltd | Antigen binding molecule that has a regulated conjugation between the heavy chain and the light chain |
EP2795335B1 (en) | 2011-12-19 | 2017-09-06 | F. Hoffmann-La Roche AG | Method for the detection of free binding partner of a multispecific binder |
WO2013092720A1 (en) | 2011-12-22 | 2013-06-27 | F. Hoffmann-La Roche Ag | Full length antibody display system for eukaryotic cells and its use |
SG10201700169PA (en) | 2011-12-22 | 2017-02-27 | Hoffmann La Roche | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
SG11201403223PA (en) | 2011-12-22 | 2014-07-30 | Hoffmann La Roche | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides |
WO2013113663A1 (en) | 2012-02-01 | 2013-08-08 | F. Hoffmann-La Roche Ag | Method for the detection of a binding partner of a multispecific binder |
MX366965B (en) | 2012-02-03 | 2019-07-31 | Hoffmann La Roche | Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine. |
JP6152120B2 (en) | 2012-02-15 | 2017-06-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Affinity chromatography based on Fc receptors |
KR101674784B1 (en) | 2012-04-05 | 2016-11-09 | 에프. 호프만-라 로슈 아게 | Bispecific antibodies against human tweak and human il17 and uses thereof |
SG10201607371UA (en) | 2012-04-20 | 2016-10-28 | Merus Nv | Methods and means for the production of ig-like molecules |
US9062120B2 (en) | 2012-05-02 | 2015-06-23 | Janssen Biotech, Inc. | Binding proteins having tethered light chains |
KR20150013188A (en) * | 2012-05-24 | 2015-02-04 | 에프. 호프만-라 로슈 아게 | Multispecific antibodies |
CA2872192A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Anti-biotin antibodies and methods of use |
BR112014030843A2 (en) | 2012-07-04 | 2019-10-15 | Hoffmann La Roche | anti-theophylline antibody, pharmaceutical formulation and use of the antibody |
CN107973856B (en) | 2012-07-04 | 2021-11-23 | 弗·哈夫曼-拉罗切有限公司 | Covalently linked antigen-antibody conjugates |
CN104471397B (en) | 2012-07-13 | 2018-03-23 | 弗·哈夫曼-拉罗切有限公司 | Method for detecting polyspecific conjugate |
RU2646159C2 (en) | 2012-09-14 | 2018-03-01 | Ф. Хоффманн-Ля Рош Аг | Method for production and selection of molecules including, at least two different groups, and application thereof |
SG10201705787VA (en) | 2012-09-27 | 2017-08-30 | Merus Nv | BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS |
WO2014056783A1 (en) * | 2012-10-08 | 2014-04-17 | Roche Glycart Ag | Fc-free antibodies comprising two fab-fragments and methods of use |
US9725512B2 (en) | 2012-11-08 | 2017-08-08 | Hoffmann-La Roche Inc. | HER3 antibodies binding to the beta-hairpin of HER3 |
EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
EP2762497A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
WO2014122143A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | Method for the selection of antibodies against bcma |
KR20150122761A (en) | 2013-02-26 | 2015-11-02 | 로슈 글리카트 아게 | Bispecific t cell activating antigen binding molecules |
UA118028C2 (en) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use |
EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
WO2014177459A2 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
KR102282134B1 (en) | 2013-04-29 | 2021-07-27 | 에프. 호프만-라 로슈 아게 | Human fcrn-binding modified antibodies and methods of use |
SG10201810481UA (en) | 2013-04-29 | 2018-12-28 | Hoffmann La Roche | Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases |
WO2015025054A1 (en) | 2013-08-22 | 2015-02-26 | Medizinische Universität Wien | Dye-specific antibodies for prestained molecular weight markers and methods producing the same |
JP6534615B2 (en) | 2013-09-27 | 2019-06-26 | 中外製薬株式会社 | Method for producing polypeptide heteromultimer |
EP3071597B1 (en) | 2013-11-21 | 2020-07-29 | F.Hoffmann-La Roche Ag | Anti-alpha-synuclein antibodies and methods of use |
MX2016008098A (en) | 2013-12-20 | 2017-01-11 | Hoffmann La Roche | Bispecific her2 antibodies and methods of use. |
PL3083680T3 (en) | 2013-12-20 | 2020-06-29 | F. Hoffmann-La Roche Ag | Humanized anti-tau(ps422) antibodies and methods of use |
CN105873615B (en) | 2014-01-03 | 2020-12-25 | 豪夫迈·罗氏有限公司 | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
WO2015101586A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
CN105873616B (en) | 2014-01-03 | 2020-06-05 | 豪夫迈·罗氏有限公司 | Covalently linked polypeptide toxin-antibody conjugates |
CA2931986A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
SG11201607109QA (en) | 2014-02-28 | 2016-09-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
EP3470435B1 (en) | 2014-02-28 | 2020-08-05 | Merus N.V. | Antibody that binds erbb-2 and erbb-3 |
SG11201608054YA (en) | 2014-04-02 | 2016-10-28 | Hoffmann La Roche | Method for detecting multispecific antibody light chain mispairing |
UA117289C2 (en) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Multispecific antibodies |
AU2015244814B2 (en) | 2014-04-07 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
WO2015171822A1 (en) * | 2014-05-06 | 2015-11-12 | Genentech, Inc. | Production of heteromultimeric proteins using mammalian cells |
AU2015260230A1 (en) | 2014-05-13 | 2016-11-17 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
AR100978A1 (en) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME |
CA2947504A1 (en) | 2014-06-26 | 2015-12-30 | F. Hoffmann-La Roche Ag | Anti-brdu antibodies and methods of use |
TW201623329A (en) | 2014-06-30 | 2016-07-01 | 亞佛瑞司股份有限公司 | Vaccines and monoclonal antibodies targeting truncated variants of osteopontin and uses thereof |
NZ728041A (en) | 2014-07-10 | 2023-01-27 | Affiris Ag | Substances and methods for the use in prevention and/or treatment in huntington’s disease |
EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
PE20170263A1 (en) | 2014-08-04 | 2017-03-30 | Hoffmann La Roche | T-CELL ACTIVATING ANTIGEN-BINDING BI-SPECIFIC MOLECULES |
MA40764A (en) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
JP6708635B2 (en) * | 2014-10-09 | 2020-06-10 | エンクマフ エスアーエールエル | Bispecific antibodies to CD3ε and ROR1 |
JP6576456B2 (en) | 2014-11-06 | 2019-09-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Fc region variants with modified FcRn binding properties and protein A binding properties |
WO2016071376A2 (en) | 2014-11-06 | 2016-05-12 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn-binding and methods of use |
SG11201703458UA (en) * | 2014-11-10 | 2017-05-30 | Hoffmann La Roche | Anti-ang2 antibodies and methods of use |
JP2017537896A (en) | 2014-11-10 | 2017-12-21 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Bispecific antibodies and methods for use in ophthalmology |
EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
SG11201704056XA (en) | 2014-11-20 | 2017-06-29 | Hoffmann La Roche | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists |
EP3227341A1 (en) | 2014-12-02 | 2017-10-11 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies |
RU2698205C2 (en) | 2014-12-18 | 2019-08-23 | Ф. Хоффманн-Ля Рош Аг | Method for determining antibodies that induce complement-dependent cytotoxicity |
AU2016252773B2 (en) | 2015-04-24 | 2022-06-02 | Genentech, Inc. | Multispecific antigen-binding proteins |
US9862763B2 (en) | 2015-06-24 | 2018-01-09 | Hoffmann-La Roche Inc. | Humanized anti-tau(pS422) antibodies and methods of use |
EP3319993B1 (en) | 2015-07-10 | 2020-01-15 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
CA2991880A1 (en) | 2015-07-10 | 2017-01-19 | Merus N.V. | Human cd3 binding antibody |
HUE048939T2 (en) | 2015-08-03 | 2020-09-28 | Engmab Sarl | Monoclonal antibodies against human b cell maturation antigen (bcma) |
BR112018006251A2 (en) | 2015-09-30 | 2018-10-16 | Janssen Biotech Inc | antagonist antibodies that specifically bind to human cd40 and methods of use |
AR106188A1 (en) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE |
EP3150636A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
US20170096485A1 (en) | 2015-10-02 | 2017-04-06 | Hoffmann-La Roche Inc. | Bispecific t cell activating antigen binding molecules |
WO2017055395A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xrob04 bispecific t cell activating antigen binding molecules |
AR106199A1 (en) * | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | T-CELL ACTIVATING ANTIGEN BINDING MOLECULES OF ANTIGEN |
PE20240096A1 (en) | 2015-10-02 | 2024-01-18 | Hoffmann La Roche | BISPECIFIC ANTIBODIES SPECIFIC FOR A CO-STIMULATORY TNF RECEPTOR |
WO2017055385A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xgd2 bispecific t cell activating antigen binding molecules |
CN108026177B (en) | 2015-10-02 | 2021-11-26 | 豪夫迈·罗氏有限公司 | Bispecific anti-CD 19XCD 3T cell activating antigen binding molecules |
MY192202A (en) | 2015-10-02 | 2022-08-06 | Hoffmann La Roche | Bispecific antibodies specific for pd1 and tim3 |
WO2017055399A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Cellular based fret assay for the determination of simultaneous binding |
WO2017055393A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules |
EP3150637A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Multispecific antibodies |
WO2017055392A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules |
KR102072317B1 (en) | 2015-10-02 | 2020-01-31 | 에프. 호프만-라 로슈 아게 | Anti-PD1 Antibodies and Methods of Use |
JP7074665B2 (en) | 2015-10-07 | 2022-05-24 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Field of Invention of Tetravalent Bispecific Antibodies to Co-Stimulated TNF Receptors |
ES2865482T3 (en) | 2015-10-23 | 2021-10-15 | Merus Nv | Binding molecules that inhibit cancer growth |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
WO2017072210A1 (en) | 2015-10-29 | 2017-05-04 | F. Hoffmann-La Roche Ag | Anti-variant fc-region antibodies and methods of use |
CN109195626B (en) | 2015-10-30 | 2022-09-13 | 银河生物技术有限责任公司 | Antibodies that bind to death receptor 4 and death receptor 5 |
JP2019500892A (en) | 2015-11-03 | 2019-01-17 | ヤンセン バイオテツク,インコーポレーテツド | Antibodies that specifically bind to TIM-3 and uses thereof |
US11649293B2 (en) | 2015-11-18 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
JP6931329B2 (en) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | Combination therapy using T cell redirection antigen-binding molecule for cells with immunosuppressive function |
EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
CN108601830B (en) * | 2015-12-18 | 2023-02-03 | 比奥根Ma公司 | Bispecific antibody platforms |
EP3398965A4 (en) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of fc region-containing polypeptide |
AU2017233658B2 (en) | 2016-03-14 | 2023-09-21 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
ES2947230T3 (en) | 2016-03-22 | 2023-08-03 | Hoffmann La Roche | Bispecific molecules for protease-activated T lymphocytes |
PE20181890A1 (en) | 2016-05-02 | 2018-12-11 | Hoffmann La Roche | CONTORSBODY - A MONOCATENARIO DIANA LEAGUE |
AU2017268234A1 (en) | 2016-05-17 | 2018-12-13 | Genentech, Inc. | Stromal gene signatures for diagnosis and use in immunotherapy |
CA3059010A1 (en) | 2016-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
AU2017286676A1 (en) | 2016-06-17 | 2018-12-13 | F. Hoffmann La-Roche Ag | Purification of multispecific antibodies |
CA3030841A1 (en) | 2016-07-14 | 2018-01-18 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
WO2018031258A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions |
CN109843916B (en) | 2016-08-12 | 2023-10-31 | 詹森生物科技公司 | Fc-engineered anti-TNFR superfamily member antibodies with enhanced agonistic activity and methods of use thereof |
EP3515932B1 (en) | 2016-09-19 | 2023-11-22 | F. Hoffmann-La Roche AG | Complement factor based affinity chromatography |
WO2018060035A1 (en) | 2016-09-30 | 2018-04-05 | F. Hoffmann-La Roche Ag | Spr-based dual-binding assay for the functional analysis of multispecific molecules |
CN109843926B (en) | 2016-09-30 | 2023-01-20 | 豪夫迈·罗氏有限公司 | Bispecific antibodies against CD3 |
SG11201903359RA (en) | 2016-11-02 | 2019-05-30 | Engmab Sarl | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
TW201829463A (en) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | Anti-hla-g antibodies and use thereof |
WO2018098363A2 (en) | 2016-11-23 | 2018-05-31 | Bioverativ Therapeutics Inc. | Bispecific antibodies binding to coagulation factor ix and coagulation factor x |
TWI829628B (en) | 2016-12-19 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | Combination therapy with targeted 4-1bb (cd137) agonists |
WO2018114748A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists |
BR112019010294A2 (en) | 2016-12-21 | 2019-09-03 | Hoffmann La Roche | method for the enzymatic production of an antibody, antibody and pharmaceutical formulation |
CA3044920C (en) | 2016-12-21 | 2022-06-28 | Roberto Falkenstein | In vitro glycoengineering of antibodies |
AU2017381656B2 (en) | 2016-12-21 | 2020-07-02 | F. Hoffmann-La Roche Ag | Re-use of enzymes in in vitro glycoengineering of antibodies |
TW201829469A (en) | 2017-01-03 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9 |
NZ756132A (en) | 2017-03-10 | 2022-02-25 | Hoffmann La Roche | Method for producing multispecific antibodies |
EP3601345A1 (en) | 2017-03-29 | 2020-02-05 | H. Hoffnabb-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
JP7205995B2 (en) | 2017-03-29 | 2023-01-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Bispecific antigen-binding molecules for co-stimulatory TNF receptors |
SG11201908772TA (en) | 2017-03-31 | 2019-10-30 | Genmab Holding B V | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof |
MX2019011660A (en) | 2017-03-31 | 2019-11-18 | Merus Nv | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene. |
ES2955852T3 (en) | 2017-04-03 | 2023-12-07 | Hoffmann La Roche | STEAP-1 binding antibodies |
EP3606947B1 (en) | 2017-04-03 | 2022-12-21 | F. Hoffmann-La Roche AG | Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody |
RU2766234C2 (en) | 2017-04-04 | 2022-02-10 | Ф. Хоффманн-Ля Рош Аг | New bispecific antigen-binding molecules with capability of specifically binding to cd40 and fap |
CN116375876A (en) | 2017-04-05 | 2023-07-04 | 豪夫迈·罗氏有限公司 | Bispecific antibodies that specifically bind PD1 and LAG3 |
SI3606954T1 (en) | 2017-04-05 | 2022-10-28 | F. Hoffmann - La Roche Ag | Anti-lag3 antibodies |
US20180344869A1 (en) | 2017-05-18 | 2018-12-06 | Hoffmann-La Roche Inc. | Reduction of application-related side reaction of a therapeutic antibody |
MX2019014577A (en) | 2017-06-05 | 2020-07-29 | Janssen Biotech Inc | Antibodies that specifically bind pd-1 and methods of use. |
MX2019014407A (en) | 2017-06-07 | 2020-02-05 | Genmab Bv | Therapeutic antibodies based on mutated igg hexamers. |
CN107325184A (en) * | 2017-08-08 | 2017-11-07 | 安徽大学 | The bispecific antibody of a kind of targeting EGFR and HER2 and its application |
MX2020001432A (en) | 2017-08-09 | 2020-03-20 | Merus Nv | Antibodies that bind egfr and cmet. |
WO2019077092A1 (en) | 2017-10-20 | 2019-04-25 | F. Hoffmann-La Roche Ag | Method for generating multispecific antibodies from monospecific antibodies |
JP7438942B2 (en) | 2017-10-30 | 2024-02-27 | エフ. ホフマン-ラ ロシュ アーゲー | Methods for in vivo generation of multispecific antibodies from monospecific antibodies |
EP3703821A2 (en) | 2017-11-01 | 2020-09-09 | F. Hoffmann-La Roche AG | Bispecific 2+1 contorsbodies |
CA3079036A1 (en) | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | Combination therapy with targeted ox40 agonists |
EP3717916A1 (en) | 2017-11-29 | 2020-10-07 | H. Hoffnabb-La Roche Ag | Target interference suppressed anti-drug antibody assay |
AU2018390881A1 (en) | 2017-12-21 | 2020-07-02 | F. Hoffmann-La Roche Ag | Antibodies binding to HLA-A2/WT1 |
JP7074859B2 (en) | 2017-12-22 | 2022-05-24 | エフ.ホフマン-ラ ロシュ アーゲー | Method of depletion of light chain mismatched antibody variants by hydrophobic interaction chromatography |
JP7436365B2 (en) | 2017-12-29 | 2024-02-21 | エフ. ホフマン-ラ ロシュ アーゲー | Anti-VEGF antibodies and methods of use |
EP3737949A1 (en) | 2018-01-12 | 2020-11-18 | Genzyme Corporation | Methods for the quantitation of polypeptides |
JP2021511782A (en) | 2018-01-31 | 2021-05-13 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Stabilized immunoglobulin domain |
WO2019149716A1 (en) | 2018-01-31 | 2019-08-08 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising an antigen-binding site binding to lag3 |
PE20211116A1 (en) | 2018-02-08 | 2021-06-23 | Genentech Inc | BISPECIFIC ANTIGEN BINDING MOLECULES AND METHODS OF USE |
TWI829667B (en) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | Antibodies binding to gprc5d |
TW202003561A (en) | 2018-03-13 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | Combination therapy with targeted 4-1BB (CD137) agonists |
AU2019236372A1 (en) | 2018-03-13 | 2020-07-30 | F. Hoffmann-La Roche Ag | Therapeutic combination of 4-1 BB agonists with anti-CD20 antibodies |
KR20200135510A (en) | 2018-03-29 | 2020-12-02 | 제넨테크, 인크. | Regulation of lactation stimulating activity in mammalian cells |
AR115052A1 (en) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | MULTI-SPECIFIC ANTIBODIES AND THE USE OF THEM |
AR114789A1 (en) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | ANTI-HLA-G ANTIBODIES AND THE USE OF THEM |
CN112166196A (en) | 2018-05-18 | 2021-01-01 | 豪夫迈·罗氏有限公司 | Targeted intracellular delivery of large nucleic acids |
EA202092830A1 (en) | 2018-05-23 | 2021-04-08 | Селджин Корпорейшн | ANTIPROLIFERATIVE COMPOUNDS AND SPECIFIC ANTIBODIES TO BCMA AND CD3 FOR COMBINED USE |
PE20211916A1 (en) | 2018-05-24 | 2021-09-28 | Janssen Biotech Inc | BINDING AGENTS OF PSMA AND USES OF THEM |
KR20210011999A (en) | 2018-05-24 | 2021-02-02 | 얀센 바이오테크 인코포레이티드 | Monospecific and multispecific anti-TMEFF2 antibodies and uses thereof |
PE20210132A1 (en) | 2018-05-24 | 2021-01-19 | Janssen Biotech Inc | ANTI-CD3 ANTIBODIES AND USES OF THEM |
WO2019233842A1 (en) | 2018-06-08 | 2019-12-12 | F. Hoffmann-La Roche Ag | Peptidic linker with reduced post-translational modification |
TW202035447A (en) | 2018-07-04 | 2020-10-01 | 瑞士商赫孚孟拉羅股份公司 | Novel bispecific agonistic 4-1bb antigen binding molecules |
CA3092456C (en) | 2018-07-25 | 2024-03-12 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-tigit antibody and use thereof |
EP3608674A1 (en) | 2018-08-09 | 2020-02-12 | Regeneron Pharmaceuticals, Inc. | Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor |
MX2021003548A (en) | 2018-10-01 | 2021-05-27 | Hoffmann La Roche | Bispecific antigen binding molecules comprising anti-fap clone 212. |
CN112654641A (en) | 2018-10-01 | 2021-04-13 | 豪夫迈·罗氏有限公司 | Bispecific antigen binding molecules with trivalent binding to CD40 |
MA53812A (en) | 2018-10-04 | 2021-08-11 | Genmab Holding B V | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTI-CD37 ANTIBODIES |
WO2020084034A1 (en) | 2018-10-26 | 2020-04-30 | F. Hoffmann-La Roche Ag | Multispecific antibody screening method using recombinase mediated cassette exchange |
WO2020089437A1 (en) | 2018-10-31 | 2020-05-07 | Engmab Sàrl | Combination therapy |
KR20210124959A (en) | 2018-11-06 | 2021-10-15 | 젠맵 에이/에스 | antibody formulation |
MX2021007421A (en) | 2018-12-21 | 2021-08-05 | Hoffmann La Roche | Antibody that binds to vegf and il-1beta and methods of use. |
CN113286821A (en) | 2018-12-21 | 2021-08-20 | 豪夫迈·罗氏有限公司 | Tumor-targeting agonistic CD28 antigen binding molecules |
CR20210325A (en) | 2018-12-21 | 2021-07-20 | Hoffmann La Roche | Antibodies binding to cd3 |
JP2022513495A (en) | 2018-12-21 | 2022-02-08 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Tumor targeting superagonist CD28 antigen binding molecule |
CN113412123A (en) | 2018-12-28 | 2021-09-17 | 豪夫迈·罗氏有限公司 | peptide-MHC-I-antibody fusion proteins for therapeutic use in patients with enhanced immune response |
CN111378045B (en) * | 2018-12-28 | 2022-08-02 | 长春金赛药业有限责任公司 | Bivalent and bispecific antibody, preparation method thereof, encoding gene, host cell and composition |
EP3903102B1 (en) | 2018-12-30 | 2023-04-12 | F. Hoffmann-La Roche AG | Ph-gradient spr-based binding assay |
JP2022521610A (en) | 2019-02-26 | 2022-04-11 | ヤンセン バイオテツク,インコーポレーテツド | Combination therapy with bispecific anti-EGFR / C-MET antibody and patient stratification |
JP7249432B2 (en) | 2019-03-29 | 2023-03-30 | エフ. ホフマン-ラ ロシュ アーゲー | SPR-based binding assays for functional analysis of multivalent molecules |
EP3947440A1 (en) | 2019-03-29 | 2022-02-09 | F. Hoffmann-La Roche AG | Method for generating avid-binding multispecific antibodies |
MA55717A (en) | 2019-04-19 | 2022-02-23 | Janssen Biotech Inc | METHODS OF TREATMENT OF PROSTATE CANCER WITH ANTI-PSMA/CD3 ANTIBODY |
CA3139508A1 (en) | 2019-05-08 | 2020-11-12 | Janssen Biotech, Inc. | Materials and methods for modulating t cell mediated immunity |
JP2022534674A (en) | 2019-05-09 | 2022-08-03 | メルス ナムローゼ フェンノートシャップ | Mutant domains that multimerize proteins and their isolation |
CN113795514A (en) | 2019-05-09 | 2021-12-14 | 豪夫迈·罗氏有限公司 | Method for producing antibody |
EP3969907A1 (en) | 2019-05-13 | 2022-03-23 | F. Hoffmann-La Roche AG | Interference-suppressed pharmacokinetic immunoassay |
WO2020230091A1 (en) | 2019-05-14 | 2020-11-19 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
KR20220024636A (en) | 2019-06-19 | 2022-03-03 | 에프. 호프만-라 로슈 아게 | Methods of Generation of Multivalent, Multispecific Antibody Expression Cells by Targeted Integration of Multiple Expression Cassettes of Defined Tissues |
CA3140318A1 (en) * | 2019-06-19 | 2020-12-24 | Johannes Auer | Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
EP3986925A1 (en) | 2019-06-19 | 2022-04-27 | F. Hoffmann-La Roche AG | Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
KR20220010549A (en) | 2019-06-19 | 2022-01-25 | 에프. 호프만-라 로슈 아게 | Methods of Generating Multivalent Bispecific Antibody Expression Cells by Targeted Integration of Multiple Expression Cassettes in Defined Tissues |
MX2021015536A (en) | 2019-06-19 | 2022-02-10 | Hoffmann La Roche | Method for the generation of a protein expressing cell by targeted integration using cre mrna. |
BR112021026286A2 (en) | 2019-06-26 | 2022-03-03 | Hoffmann La Roche | Method for increasing the heterologous polypeptide titer and/or reducing lactate production of a recombinant mammalian cell and methods for producing a heterologous polypeptide and a recombinant mammalian cell |
AR119393A1 (en) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | ANTIBODIES THAT BIND NKG2D |
CN114174338A (en) | 2019-07-31 | 2022-03-11 | 豪夫迈·罗氏有限公司 | Antibodies that bind to GPRC5D |
SG11202112491WA (en) | 2019-07-31 | 2021-12-30 | Hoffmann La Roche | Antibodies binding to gprc5d |
WO2021048034A1 (en) | 2019-09-09 | 2021-03-18 | F. Hoffmann-La Roche Ag | Glucocerebrosidase mutants |
BR112022004972A2 (en) | 2019-09-18 | 2022-06-28 | Genentech Inc | ANTIBODIES, ISOLATED NUCLEIC ACIDS, ISOLATED HOST CELLS, METHODS OF PRODUCTION OF AN ANTIBODY, OF PRODUCTION OF A BIESPECIFIC ANTIBODY, AND OF TREATMENT OF AN INDIVIDUAL, BIESPECIFIC ANTIBODIES, PHARMACEUTICAL COMPOSITION, ANTIBODY, BIESPECIFIC ANTIBODY OR PHARMACEUTICAL COMPOSITION OF THE ANTIBODY, USE OF A COMBINATION OF THE ANTIBODY AND METHODS TO REDUCE INFLAMMATION AND TO IMPROVE SCALING AND/OR SKIN ERUPTION AND COMBINATION FOR USE |
CN112574308A (en) | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | Antibodies targeting BCMA, bispecific antibodies and uses thereof |
AU2020384917A1 (en) | 2019-11-15 | 2022-03-31 | F. Hoffmann-La Roche Ag | Prevention of visible particle formation in aqueous protein solutions |
CN114867532A (en) | 2019-12-18 | 2022-08-05 | 豪夫迈·罗氏有限公司 | Bispecific anti-CCL 2 antibodies |
JP7296467B2 (en) | 2019-12-18 | 2023-06-22 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Antibodies that bind to HLA-A2/MAGE-A4 |
MX2022007746A (en) | 2019-12-23 | 2022-10-07 | Genentech Inc | Apolipoprotein l1-specific antibodies and methods of use. |
CN114930170A (en) | 2020-01-02 | 2022-08-19 | 豪夫迈·罗氏有限公司 | Method for determining the amount of therapeutic antibody in the brain |
JP2023510382A (en) | 2020-01-15 | 2023-03-13 | エフ. ホフマン-ラ ロシュ アーゲー | Methods for reducing impurities from recombinant protein manufacturing processes |
EP4114860A1 (en) | 2020-03-06 | 2023-01-11 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
CN115315512A (en) | 2020-03-26 | 2022-11-08 | 基因泰克公司 | Modified mammalian cells with reduced host cell proteins |
WO2021198034A1 (en) | 2020-03-30 | 2021-10-07 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf and pdgf-b and methods of use |
AR121706A1 (en) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | OX40 AND FAP-TARGETED BSPECIFIC ANTIGEN-BINDING MOLECULES |
WO2021222552A1 (en) | 2020-04-30 | 2021-11-04 | Celgene Corporation | Methods of treating cytokine-related adverse events |
JP2023520249A (en) | 2020-05-15 | 2023-05-16 | エフ. ホフマン-ラ ロシュ アーゲー | Method for preventing visible particle formation in parenteral protein solutions |
CN115605185A (en) | 2020-05-19 | 2023-01-13 | 豪夫迈·罗氏有限公司(Ch) | Use of a chelating agent to prevent the formation of visible particles in parenteral protein solutions |
CN116462766A (en) | 2020-05-21 | 2023-07-21 | 美勒斯公司 | Methods and means for producing IG-like molecules |
CR20220659A (en) | 2020-06-08 | 2023-08-21 | Hoffmann La Roche | Anti-hbv antibodies and methods of use |
EP4165409A1 (en) | 2020-06-16 | 2023-04-19 | F. Hoffmann-La Roche AG | Method for determining the free antigen of an antibody in a sample |
EP4168456A1 (en) | 2020-06-19 | 2023-04-26 | F. Hoffmann-La Roche AG | Antibodies binding to cd3 |
TWI811703B (en) | 2020-06-19 | 2023-08-11 | 瑞士商赫孚孟拉羅股份公司 | Antibodies binding to cd3 and cd19 |
EP4168446A1 (en) | 2020-06-19 | 2023-04-26 | F. Hoffmann-La Roche AG | Antibodies binding to cd3 and folr1 |
WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
MX2022015795A (en) | 2020-06-23 | 2023-01-24 | Hoffmann La Roche | Agonistic cd28 antigen binding molecules targeting her2. |
CA3184747A1 (en) | 2020-06-24 | 2021-12-30 | Genentech, Inc. | Apoptosis resistant cell lines |
WO2021260064A1 (en) | 2020-06-25 | 2021-12-30 | F. Hoffmann-La Roche Ag | Anti-cd3/anti-cd28 bispecific antigen binding molecules |
US20230235090A1 (en) | 2020-06-30 | 2023-07-27 | Harbour Biomed US, Inc. | Bispecific antibody and use thereof |
JP2023531670A (en) | 2020-06-30 | 2023-07-25 | 諾納生物(蘇州)有限公司 | Anti-B7H4 Antibodies and Bispecific Antibodies Thereof and Uses |
JP2023532764A (en) | 2020-07-07 | 2023-07-31 | エフ. ホフマン-ラ ロシュ アーゲー | Alternative surfactants as stabilizers for therapeutic protein formulations |
US20230303682A1 (en) | 2020-07-17 | 2023-09-28 | Genentech, Inc. | Anti-Notch2 Antibodies and Methods of Use |
WO2022018178A1 (en) | 2020-07-24 | 2022-01-27 | F. Hoffmann-La Roche Ag | Method for the expression of an antibody-multimer-fusion |
TW202227625A (en) | 2020-08-28 | 2022-07-16 | 美商建南德克公司 | Crispr/cas9 multiplex knockout of host cell proteins |
WO2022049165A1 (en) | 2020-09-04 | 2022-03-10 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf-a and ang2 and methods of use |
AU2021342566A1 (en) | 2020-09-21 | 2023-03-02 | Genentech, Inc. | Purification of multispecific antibodies |
CA3195257A1 (en) | 2020-09-24 | 2022-03-31 | F. Hoffmann-La Roche Ag | Mammalian cell lines with gene knockout |
AR123855A1 (en) | 2020-10-20 | 2023-01-18 | Genentech Inc | PEG-CONJUGATED ANTI-MERTK ANTIBODIES AND METHODS OF USE |
EP4244254A1 (en) | 2020-11-16 | 2023-09-20 | F. Hoffmann-La Roche AG | Combination therapy with fap-targeted cd40 agonists |
JP2023553157A (en) | 2020-12-10 | 2023-12-20 | ユーティレックス カンパニー リミテッド | Anti-PD-1 antibody and its uses |
AU2021399841A1 (en) | 2020-12-17 | 2023-07-06 | F. Hoffmann-La Roche Ag | Anti-hla-g antibodies and use thereof |
WO2022136140A1 (en) | 2020-12-22 | 2022-06-30 | F. Hoffmann-La Roche Ag | Oligonucleotides targeting xbp1 |
US20240043540A1 (en) | 2020-12-23 | 2024-02-08 | Innovent Biologics (Singapore) Pte. Ltd. | Anti-b7-h3 antibody and uses thereof |
CN114716548A (en) | 2021-01-05 | 2022-07-08 | (株)爱恩德生物 | anti-FGFR 3 antibodies and uses thereof |
JP2024503826A (en) | 2021-01-06 | 2024-01-29 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Combination therapy using PD1-LAG3 bispecific antibody and CD20 T cell bispecific antibody |
CA3210246A1 (en) | 2021-01-28 | 2022-08-04 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
JP2024505600A (en) | 2021-02-03 | 2024-02-06 | モーツァルト セラピューティクス, インコーポレイテッド | Binders and how to use them |
JP2024509695A (en) | 2021-02-03 | 2024-03-05 | ジェネンテック, インコーポレイテッド | Multispecific binding proteolysis platform and methods of use |
JP2024505987A (en) | 2021-02-04 | 2024-02-08 | イノベント バイオロジクス(スーチョウ)カンパニー,リミティド | Anti-TNFR2 antibodies and their uses |
JP2024512240A (en) | 2021-02-18 | 2024-03-19 | エフ. ホフマン-ラ ロシュ アーゲー | Methods for elucidating complex multistep antibody interactions |
JP2024512324A (en) | 2021-03-05 | 2024-03-19 | ジーオー セラピューティクス,インコーポレイテッド | Anti-glycoCD44 antibodies and their uses |
CA3212669A1 (en) | 2021-03-09 | 2022-09-15 | Janssen Biotech, Inc. | Treatment of cancers lacking egfr-activating mutations |
WO2022192647A1 (en) | 2021-03-12 | 2022-09-15 | Genentech, Inc. | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
JP2024513474A (en) | 2021-04-09 | 2024-03-25 | エフ. ホフマン-ラ ロシュ アーゲー | Method for selecting cell clones expressing heterologous polypeptides |
EP4319820A1 (en) | 2021-04-10 | 2024-02-14 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
EP4326855A1 (en) | 2021-04-19 | 2024-02-28 | Genentech, Inc. | Modified mammalian cells |
WO2022226317A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
IL307821A (en) | 2021-04-30 | 2023-12-01 | Hoffmann La Roche | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
CN117321078A (en) | 2021-04-30 | 2023-12-29 | 豪夫迈·罗氏有限公司 | Administration for combination therapy with anti-CD 20/anti-CD 3 bispecific antibody and anti-CD 79B antibody drug conjugates |
TW202309094A (en) | 2021-05-18 | 2023-03-01 | 美商健生生物科技公司 | Methods for identifying cancer patients for combination treatment |
WO2022243261A1 (en) | 2021-05-19 | 2022-11-24 | F. Hoffmann-La Roche Ag | Agonistic cd40 antigen binding molecules targeting cea |
WO2022246259A1 (en) | 2021-05-21 | 2022-11-24 | Genentech, Inc. | Modified cells for the production of a recombinant product of interest |
CN113278071B (en) | 2021-05-27 | 2021-12-21 | 江苏荃信生物医药股份有限公司 | Anti-human interferon alpha receptor1 monoclonal antibody and application thereof |
AR126009A1 (en) | 2021-06-02 | 2023-08-30 | Hoffmann La Roche | CD28 ANTIGEN-BINDING AGONIST MOLECULES THAT TARGET EPCAM |
WO2022263501A1 (en) | 2021-06-18 | 2022-12-22 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
WO2022262868A1 (en) | 2021-06-18 | 2022-12-22 | 和铂医药(上海)有限责任公司 | Bispecific antibody combination and use thereof |
KR20240028452A (en) | 2021-07-02 | 2024-03-05 | 제넨테크, 인크. | Methods and compositions for treating cancer |
WO2023287663A1 (en) | 2021-07-13 | 2023-01-19 | Genentech, Inc. | Multi-variate model for predicting cytokine release syndrome |
CA3219606A1 (en) | 2021-07-22 | 2023-01-26 | F. Hoffmann-La Roche Ag | Heterodimeric fc domain antibodies |
AU2022317820A1 (en) | 2021-07-28 | 2023-12-14 | F. Hoffmann-La Roche Ag | Methods and compositions for treating cancer |
WO2023012147A1 (en) | 2021-08-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use |
CA3228178A1 (en) | 2021-08-05 | 2023-02-09 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
IL310578A (en) | 2021-08-09 | 2024-03-01 | Harbour Biomed Shanghai Co Ltd | Cldn18.2-targeting antibody, bispecific antibody and use thereof |
AU2022339667A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
WO2023034571A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
CN113683694B (en) | 2021-09-03 | 2022-05-13 | 江苏荃信生物医药股份有限公司 | Anti-human TSLP monoclonal antibody and application thereof |
CN113603775B (en) | 2021-09-03 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | Anti-human interleukin-33 monoclonal antibody and application thereof |
EP4148067A1 (en) | 2021-09-08 | 2023-03-15 | F. Hoffmann-La Roche AG | Method for the expression of an antibody-multimer-fusion |
WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
WO2023094282A1 (en) | 2021-11-25 | 2023-06-01 | F. Hoffmann-La Roche Ag | Quantification of low amounts of antibody sideproducts |
US20230183360A1 (en) | 2021-12-09 | 2023-06-15 | Janssen Biotech, Inc. | Use of Amivantamab to Treat Colorectal Cancer |
AR127887A1 (en) | 2021-12-10 | 2024-03-06 | Hoffmann La Roche | ANTIBODIES THAT BIND CD3 AND PLAP |
TW202340248A (en) | 2021-12-20 | 2023-10-16 | 瑞士商赫孚孟拉羅股份公司 | Agonistic ltbr antibodies and bispecific antibodies comprising them |
WO2023117325A1 (en) | 2021-12-21 | 2023-06-29 | F. Hoffmann-La Roche Ag | Method for the determination of hydrolytic activity |
WO2023129974A1 (en) | 2021-12-29 | 2023-07-06 | Bristol-Myers Squibb Company | Generation of landing pad cell lines |
WO2023141445A1 (en) | 2022-01-19 | 2023-07-27 | Genentech, Inc. | Anti-notch2 antibodies and conjugates and methods of use |
TW202342057A (en) | 2022-02-07 | 2023-11-01 | 美商健生生物科技公司 | Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies |
US20230414750A1 (en) | 2022-03-23 | 2023-12-28 | Hoffmann-La Roche Inc. | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
TW202346337A (en) | 2022-03-29 | 2023-12-01 | 美商恩格姆生物製藥公司 | Ilt3 and cd3 binding agents and methods of use thereof |
WO2023198661A1 (en) | 2022-04-12 | 2023-10-19 | F. Hoffmann-La Roche Ag | Fusion proteins targeted to the central nervous system |
WO2023198727A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
WO2023202967A1 (en) | 2022-04-19 | 2023-10-26 | F. Hoffmann-La Roche Ag | Improved production cells |
WO2023217933A1 (en) | 2022-05-11 | 2023-11-16 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf-a and il6 and methods of use |
WO2023232961A1 (en) | 2022-06-03 | 2023-12-07 | F. Hoffmann-La Roche Ag | Improved production cells |
WO2024003837A1 (en) | 2022-06-30 | 2024-01-04 | Janssen Biotech, Inc. | Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
WO2024030956A2 (en) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
Family Cites Families (222)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
DE4118120A1 (en) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE |
US6511663B1 (en) | 1991-06-11 | 2003-01-28 | Celltech R&D Limited | Tri- and tetra-valent monospecific antigen-binding proteins |
US7018809B1 (en) * | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
EP0614375A1 (en) | 1991-11-26 | 1994-09-14 | Alkermes, Inc. | Process for the preparation of transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
GB9221657D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
ATE348110T1 (en) | 1992-10-28 | 2007-01-15 | Genentech Inc | HVEGF RECEPTOR AS A VEGF ANTAGONIST |
US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
US6476198B1 (en) | 1993-07-13 | 2002-11-05 | The Scripps Research Institute | Multispecific and multivalent antigen-binding polypeptide molecules |
UA40577C2 (en) | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Bispecific antigen molecule for lysis of tumor cells, method for preparing of bispecific antigen molecule, monoclonal antibody (variants), pharmaceutical preparation, pharmaceutical kit for lysis of tumor cells (variants), method of lysis of tumor cells |
WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
GB9504344D0 (en) | 1995-03-03 | 1995-04-19 | Unilever Plc | Antibody fragment production |
US5989830A (en) | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
US6239259B1 (en) | 1996-04-04 | 2001-05-29 | Unilever Patent Holdings B.V. | Multivalent and multispecific antigen-binding protein |
KR100794454B1 (en) | 1997-04-07 | 2008-01-16 | 제넨테크, 인크. | Anti-VEGF Antibodies |
ES2236634T3 (en) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | ANTI-VEGF ANTIBODIES. |
US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
IL132560A0 (en) | 1997-05-02 | 2001-03-19 | Genentech Inc | A method for making multispecific antibodies having heteromultimeric and common components |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
CA2317727C (en) * | 1998-01-23 | 2013-01-08 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Multipurpose antibody derivatives |
DK1071700T3 (en) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glycosylation modification of antibodies to enhance antibody-dependent cellular cytotoxicity |
DE19819846B4 (en) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalent antibody constructs |
US7138103B2 (en) | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
CA2690395C (en) | 1998-06-22 | 2013-11-05 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
US6312689B1 (en) | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
WO2000035956A1 (en) | 1998-12-16 | 2000-06-22 | Kyowa Hakko Kogyo Co., Ltd. | Antihuman vegf monoclonal antibody |
US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
CN1232039A (en) | 1999-04-02 | 1999-10-20 | 中国人民解放军海军总医院 | Genetic engineering double specific antibody and its use |
ES2420835T3 (en) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedure to control the activity of immunofunctional molecules |
PL358215A1 (en) | 2000-03-24 | 2004-08-09 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
LT2857516T (en) | 2000-04-11 | 2017-09-11 | Genentech, Inc. | Multivalent antibodies and uses therefor |
FR2807767B1 (en) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | MONOCLONAL ANTIBODIES ANTI-D |
JP2004511430A (en) | 2000-05-24 | 2004-04-15 | イムクローン システムズ インコーポレイティド | Bispecific immunoglobulin-like antigen binding protein and production method |
US20040220388A1 (en) | 2000-06-30 | 2004-11-04 | Nico Mertens | Novel heterodimeric fusion proteins |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
RU2295537C2 (en) * | 2000-10-20 | 2007-03-20 | Тугаи Сейяку Кабусики Кайся | Modified antagonistic antibody |
CA2424371A1 (en) | 2000-10-20 | 2003-04-01 | Chugai Seiyaku Kabushiki Kaisha | Agonistic monoclonal antibody fragments |
US7319139B2 (en) | 2001-01-29 | 2008-01-15 | Biogen Idec, Inc. | TAG-72 specific CH2 domain deleted antibodies |
US20030099974A1 (en) | 2001-07-18 | 2003-05-29 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer |
DE60124912T2 (en) | 2001-09-14 | 2007-06-14 | Affimed Therapeutics Ag | Multimeric, single chain, tandem Fv antibodies |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
JP2005532253A (en) | 2001-10-25 | 2005-10-27 | ジェネンテック・インコーポレーテッド | Glycoprotein composition |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US20040018557A1 (en) | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
CA2484182A1 (en) | 2002-04-29 | 2003-11-13 | Genpat77 Pharmacogenetics Ag | Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis |
US7081443B2 (en) | 2002-05-21 | 2006-07-25 | Korea Advanced Institutes Of Science And Technology (Kaist) | Chimeric comp-ang1 molecule |
SI1517921T1 (en) | 2002-06-28 | 2006-10-31 | Domantis Ltd | Dual specific ligands with increased serum half-life |
KR20050057631A (en) | 2002-10-10 | 2005-06-16 | 메르크 파텐트 게엠베하 | Bispecific anti-erb-b antibodies and their use in tumor therapy |
US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
PL222222B1 (en) | 2003-01-22 | 2016-07-29 | Glycart Biotechnology Ag | Method for polypeptide production |
WO2004072117A2 (en) | 2003-02-13 | 2004-08-26 | Pharmacia Corporation | Antibodies to c-met for the treatment of cancers |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
UA101945C2 (en) | 2003-05-30 | 2013-05-27 | Дженентек, Инк. | Treatment of cancer using bevacizumab |
WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
JP5068072B2 (en) | 2003-06-27 | 2012-11-07 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Modified binding molecule comprising a linking peptide |
WO2005004809A2 (en) | 2003-07-01 | 2005-01-20 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
AR046071A1 (en) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | ANTIBODIES AGAINST RECEIVER I OF THE INSULINAL TYPE GROWTH FACTOR AND THE USES OF THE SAME |
CA2534077A1 (en) | 2003-07-29 | 2005-02-10 | Morphotek Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
CA2536408A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
EP1663306A2 (en) | 2003-09-05 | 2006-06-07 | Genentech, Inc. | Antibodies with altered effector functions |
US20050064509A1 (en) | 2003-09-23 | 2005-03-24 | The Regents Of The University Of California | Use of templated self assembly to create novel multifunctional species |
CN1326881C (en) | 2003-09-29 | 2007-07-18 | 中国人民解放军军事医学科学院基础医学研究所 | Trivalent bispecific antibody and its preparation process and use |
WO2005044859A2 (en) | 2003-11-05 | 2005-05-19 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
PL1983000T3 (en) | 2003-11-21 | 2016-02-29 | Ucb Biopharma Sprl | Method for the treatment of multiple sclerosis by inhibiting IL-17 activity |
JP2008504007A (en) | 2003-12-19 | 2008-02-14 | ジェネンテック・インコーポレーテッド | Monovalent antibody fragments useful as therapeutic agents |
US20080187954A1 (en) | 2004-03-10 | 2008-08-07 | Lonza Ltd. | Method For Producing Antibodies |
EP2053062A1 (en) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
JP2008512352A (en) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | Novel tetravalent bispecific antibody |
EP1778728A2 (en) | 2004-08-19 | 2007-05-02 | Genentech, Inc. | Polypeptide variants with altered effector function |
RU2412947C2 (en) | 2004-09-23 | 2011-02-27 | Дженентек, Инк. | Antibodies, constructed on cysteine basis and their conjugates |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
PT1838733E (en) | 2004-12-21 | 2011-12-13 | Medimmune Ltd | Antibodies directed to angiopoietin-2 and uses thereof |
EP2404937A1 (en) | 2005-02-07 | 2012-01-11 | GlycArt Biotechnology AG | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
AU2005327973A1 (en) | 2005-02-23 | 2006-08-31 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
AU2006218876A1 (en) | 2005-02-28 | 2006-09-08 | Centocor, Inc. | Heterodimeric protein binding compositions |
KR101374454B1 (en) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | Methods for producing polypeptides by regulating polypeptide association |
TW200722518A (en) | 2005-03-31 | 2007-06-16 | Chugai Pharmaceutical Co Ltd | Sc(fv)2 structural isomers |
TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
ES2707152T3 (en) | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Covalent diabodies and uses thereof |
WO2006114700A2 (en) | 2005-04-26 | 2006-11-02 | Bioren, Inc. | Method of producing human igg antibodies with enhanced effector functions |
WO2006116260A2 (en) | 2005-04-26 | 2006-11-02 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
JP5085322B2 (en) | 2005-06-10 | 2012-11-28 | 中外製薬株式会社 | Pharmaceutical composition containing sc (Fv) 2 |
WO2006132352A1 (en) | 2005-06-10 | 2006-12-14 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing sc(fv)2 |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007024715A2 (en) | 2005-08-19 | 2007-03-01 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
SG192479A1 (en) | 2005-08-26 | 2013-08-30 | Roche Glycart Ag | Modified antigen binding molecules with altered cell signaling activity |
WO2007044887A2 (en) | 2005-10-11 | 2007-04-19 | Transtarget, Inc. | Method for producing a population of homogenous tetravalent bispecific antibodies |
US7666622B2 (en) | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
AR056142A1 (en) | 2005-10-21 | 2007-09-19 | Amgen Inc | METHODS TO GENERATE THE MONOVALENT IGG ANTIBODY |
FR2894959B1 (en) | 2005-12-15 | 2008-02-29 | Galderma Res & Dev | RAR-GAMMA RECEPTOR SELECTIVE AGONIST BIPHENYL DERIVATIVES |
BRPI0619853A2 (en) | 2005-12-15 | 2016-08-23 | Astrazeneca Ab | combination, pharmaceutical composition, and methods of antagonizing biological activity, treating disease-related angiogenesis in a mammal, and treating cancer in a mammal |
AR059066A1 (en) | 2006-01-27 | 2008-03-12 | Amgen Inc | COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF) |
MX2008010561A (en) | 2006-02-15 | 2009-03-02 | Imclone Systems Inc | Functional antibodies. |
US20090304715A1 (en) | 2006-03-03 | 2009-12-10 | Tokyo University Of Science | Modified antibodies with enhanced biological activities |
CN103073639A (en) | 2006-03-17 | 2013-05-01 | 比奥根艾迪克Ma公司 | Stabilized polypeptide compositions |
WO2007108013A2 (en) | 2006-03-22 | 2007-09-27 | National Institute Of Immunology | Novel bioconjugates as therapeutic agent and synthesis thereof |
AU2007229698B9 (en) | 2006-03-24 | 2012-11-08 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
US20070274985A1 (en) | 2006-05-26 | 2007-11-29 | Stefan Dubel | Antibody |
KR20090031897A (en) | 2006-06-12 | 2009-03-30 | 리셉터 바이오로직스 인크 | Pan-cell surface receptor-specific therapeutics |
US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
WO2008005828A2 (en) | 2006-06-30 | 2008-01-10 | Novo Nordisk A/S | PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS COMPRISING ANTIBODY MOLECULES SPECIFIC TO LAMININ-5 α3 CHAIN DOMAINS G1G2 AND USE THEREOF |
AR062223A1 (en) | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | MOLECULES OF ADHESION TO THE ANTIGEN THAT ADHER TO EGFR, VECTORS THAT CODE THEM, AND THEIR USES OF THESE |
JP5959795B2 (en) | 2006-08-18 | 2016-08-02 | アーメイゲン・テクノロジーズ・インコーポレイテッドArmagen Technologies, Inc. | Substances for blood-brain barrier delivery |
EP2059533B1 (en) | 2006-08-30 | 2012-11-14 | Genentech, Inc. | Multispecific antibodies |
CN101205255A (en) | 2006-12-14 | 2008-06-25 | 上海中信国健药业有限公司 | Anti CD20 tetravalent antibody, preparation method and uses thereof |
TW200831538A (en) | 2006-12-19 | 2008-08-01 | Genentech Inc | VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
EP3248617A3 (en) | 2007-02-16 | 2018-02-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
US10259860B2 (en) | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
JP2010535032A (en) | 2007-07-31 | 2010-11-18 | メディミューン,エルエルシー | Multispecific epitope binding proteins and uses thereof |
AU2008286759B2 (en) | 2007-08-15 | 2014-05-08 | Isp Investments Inc. | Polyvinylamide polymers containing polymerizable functionalities |
CA2696263C (en) | 2007-08-15 | 2017-06-13 | Bing Liu | Monospecific and multispecific antibodies and method of use |
DE102007038753A1 (en) | 2007-08-16 | 2009-02-19 | Giesecke & Devrient Gmbh | Device and method for the calibration of a sensor system |
JP2010538012A (en) | 2007-08-28 | 2010-12-09 | バイオジェン アイデック マサチューセッツ インコーポレイテッド | Compositions that bind to multiple epitopes of IGF-1R |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
CA2709847C (en) | 2008-01-07 | 2018-07-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
JP2009181819A (en) | 2008-01-31 | 2009-08-13 | Hitachi High-Technologies Corp | Charged particle beam device |
JP4438875B2 (en) | 2008-02-27 | 2010-03-24 | 三菱自動車工業株式会社 | Vehicle fuel storage amount estimation device |
EP2365003A1 (en) | 2008-04-11 | 2011-09-14 | Emergent Product Development Seattle, LLC | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
WO2010006060A2 (en) | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
CA2736408A1 (en) | 2008-09-26 | 2010-04-01 | Roche Glycart Ag | Bispecific anti-egfr/anti-igf-1r antibodies |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
RU2011127198A (en) | 2008-12-04 | 2013-01-10 | Эбботт Лэборетриз | IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATION |
TW201544123A (en) | 2009-03-20 | 2015-12-01 | Genentech Inc | Anti-HER antibodies |
RU2598248C2 (en) | 2009-04-02 | 2016-09-20 | Роше Гликарт Аг | Polyspecific antibodies containing antibody of full length and one-chain fragments fab |
WO2010112194A1 (en) | 2009-04-02 | 2010-10-07 | F. Hoffmann-La Roche Ag | Antigen-binding polypeptides and multispecific antibodies comprising them |
CN102378768A (en) | 2009-04-07 | 2012-03-14 | 罗氏格黎卡特股份公司 | Bispecific anti-erbb-3/anti-c-met antibodies |
KR20110124368A (en) | 2009-04-07 | 2011-11-16 | 로슈 글리카트 아게 | Bispecific anti-erbb-2/anti-c-met antibodies |
AU2010234031B2 (en) | 2009-04-07 | 2015-10-01 | Roche Glycart Ag | Trivalent, bispecific antibodies |
JP2012525149A (en) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Method for making heteromultimeric molecules |
BRPI1007602A2 (en) | 2009-05-27 | 2016-02-16 | Hoffmann La Roche | "tri or tetraspecific antibody, method for preparing a trispecific or tetraspecific antibody, host cell, composition, pharmaceutical composition and method for treating a patient in need of therapy" |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
SG179196A1 (en) | 2009-09-16 | 2012-04-27 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
PT2483310E (en) | 2009-09-29 | 2014-10-07 | Roche Glycart Ag | Bispecific death receptor agonistic antibodies |
JP5856073B2 (en) | 2009-12-29 | 2016-02-09 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | RON binding construct and method of use thereof |
US8318406B2 (en) | 2010-02-03 | 2012-11-27 | Eastman Kodak Company | Method for fixing a flexographic plate |
JP5767207B2 (en) | 2010-03-26 | 2015-08-19 | 協和発酵キリン株式会社 | Novel modified site-introduced antibodies and antibody fragments |
AR080794A1 (en) * | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2 |
CA2797981C (en) | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
ES2537207T3 (en) | 2010-08-16 | 2015-06-03 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
CA2807269A1 (en) | 2010-08-24 | 2012-03-01 | Roche Glycart Ag | Activatable bispecific antibodies |
KR101584416B1 (en) | 2010-10-05 | 2016-01-13 | 에프. 호프만-라 로슈 아게 | Antibodies against human tweak and uses thereof |
DK2635607T3 (en) | 2010-11-05 | 2019-11-18 | Zymeworks Inc | STABLE HETERODIMED ANTIBODY DESIGN WITH MUTATIONS IN THE FC DOMAIN |
TR201815863T4 (en) | 2010-11-30 | 2018-11-21 | Chugai Pharmaceutical Co Ltd | Therapeutic agent that induces cytotoxicity. |
CN103443125B (en) | 2010-11-30 | 2019-05-03 | 霍夫曼-拉罗奇有限公司 | Low-affinity blood-brain barrier receptor antibody and application thereof |
BR112013019975A2 (en) | 2011-02-28 | 2017-08-01 | Hoffmann La Roche | "Antigen binding proteins, pharmaceutical composition, use of an antigen binding protein, method for treating a patient and method for preparing an antigen binding protein, nucleic acid, vector and host cell" |
EP2681240B1 (en) | 2011-02-28 | 2017-08-16 | F. Hoffmann-La Roche AG | Monovalent antigen binding proteins |
MX358752B (en) | 2011-03-25 | 2018-08-31 | Glenmark Pharmaceuticals Sa | Hetero-dimeric immunoglobulins. |
CN103502273A (en) | 2011-04-20 | 2014-01-08 | 罗氏格黎卡特股份公司 | Method and constructs for the pH dependent passage of the blood-brain-barrier |
CN102302039B (en) | 2011-06-16 | 2014-01-29 | 北京泛博化学股份有限公司 | Dication quaternary ammonium complex iodine disinfectant, and application thereof |
TWI687441B (en) | 2011-06-30 | 2020-03-11 | 中外製藥股份有限公司 | Heterodimerized polypeptide |
WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
EP2748200B1 (en) | 2011-08-23 | 2018-04-11 | Roche Glycart AG | Fc-free antibodies comprising two fab fragments and methods of use |
PT2748202T (en) | 2011-08-23 | 2018-10-08 | Roche Glycart Ag | Bispecific antigen binding molecules |
HUE038225T2 (en) | 2011-08-23 | 2018-10-29 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
BR112014004168A2 (en) | 2011-08-23 | 2017-12-12 | Roche Glycart Ag | bispecific antibody, pharmaceutical composition, use of bispecific antibody, prokaryotic or eukaryotic host cell, antibody production method and invention |
ES2732712T3 (en) | 2011-10-31 | 2019-11-25 | Chugai Pharmaceutical Co Ltd | Antigen binding molecule that has a regulated conjugation between the heavy chain and the light chain |
EA201400709A1 (en) | 2011-12-19 | 2016-08-31 | Синиммун Гмбх | MOLECULE OF BISPECIFIC ANTIBODY |
RS60499B1 (en) | 2011-12-20 | 2020-08-31 | Medimmune Llc | Modified polypeptides for bispecific antibody scaffolds |
KR101674784B1 (en) | 2012-04-05 | 2016-11-09 | 에프. 호프만-라 로슈 아게 | Bispecific antibodies against human tweak and human il17 and uses thereof |
SG10201607371UA (en) | 2012-04-20 | 2016-10-28 | Merus Nv | Methods and means for the production of ig-like molecules |
KR20150013188A (en) | 2012-05-24 | 2015-02-04 | 에프. 호프만-라 로슈 아게 | Multispecific antibodies |
EP3401337A1 (en) | 2012-09-25 | 2018-11-14 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
WO2014056783A1 (en) | 2012-10-08 | 2014-04-17 | Roche Glycart Ag | Fc-free antibodies comprising two fab-fragments and methods of use |
UY35148A (en) | 2012-11-21 | 2014-05-30 | Amgen Inc | HETERODIMERIC IMMUNOGLOBULINS |
EP2925785A4 (en) | 2012-11-28 | 2016-11-16 | Zymeworks Inc | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
KR102249779B1 (en) | 2012-12-27 | 2021-05-07 | 추가이 세이야쿠 가부시키가이샤 | Heterodimerized polypeptide |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
UA118028C2 (en) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use |
EP3041862B1 (en) | 2013-09-05 | 2020-05-06 | IGM Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent ig-m antibodies |
WO2015052230A1 (en) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Multispecific domain exchanged common variable light chain antibodies |
MX2016008098A (en) | 2013-12-20 | 2017-01-11 | Hoffmann La Roche | Bispecific her2 antibodies and methods of use. |
PL3092251T3 (en) | 2014-01-06 | 2021-08-02 | F. Hoffmann-La Roche Ag | Monovalent blood brain barrier shuttle modules |
EP3094648A1 (en) | 2014-01-15 | 2016-11-23 | F. Hoffmann-La Roche AG | Fc-region variants with improved protein a-binding |
KR20160104009A (en) | 2014-01-15 | 2016-09-02 | 에프. 호프만-라 로슈 아게 | Fc-region variants with modified fcrn-binding properties |
CA2931986A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
UA117289C2 (en) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Multispecific antibodies |
WO2016016299A1 (en) | 2014-07-29 | 2016-02-04 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
PE20170263A1 (en) | 2014-08-04 | 2017-03-30 | Hoffmann La Roche | T-CELL ACTIVATING ANTIGEN-BINDING BI-SPECIFIC MOLECULES |
EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
EP3204412B1 (en) | 2014-10-08 | 2020-08-19 | F.Hoffmann-La Roche Ag | Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents |
JP6708635B2 (en) | 2014-10-09 | 2020-06-10 | エンクマフ エスアーエールエル | Bispecific antibodies to CD3ε and ROR1 |
SI3221357T1 (en) | 2014-11-20 | 2020-09-30 | F. Hoffmann-La Roche Ag | Common light chains and methods of use |
WO2016079076A1 (en) | 2014-11-20 | 2016-05-26 | F. Hoffmann-La Roche Ag | T cell activating bispecific antigen binding molecules agiant folr1 and cd3 |
WO2017055392A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules |
CN107849137B (en) | 2015-10-02 | 2021-11-26 | 豪夫迈·罗氏有限公司 | Bispecific anti-CEAXCD 3T cell activating antigen binding molecules |
EP3150636A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
WO2017055385A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xgd2 bispecific t cell activating antigen binding molecules |
WO2017055393A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules |
MY192202A (en) | 2015-10-02 | 2022-08-06 | Hoffmann La Roche | Bispecific antibodies specific for pd1 and tim3 |
AR106199A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | T-CELL ACTIVATING ANTIGEN BINDING MOLECULES OF ANTIGEN |
PE20240096A1 (en) | 2015-10-02 | 2024-01-18 | Hoffmann La Roche | BISPECIFIC ANTIBODIES SPECIFIC FOR A CO-STIMULATORY TNF RECEPTOR |
US20170129962A1 (en) | 2015-10-02 | 2017-05-11 | Hoffmann-La Roche Inc. | Multispecific antibodies |
CN108026177B (en) | 2015-10-02 | 2021-11-26 | 豪夫迈·罗氏有限公司 | Bispecific anti-CD 19XCD 3T cell activating antigen binding molecules |
WO2017055318A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Cd33xcd3 bispecific t cell activating antigen binding molecules |
US20170096485A1 (en) | 2015-10-02 | 2017-04-06 | Hoffmann-La Roche Inc. | Bispecific t cell activating antigen binding molecules |
JP7074665B2 (en) | 2015-10-07 | 2022-05-24 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Field of Invention of Tetravalent Bispecific Antibodies to Co-Stimulated TNF Receptors |
-
2008
- 2008-12-11 US US12/332,486 patent/US20090162359A1/en not_active Abandoned
- 2008-12-16 MX MX2010006396A patent/MX2010006396A/en active IP Right Grant
- 2008-12-16 WO PCT/EP2008/010703 patent/WO2009080252A1/en active Application Filing
- 2008-12-16 BR BRPI0821791-2A patent/BRPI0821791B1/en active IP Right Grant
- 2008-12-16 AU AU2008340693A patent/AU2008340693A1/en not_active Abandoned
- 2008-12-16 CA CA2709023A patent/CA2709023C/en active Active
- 2008-12-16 NZ NZ585627A patent/NZ585627A/en not_active IP Right Cessation
- 2008-12-16 RU RU2010129549/10A patent/RU2587616C2/en active
- 2008-12-16 CN CN2008801219004A patent/CN101903404B/en active Active
- 2008-12-16 KR KR1020107013760A patent/KR101249607B1/en active IP Right Grant
- 2008-12-16 EP EP08864374.7A patent/EP2225279B1/en active Active
- 2008-12-16 JP JP2010538441A patent/JP5281097B2/en active Active
- 2008-12-16 ES ES08864374.7T patent/ES2469791T3/en active Active
- 2008-12-17 AR ARP080105485A patent/AR071547A1/en not_active Application Discontinuation
- 2008-12-17 PE PE2008002108A patent/PE20091172A1/en not_active Application Discontinuation
- 2008-12-17 CL CL2008003781A patent/CL2008003781A1/en unknown
- 2008-12-17 TW TW097149168A patent/TWI359027B/en not_active IP Right Cessation
-
2010
- 2010-05-25 CR CR11460A patent/CR11460A/en not_active Application Discontinuation
- 2010-05-31 CO CO10065316A patent/CO6280542A2/en not_active Application Discontinuation
- 2010-06-03 IL IL206161A patent/IL206161A0/en unknown
- 2010-06-09 MA MA32899A patent/MA31904B1/en unknown
- 2010-06-18 EC EC2010010270A patent/ECSP10010270A/en unknown
-
2012
- 2012-01-31 US US13/362,010 patent/US20120164726A1/en not_active Abandoned
- 2012-01-31 US US13/362,000 patent/US10138293B2/en active Active
-
2013
- 2013-08-30 US US14/015,952 patent/US20140120613A1/en not_active Abandoned
-
2018
- 2018-11-26 US US16/200,295 patent/US10927163B2/en active Active
Cited By (146)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US10927163B2 (en) | 2007-12-21 | 2021-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162360A1 (en) * | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9708396B2 (en) | 2008-10-08 | 2017-07-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
US8703130B2 (en) | 2008-10-08 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
US9382323B2 (en) | 2009-04-02 | 2016-07-05 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
US20100256338A1 (en) * | 2009-04-02 | 2010-10-07 | Ulrich Brinkmann | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
US9890204B2 (en) | 2009-04-07 | 2018-02-13 | Hoffmann-La Roche Inc. | Trivalent, bispecific antibodies |
US8796424B2 (en) * | 2009-05-27 | 2014-08-05 | Hoffmann-La Roche Inc. | Tri- or tetraspecific antibodies |
US20100322935A1 (en) * | 2009-05-27 | 2010-12-23 | Rebecca Croasdale | Tri- or Tetraspecific Antibodies |
US10640555B2 (en) | 2009-06-16 | 2020-05-05 | Hoffmann-La Roche Inc. | Bispecific antigen binding proteins |
US11673945B2 (en) | 2009-06-16 | 2023-06-13 | Hoffmann-La Roche Inc. | Bispecific antigen binding proteins |
US20100316645A1 (en) * | 2009-06-16 | 2010-12-16 | Sabine Imhof-Jung | Bispecific Antigen Binding Proteins |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US9994646B2 (en) | 2009-09-16 | 2018-06-12 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
US10106600B2 (en) | 2010-03-26 | 2018-10-23 | Roche Glycart Ag | Bispecific antibodies |
US9879095B2 (en) | 2010-08-24 | 2018-01-30 | Hoffman-La Roche Inc. | Bispecific antibodies comprising a disulfide stabilized-Fv fragment |
US11618790B2 (en) | 2010-12-23 | 2023-04-04 | Hoffmann-La Roche Inc. | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
US10611825B2 (en) | 2011-02-28 | 2020-04-07 | Hoffmann La-Roche Inc. | Monovalent antigen binding proteins |
US9982036B2 (en) | 2011-02-28 | 2018-05-29 | Hoffmann-La Roche Inc. | Dual FC antigen binding proteins |
US10793621B2 (en) * | 2011-02-28 | 2020-10-06 | Hoffmann-La Roche Inc. | Nucleic acid encoding dual Fc antigen binding proteins |
US20210189011A1 (en) * | 2011-03-28 | 2021-06-24 | Sanofi | Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation |
US20150210765A1 (en) * | 2011-05-24 | 2015-07-30 | Zyngenia, Inc. | Multivalent and Monovalent Multispecific Complexes and Their Uses |
US10526381B2 (en) | 2011-05-24 | 2020-01-07 | Zygenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
US20130058937A1 (en) * | 2011-08-23 | 2013-03-07 | Johannes Auer | Bispecific antigen binding molecules |
US9688758B2 (en) | 2012-02-10 | 2017-06-27 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
US11407836B2 (en) | 2012-06-27 | 2022-08-09 | Hoffmann-La Roche Inc. | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
US10106612B2 (en) | 2012-06-27 | 2018-10-23 | Hoffmann-La Roche Inc. | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
US11421022B2 (en) | 2012-06-27 | 2022-08-23 | Hoffmann-La Roche Inc. | Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
US10683345B2 (en) | 2012-07-13 | 2020-06-16 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
US9695233B2 (en) | 2012-07-13 | 2017-07-04 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
US10155815B2 (en) | 2013-02-26 | 2018-12-18 | Roche Glycart Ag | Bispecific T cell activating antigen binding molecules |
US10781258B2 (en) | 2013-02-26 | 2020-09-22 | Roche Glycart Ag | Bispecific T cell activating antigen binding molecules |
US20140242080A1 (en) * | 2013-02-26 | 2014-08-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
US10781257B2 (en) | 2013-02-26 | 2020-09-22 | Roche GlyeArt AG | Bispecific T cell activating antigen binding molecules |
US10150800B2 (en) | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
US10323099B2 (en) | 2013-10-11 | 2019-06-18 | Hoffmann-La Roche Inc. | Multispecific domain exchanged common variable light chain antibodies |
US10364292B2 (en) | 2014-01-06 | 2019-07-30 | Hoffmann-La Roche Inc. | Monovalent blood brain barrier shuttle modules |
EP3514179A1 (en) | 2014-01-24 | 2019-07-24 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
EP4324518A2 (en) | 2014-01-31 | 2024-02-21 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
EP3660050A1 (en) | 2014-03-14 | 2020-06-03 | Novartis AG | Antibody molecules to lag-3 and uses thereof |
WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
US9884921B2 (en) | 2014-07-01 | 2018-02-06 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
EP3722316A1 (en) | 2014-07-21 | 2020-10-14 | Novartis AG | Treatment of cancer using a cd33 chimeric antigen receptor |
WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
EP3660042A1 (en) | 2014-07-31 | 2020-06-03 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
WO2016044605A1 (en) | 2014-09-17 | 2016-03-24 | Beatty, Gregory | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
EP3967709A1 (en) | 2014-09-17 | 2022-03-16 | Novartis AG | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
EP4245376A2 (en) | 2014-10-14 | 2023-09-20 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
WO2016090034A2 (en) | 2014-12-03 | 2016-06-09 | Novartis Ag | Methods for b cell preconditioning in car therapy |
US10633457B2 (en) | 2014-12-03 | 2020-04-28 | Hoffmann-La Roche Inc. | Multispecific antibodies |
WO2016164731A2 (en) | 2015-04-08 | 2016-10-13 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
EP4056588A1 (en) | 2015-04-08 | 2022-09-14 | Novartis AG | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell |
WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
WO2016207240A1 (en) * | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
US10323089B2 (en) | 2015-06-24 | 2019-06-18 | Hoffmann-La Roche Inc. | Anti-transferrin receptor antibodies with tailored affinity |
US11584793B2 (en) | 2015-06-24 | 2023-02-21 | Hoffmann-La Roche Inc. | Anti-transferrin receptor antibodies with tailored affinity |
EP4074730A1 (en) * | 2015-06-24 | 2022-10-19 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies with tailored affinity |
EP3964528A1 (en) | 2015-07-29 | 2022-03-09 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
WO2017019894A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
US10941205B2 (en) | 2015-10-02 | 2021-03-09 | Hoffmann-La Roche Inc. | Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use |
US10766967B2 (en) | 2015-10-02 | 2020-09-08 | Hoffmann-La Roche Inc. | Bispecific T cell activating antigen binding molecules |
US11603411B2 (en) | 2015-10-02 | 2023-03-14 | Hoffmann-La Roche Inc. | Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use |
US11013801B2 (en) | 2015-12-09 | 2021-05-25 | Hoffmann-La Roche Inc. | Treatment method |
WO2017106810A2 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof |
WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
US10596257B2 (en) | 2016-01-08 | 2020-03-24 | Hoffmann-La Roche Inc. | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
WO2017125897A1 (en) | 2016-01-21 | 2017-07-27 | Novartis Ag | Multispecific molecules targeting cll-1 |
EP3851457A1 (en) | 2016-01-21 | 2021-07-21 | Novartis AG | Multispecific molecules targeting cll-1 |
WO2017149515A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
EP4219721A2 (en) | 2016-04-15 | 2023-08-02 | Novartis AG | Compositions and methods for selective protein expression |
WO2017181119A2 (en) | 2016-04-15 | 2017-10-19 | Novartis Ag | Compositions and methods for selective protein expression |
WO2017210617A2 (en) | 2016-06-02 | 2017-12-07 | Porter, David, L. | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
WO2018013918A2 (en) | 2016-07-15 | 2018-01-18 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
WO2018023025A1 (en) | 2016-07-28 | 2018-02-01 | Novartis Ag | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors |
WO2018026819A2 (en) | 2016-08-01 | 2018-02-08 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
WO2018160731A1 (en) | 2017-02-28 | 2018-09-07 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
WO2018237157A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
WO2019006007A1 (en) | 2017-06-27 | 2019-01-03 | Novartis Ag | Dosage regimens for anti-tim-3 antibodies and uses thereof |
US11752207B2 (en) | 2017-07-11 | 2023-09-12 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and uses thereof |
WO2019018730A1 (en) | 2017-07-20 | 2019-01-24 | Novartis Ag | Dosage regimens of anti-lag-3 antibodies and uses thereof |
US11161911B2 (en) | 2017-10-23 | 2021-11-02 | Go Therapeutics, Inc. | Anti-glyco-MUC1 antibodies and their uses |
WO2019089798A1 (en) | 2017-10-31 | 2019-05-09 | Novartis Ag | Anti-car compositions and methods |
US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
WO2019099838A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
WO2019152660A1 (en) | 2018-01-31 | 2019-08-08 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
WO2019200229A1 (en) | 2018-04-13 | 2019-10-17 | Novartis Ag | Dosage regimens for anti-pd-l1 antibodies and uses thereof |
WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
WO2019226658A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Multispecific antigen-binding compositions and methods of use |
WO2019226617A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions and methods for enhancing the killing of target cells by nk cells |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
WO2019241426A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
WO2019246293A2 (en) | 2018-06-19 | 2019-12-26 | Atarga, Llc | Antibody molecules to complement component 5 and uses thereof |
WO2020012337A1 (en) | 2018-07-10 | 2020-01-16 | Novartis Ag | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
US11046769B2 (en) | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
WO2020128898A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Pharmaceutical combinations |
WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020165868A1 (en) | 2019-02-15 | 2020-08-20 | Perkinelmer Cellular Technologies Germany Gmbh | Low-power microscope-objective pre-scan and high-power microscope-objective scan in x,y and z-direction for imaging objects such as cells using a microscope |
WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020172553A1 (en) | 2019-02-22 | 2020-08-27 | Novartis Ag | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
WO2020205523A1 (en) | 2019-03-29 | 2020-10-08 | Atarga, Llc | Anti fgf23 antibody |
WO2021079188A1 (en) | 2019-10-21 | 2021-04-29 | Novartis Ag | Combination therapies with venetoclax and tim-3 inhibitors |
WO2021079195A1 (en) | 2019-10-21 | 2021-04-29 | Novartis Ag | Tim-3 inhibitors and uses thereof |
WO2021108661A2 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
WO2021123996A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
WO2021123902A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
WO2021146636A1 (en) | 2020-01-17 | 2021-07-22 | Becton, Dickinson And Company | Methods and compositions for single cell secretomics |
WO2021144657A1 (en) | 2020-01-17 | 2021-07-22 | Novartis Ag | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
WO2021173995A2 (en) | 2020-02-27 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2022013787A1 (en) | 2020-07-16 | 2022-01-20 | Novartis Ag | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules |
WO2022026592A2 (en) | 2020-07-28 | 2022-02-03 | Celltas Bio, Inc. | Antibody molecules to coronavirus and uses thereof |
WO2022029573A1 (en) | 2020-08-03 | 2022-02-10 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022097065A2 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | ANTIBODY Fc VARIANTS |
WO2022104061A1 (en) | 2020-11-13 | 2022-05-19 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
WO2022162569A1 (en) | 2021-01-29 | 2022-08-04 | Novartis Ag | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
WO2022215011A1 (en) | 2021-04-07 | 2022-10-13 | Novartis Ag | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
WO2022243846A1 (en) | 2021-05-18 | 2022-11-24 | Novartis Ag | Combination therapies |
US11970538B2 (en) | 2021-05-20 | 2024-04-30 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
WO2023150778A1 (en) | 2022-02-07 | 2023-08-10 | Visterra, Inc. | Anti-idiotype antibody molecules and uses thereof |
WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
WO2024030976A2 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10927163B2 (en) | Bivalent, bispecific antibodies | |
US8242247B2 (en) | Bivalent, bispecific antibodies | |
US9266967B2 (en) | Bivalent, bispecific antibodies | |
US8227577B2 (en) | Bivalent, bispecific antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: F. HOFFMANN-LA ROCHE AG,SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KLEIN, CHRISTIAN;SCHAEFER, WOLFGANG;REEL/FRAME:022406/0098 Effective date: 20090108 Owner name: HOFFMANN-LA ROCHE, INC.,NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F. HOFFMANN-LA ROCHE AG;REEL/FRAME:022406/0807 Effective date: 20090115 |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING PUBLICATION PROCESS |